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Obesity is now a major health threat in the developed world. To investigate the 
impact of obesity-induced steatosis on hepatic blood flow, portal venous and hepatic 
arterial blood flow were measured in the anaesthetized lean and obese Zucker rats. 
Hepatic tissue oxygenation status was assessed by analyzing the NAD(P)H 
fluorescence. The results show that although the steatotic liver has a remarkably 
reduced total and portal venous blood flow, the hepatic arterial blood flow is well 
maintained. However, the tissue in the steatotic liver is still in a relatively hypoxic 
state as compared with the lean Zucker rats. 
The impact of systemic metabolic conditions on the development of liver 
steatosis was studied by transplanting normal non-steatotic liver grafts from lean 
Zucker rats to their obese littermates and following the changes in plasma lipid profile, 
body weight, graft perfusion, microvascular structure, and liver histology for 3 
months. The results demonstrate that transplantation of a non-steatotic liver into an 
obese Zucker rat initially has a positive effect on lipid metabolism. However, 3 months 
after transplantation, the donor liver became steatotic with reduced perfusion. Hence, 
the recipient's metabolic status is pivotal in the maintenance of normal liver graft 
perfusion after transplantation. 
To investigate the vulnerability of the steatotic liver to ischaemia-reperfusion 
(IR) injury, partial hepatic IR ( 45' /60') was induced in anaesthetized lean and obese 
Zucker rats. Mitochondrial membrane potential, hepatocyte nucleus density, and 
leukocyte adherence were quantitated using intravital fluorescent microscopy (IVFM) 
during the process. Plasma transaminases and liver histology were also studied. The 
results indicate that IR leads to significantly depressed mitochondrial membrane 
potential and greater injury in the steatotic than in the normal liver. In conclusion, the 
increased sensitivity of the steatotic liver to IR injury would appear to involve both 







To elucidate the role of nitric oxide (NO) in the maintenance of hepatic 
haemodynamics under steatotic condition and during IR injury, hepatic haemodynamic 
parameters, hepatic microvascular features, and changes in mitochondrial membrane 
potential were measured during IR (60' /120') in the anaesthetized obese and lean 
Zucker rats with and without pretreatment with L-NAME (lOmg·kg-1 i.a.). Plasma 
transaminase activities were also compared. The findings suggest that not only is NO 
vital in the control of hepatic haemodynamics and hepatic microcirculatory perfusion, 
it is also important in the maintenance of hepatic architecture and the alleviation of 
hepatic IR injury in both lean and obese Zucker rats. The results also suggest a 
protective role of NO in the maintenance of metabolic functions and cellular integrity 
during short-term IR in the steatotic liver. 
In an attempt to address in vivo the function of specific nitric oxide synthase 
(NOS) isoform in hepatic haemodynamics and during hepatic IR, age-matched wild-
type (WT), iNOS knockout (iNOS-/-), and eNOS knockout (eNOS-/-) mice were 
subjected to 60 min partial hepatic ischaemia and examined before and at 2h, 8h, and 
24h after reperfusion. The results imply that eNOS is protective in the subacute phase 
of hepatic IR injury. Moreover, although a role of iNOS in reactive oxygen species 
(ROS) formation during IR is suggested, there is no evidence of significant protective 
effect in iNOS-/- mice toward IR injury. On the contrary, the iNOS-/- mutants 
exhibited delayed histologic recovery after IR insult, implying that iNOS-derived NO 
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1.1 Functional anatomy of the liver 
1.1.1 Liver: the metabolic powerhouse of the body 
The liver, which is situated in the right hypochondriac region and extends across 
the epigastrium into the left hypochondrium, is the largest internal glandular organ in 
the human body. It weighs from 1,200 to 1,500 g and accounts for 4% of the body 
weight (Fischer and McFadden 1993; Gray 2002). It has a transverse diameter 
between ten to twelve inches and an antero-posterior diameter from 15 to 18 cm. 
Myriad chemical reactions takes place in the liver that receives about 20% of the 
cardiac output (Howard and Billiar 1992). Under physiological conditions, the liver 
accounts for up to 20% to 25% of the total oxygen consumption and expends 20% of 
the energy of the body (Fischer and McFadden 1993). Its metabolic efficiency is so 
high that it can clear as much as 75% to 100% of the portal venous nutrient supply in a 
single pass (Fischer and McFadden 1993). It also processes, stores, or releases its 
products at the appropriate time in accordance with hormonal and neural stimuli 
(Fischer and McFadden 1993). Since blood enters the hepatic sinusoids from the portal 
vein and hepatic artery at different levels, it results in a mixture of blood with varying 
degrees of oxygenation, toxification, or nutritional repletion from the gut. As a result, 
some authors proposed that about two thirds of all hepatocytes are dormant at any 
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given time (Meyers and Jones 1990). On the other hand, the liver is also remarkable in 
its ability in regeneration. The hepatocytes continually divide with an average life span 
about 30 days (Fischer and McFadden 1993) and it is estimated that the entire cell 
mass of the liver could be replaced every 50 days (Howard and Billiar 1992). Beside 
metabolism, the liver also has remarkable synthetic functions that include 13 proteins 
required for haemostasis and up to 20% of the major human plasma proteins (Fischer 
and McFadden 1993). Secretory function ( e.g bile) and immune function, especially T-
cell homeostasis (Wick et al. 2002), are also features of the liver. 
1.1.2 Embryology of the liver 
Developmentally, the liver, gallbladder and biliary duct system are endodermal 
derivatives and originate as a ventral outgrowth from the caudal part of the foregut 
early in the fourth week of embryonic growth and is known as the "hepatic 
diverticulum" (or "liver bud") (Moore and Persaud 1998). The enlarging hepatic 
anlage is breached by vitelline venous radicals that fuse to form the portal vein, and by 
placental umbilical venous radicals to create a sinusoidal capillary network allowing 
contiguous hepatocyte proliferation (Meyers and Jones 1990). After birth the umbilical 
vein regresses, leaving the liver with two sources of blood supply: the portal vein and 
the hepatic artery (Merrell 1988). 
1.1.3 Surgical anatomy of the liver 
Anatomically, the liver is attached superiorly to the diaphragm through the 
falciform, coronary and triangular ligaments (Fig. l. lA). The round ligament passing 
anteriorly to the umbilicus is the remnant of the fetal umbilical cord. Most of the liver 
is under peritoneal cover with the exception of the upper posterior area behind the 
ligamentous attachments where the liver is attached directly to the diaphragm and is 
called the "bare area" (Fig. l. lB). 
Contrary to the anatomical features of many other smaller mammals such as the 
rat and the mouse which have grossly identifiable and separated hepatic lobes (Fig. 
2.22A), the human liver is one large integrative organ the surface anatomy of which 
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Figure 1.1 Anatomy of the liver. 
A. Anterior view; 
B. Visceral surface. 
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eight functional segments (i.e. segment I to VIII) according to the blood supply to this 
complex organ after Couinaud (Couinaud 1957). To divide the liver functionally into 
right and left lobes, an imaginary line is drawn posteriorly from the hepatic hilum 
through the gallbladder bed to the vena cava (Fig. 1. lB). This division is in 
accordance with the distribution of the right and left branches of the portal vein and 
hepatic artery. Based on the subdivision of the portal vein and hepatic artery, the right 
lobe is further divided into four segments (i.e. V, VI, VII, VIII) which are the anterior-
inferior, posterior-inferior, posterior-superior, and anterior-superior segments, 
respectively (Fig. 1.2). Similarly, the left lobe is divided into three segments which are 
medial (IV), superior-lateral (II) and inferior-lateral (III). The caudate lobe (I) has 
unique arterial and venous distribution derived from branches of both the right and left 
hepatic artery and portal vein. The hepatic venous drainage essentially follows the 
same pattern with the right hepatic vein draining the right lobe, the middle hepatic 
vein draining mainly the medial segment of the left lobe and also portions of the right 
lobe, the left hepatic vein draining the lateral segments of the left lobe (Fig. 1.2). 
Posteriorly, several medium and small hepatic veins drain directly from the right lobe 
into the vena cava. Accordingly, the caudate lobe has separate drainage into the vena 
cava. This clinical anatomical division is pivotal in that, under sonographic guidance, 
it allows different parts of the organ to be surgically separated without affecting the 
blood supply to the rest of the organ as in the case of tumor excision. Portions of the 
liver can even be divided and excised with intact vascular supply and drainage which 
forms the basis of modern living-related and split liver transplantation. 
1.1.4 Histology of the liver 
The liver is composed of hepatocytes arranged in cords or plates of one cell 
thickness surrounded by the capillary system of the liver known as "sinusoids". A 
hepatic perfusion unit is traditionally known as a hepatic lobule which is centered 
around a hepatic venule with hepatic cords radiating away from its centre and six 
portal triads (i.e. portal venule, hepatic arteriole, and bile duct) arranged peripherally 
over the corners of a hexagon that can be easily discernible microscopically (Fig. 
1.3A). Physiologically, however, hepatologists preferred a more functional 
classification of a hepatic lobule. As a result, the term "hepatic acinus" was introduced 







Figure 1.2 Surgical anatomy of the liver. 









Figure 1.3 Azocarmine B / Aniline blue (AZAN)-stained pig liver section with 
blue staining of connective tissue. 
A. Classic hepatic lobule with central vein (CV) located in the middle, surrounded by 
portal triads (PT: Portal venule, hepatic arterial, and bile ductule). 
B. The functional unit of the liver, the hepatic acinus, consists of 3 zones: Periportal 
(pp) segment (zone 1), midzonal (mz) segment (zone 2), and pericentral (pc) 
segment (zone 3). Hepatocytes over the 3 zones of an acinus have different 
oxygenation and metabolism status because of their progressive increase in 
distance from the portal triad. 
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triad flowing outward along the sinusoids to multiple terminal hepatic venules 
(Rappaport 1987) (Fig. 1.3B). The hepatocytes lying between the portal triad and 
hepatic venule have thus been classified into three zones with zone 1 located in closest 
proximity to the periportal region, zone 3 closest to the hepatic venule (i.e. 
pericentral), and zone 2 in between the formers (Fig. 1.3B). 
- 8 -
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1.2 Hepatic cellular elements, their functions and interactions 
The three major cell types of the liver are hepatocytes (50% ), endothelial cells 
(25% ), and Kupffer cells (20% ). Other cell types including hepatic stellate cells 
(HSC), fibroblasts, neurons, bile duct cells, and pit cells constitute the remaining 
cellular components of the liver (Howard and Billiar 1992). While the hepatocytes 
make up about 80% of the liver volume, the nonparenchymal cells contribute only 
6.5% (Kmiec 2001). 
1.2.1 Hepatocyte 
The hepatocytes are large, polyhedral cells with a diameter of 25 to 30 µm. They 
are mainly responsible for the metabolic, synthetic and excretory functions of the liver. 
The plasma side of the hepatocyte possesses a rich array of receptors to gather 
information and instructions while transporting essential substrates, hormones and 
carrier proteins intracellularly. The hepatocyte then processes the information and 
dispenses appropriate metabolic products back into the plasma or into the bile 
canaliculus on the other side of the cell (Jones and Burwen 1985). As blood flows 
from zone 1 to zone 3 of an acinus, the substrates and metabolic products thus formed 
may induce hepatocyte enzyme synthesis and regulate the function of individual 
hepatocyte. The function of an hepatocyte therefore depends on its position within an 
acinus and hence the proximity of the cell to the blood supply. Since hepatocytes in 
zone 1 lie in closest proximity to the portal triad and are the first exposed to oxygen 
and nutrients delivered to the liver, they contain the highest concentration of enzymes 
for glycogenesis and gluconeogenesis. They are also responsible for protein 
metabolism and produce the majority of proteins from the liver. On the other hand, 
zone 3 hepatocytes are responsible for glycolysis and lipogenesis due to the reduced 
oxygen content. Processes like ureagenesis also occurs in zones 2 and 3 of an acinus 
(Howard and Billiar 1992). 
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1.2.2 Kupffer cell 
Deriving from a monocyte bone marrow precursor, the Kupffer cells constitute the 
largest population (80%-90%) of the fixed macrophages of the body and are subject to 
constant turnover (Billiar and Curran 1990). Not only are they phagocytic cells with 
endocytic capacity residing within the sinusoids, they also participate in antigen 
processing and presentation. Hence, they represent a major portion of the 
reticuloendothelial system and the non-specific immune response. Lying close to each 
other, Kupffer cells and hepatocytes interact under physiological conditions. For 
example, the phagocytosis of senescent erythrocytes by Kupffer cells with the 
resulting formation of ferritin has been demonstrated to be a route to facilitate iron 
processing by hepatocytes (Fischer and McFadden 1993). On the other hand, a body of 
evidence showed that Kupffer cells are the major mediators of hepatic injury when 
stimulated through the release of cytokines (e.g. tumor necrosis factor alpha, TNF-a, 
and interleukin 1, IL-1), free radicals (e.g. nitric oxide, NO, and other oxygen 
radicals), and proteases under pathological conditions such as endotoxemia (Billiar et 
al. 1990; Spolarics 1998; Thurman 1998), early phase of hepatic ischaemia-
reperfusion injury (Lindell et al. 1994; Imamura et al. 1995), and cirrhosis (Winwood 
and Arthur 1993). In this way they are active in the remodeling of extracellular matrix 
(Kmiec 2001). The number of Kupffer cells varies under different conditions, 
increasing in sepsis and decreasing in germ-free state or following portasystemic 
shunting, when toxins normally carried by portal venous blood are diverted into the 
systemic circulation (Billiar et al. 1988; Billiar and Curran 1990). The mechanism of 
the regulatory system, however, remains unclear (Fischer and McFadden 1993). 
1.2.3 Endothelial cell 
Unlike ordinary capillaries, the endothelial cells lining the hepatic sinusoids have 
wide intercellular gaps and fenestrated cytoplasm through which most large molecules 
can pass to a small space between the endothelial linings and the hepatocytes known 
as the "space of Disse" where the exchange of materials between the sinusoids and 
hepatocytes take place (Howard and Billiar 1992; Fischer and McFadden 1993) (Fig. 
1.4). In this way, the sinusoidal endothelial cells (SEC) perform an important filtration 
function between the blood and the hepatocyte surface (Kmiec 2001) (section 1.3.2). 
SEC also have remarkable endocytic capacity for a variety of lignands including 
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glycoproteins, components of extracellular matrix, immune complexes, and metal-
transporting protein such as transferrin and ceruloplasmin. They also secrete 
cytokines, eicosanoids, some components of extracellular matrix, and vasoactive 
substances such as endothelin (ET) and NO (Kmiec 2001). On the other hand, just like 
Kupffer cells, SEC may function as antigen-presenting cells in the context of both 
MHC-I and MHC-II restriction, resulting in the development of antigen-specific T-cell 
tolerance (Kmiec 2001). SEC also have a role to play under pathological conditions. 
They have been shown to participate, along with Kupffer cells, in the production of 
free oxygen radicals in alcohol-induced liver injury (Bautista and Spitzer 1999; 
Hasegawa et al. 2002). SEC have also been shown to be the primary target of 
endotoxin-induced injury (McCuskey et al. 1995). In addition, it was.also reported that 
SEC are the first to undergo rapid apoptosis on re-oxygenation after cold storage and 
warm-ischaemia (Clavien 1998; Kohli et al. 1999b). 
1.2.4 Hepatic stellate cell 
In the liver, the population ratio of hepatic stellate cells (HSCs) to hepatocytes is 
about 1 to 20 (Howard and Billiar 1992). HSCs, which are also known as Ito cells, 
perisinusoidal cells, fat storing cells or lipocytes, reside within the space of Disse and 
have been reported to act as liver-specific pericytes which contain perisinusoidal and 
intrahepatocellular branching processes with smooth muscle-specific intermediate 
desmin-like and actin-like filaments that encircle neighbouring sinusoids (Pinzani et 
al. 1992; Friedman 1997). Multiple physiopathological functions have been identified 
in HSCs, such as synthesis and secretion of extracellular matrix (ECM) and cytokine 
production following their activation that transforms them into myofibroblast-like 
cells. They control ECM turnover in the space of Disse by secreting the correct 
amounts of ECM molecules, and by releasing matrix metalloproteinases and their 
inhibitors (Geerts 2001). Hence, they are proposed to be a key mediator in the process 
of hepatic fibrosis (Friedman 1997). They are also believed to act as the effectors in 
response to various vasoactive substances (e.g. ET) for controlling sinusoidal diameter 
through their dendrites that ramify over the sinusoids (section 1.3.3.3). HSCs can be 
distinguished under fluorescence microscope by their characteristic autofluorescence 
derived from intra-cellular retinoids (i.e. vitamin-A substances) on ultraviolet light 
epi-illumination due to their role in storage and controlled release of retinoids (Geerts 
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2001). The loss of vitamin A-storing capacity is commonly associated with HSC 
activation (Bachem et al. 1992) (Chapter 3). 
1.2.5 Other hepatic cell types and their functions 
Under physiological conditions, the liver also contains other nonparenchymal 
cells, including fibroblasts, neurons, bile duct cells, and pit cells (Fischer and 
McFadden 1993). The pit cells are of particular interest. They are intrahepatic large 
granular lymphocytes (i.e. natural killer cells) that can eliminate a variety of tumor 
cells in an MHC-unrestricted way. The adult liver also contains other subpopultions of 
lymphocytes such as gamma delta and alpha beta T cells (Kmiec 2001). 
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1.3 Hepatic circulation 
1.3.1 The hepatic blood supply 
The liver has a dual blood supply which consists of the portal vein and the hepatic 
artery. The total liver blood flow is 1-2 L/min/1.73 m2 (average 1.5 L/min/1.73 m\ 
The arterial and portal venous components converge in the liver sinusoids and have a 
common outlet via the hepatic vein which is the drainage tract of the entire splanchnic 
circulation. Hepatic arterial blood supply to the liver is about 30 ml/min per 100 g 
liver tissue. The arterial blood flow accounts for 25% to 30% of the total blood supply 
to the liver and is controlled by mechanisms that possess many features in common 
with those of other peripheral arteries. It may provide up to 30-50% of the liver's 
normal oxygen requirement. In contrast, the portal venous inflow, which comprises the 
remaining 70% to 75% of hepatic blood supply, is largely a passive consequence of 
outflow from the intestines, spleen and pancreas (Mathie 1998). The portal venous 
blood supply is about 90 ml/min per 100 g liver weight. It normally supplies 50-70% 
of the liver's normal oxygen requirement despite its relatively high flow rate because 
of the partly deoxygenated nature of its postcapillary blood. The normal portal venous 
pressure is around 5-8 mmHg (Mathie and Wheatley 2000). The portal blood flow is 
also distinctive in its nutrient load, relatively high oxygen content, presence of 
bacterial and other toxic products, and greater pressure than other venous systems 
(Fischer and McFadden 1993). The venous drainage of the liver is primarily through 
the right, middle and left hepatic veins to the supra-hepatic vena cava (Fig. 1.2). Some 
small and medium-sized veins also drain directly to the vena cava. The caudate lobe, 
as mentioned above, has separate venous drainage. 
1.3.2 The hepatic microcirculation 
The capillary system of the liver is known as the hepatic "sinusoidal" system. The 
walls of hepatic sinusoid are lined by three different cell types: sinusoidal endothelial 
cells (SEC), Kupffer cells, and hepatic stellate cells (HSC) (Kmiec 2001). A schematic 
presentation of the hepatic microcirculation is shown in Fig. 1.4. The bile ductule is 














Figure 1.4 The micro-structure of hepatic sinusoidal system, showing the 
relationship among different cellular elements. 
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the ordinary capillary system, the endothelial lining of the sinusoid has no basal 
lamina and is more "leaky" due to the presence of open fenestrae that allow larger 
molecule to pass to the "space of Disse" where exchange of fluids, solutes, and 
macromolecules occurs (section 1.2.3). The fenestrae account for about 10% of the 
total surface area of the endothelial lining and show a lobular gradient in terms of size 
and number (Wisse et al. 1985). Liver sinusoids are also unique in that the fenestrae 
are actually dynamic structures that vary in size and number in response to various 
drugs, hormones, toxins, and diseases (Braet et al. 1998; Oda et al. 2000). Recent 
evidence suggested that each of the fenestrae is surrounded by an actin skeleton ring in 
which contractile bundles of actin and myosin regulate the size and number of 
fenestrae (Braet et al. 1995) seemingly under the control of intracellular calcium levels 
(Gatmaitan et al. 1996). Direct minute communications between the hepatic arteriole 
and portal venule can be identified under electron microscope inside the liver 
(McCuskey 1994). Such arteriovenous shunting between the hepatic arteriole and 
portal venule, although insignificant in normal hepatic microcirculation, plays an 
essential role in pathological conditions such as liver cirrhosis in which the hepatic 
sinusoids undergo the process of "capillarization" with remarkably increased 
resistance, resulting in an elevated portal venous pressure and an enhancement of 
arteriovenous shunting and the bypassing of blood through the sinusoids (Kawasaki et 
al. 1990). 
The architecture of the acinus facilitates blood from the portal vein and hepatic 
artery to flow past 10 to 20 cells before entering a central vein. Due to the fenestrations 
over the endothelial surface as mentioned above, the oncotic pressure difference 
cannot be maintained between the sinusoid and the space of Disse and the net filtration 
rate across the sinusoid is about 30 times of that in normal muscle capillary bed (Wisse 
et al. 1985). As the drop of pressure across the sinusoidal bed is only 2 to 3 mm 
(Howard and Billiar 1992), fluid flow into the space of Disse is very sensitive to 
hydrostatic pressure and any cause of increased sinusoidal resistance or post-sinusoidal 
obstruction (e.g. cirrhosis and hepatic vein obstruction as in Budd-Chiari syndrome, 
respectively) as well as other causes of elevated sinusoidal pressure (e.g. right heart 
failure) result in a remarkable elevation in trans-sinusoidal filtration. The fluid thus 
formed is drained by the hepatic lymphatic system that exits the liver through the porta 
hepatis and the hepatic (i.e. Glisson's) capsule to the diaphragmatic lymphatics 
- 15 -
(Howard and Billiar 1992; Fischer and McFadden 1993). Ascites results when the net 
trans-sinusoidal filtration rate exceeds the maximal capacity of lymphatic drainage 
which is about 20 L/day (Howard and Billiar 1992). 
1.3.3 The regulation of hepatic blood flow 
1.3.3.1 General control of hepatic blood flow 
The control of liver blood flow occurs in four distinct reg10ns: the hepatic 
arterioles, the portal venules, the hepatic venules, and the arterioles of the prehepatic 
sphanchnic bed. Because of the discrepancy in pressure between the arterial and portal 
venous system, two mechanisms exist to reduce the pressure in the hepatic arterial 
system as it combines with the portal venous system: (1) the presinusoidal arteriolar 
resistance (especially that provided by the peribiliary plexus), and (2) the intermittent 
closure of the arterioles (Rappaport 1987). Resistance to portal venous blood flow is 
minimal in the portal venules and hepatic sinusoids and is largely controlled outside 
the liver by arterial resistance vessels within the organs of the digestive tract and 
spleen (Mathie and Wheatley 2000). Hepatic arterial, but not portal venous, blood 
flow is closely regulated by neural reflexes by the periarterial neural plexus (Fischer 
and McFadden 1993). 
Other known physiological factors which affect hepatic blood flow include blood 
gas tension, sympathetic tone, and also a variety of endogenous vasoactive agents. 
Arterial blood gas tensions and pH have been shown to affect hepatic circulation. 
While hypercapnia (PaC02 > 70 mmHg) increases portal venous blood flow and 
decreases hepatic arterial flow in dogs (Hughes et al. 1979a), hypocapnia (PaC02 < 30 
mmHg) decreases both (Hughes et al. 1979b). Systemic hypoxia (Pa02 < 70 mmHg) 
causes a fall in hepatic arterial blood flow without a significant influence on portal 
venous flow (Hughes et al. 1979c). A decrease in systemic pH in metabolic acidosis 
has similar effects on hepatic circulation compared to hypercapnia, whereas metabolic 
alkalosis has no significant impact on hepatic haemodynamics (Hughes et al. 1980). 
Under these conditions, sympathetic control is believed to be the key mechanism 
responsible for hepatic arterial vasoconstriction, although results of denervation 
experiments show no evidence of sympathetic control in the maintenance of basal 
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arterial tone (Mathie and Blumgart 1983). Increase in sympathetic tone also elevates 
portal venous resistance and pressure. However, portal venous flow remains 
unaffected unless there is a simultaneous reduction in splanchnic blood flow by the 
sympathetic stimulus (Lautt and Greenway 1987a). Although both a- and ~-adrenergic 
receptors are found in the hepatic artery, only a- and ~-adrenergic receptors exist in 
the portal venous system (Richardson and Withrington 1981). The effect of 
noradrenaline is dose-dependent; while low doses cause hepatic and mesenteric arterial 
vasodilatation, vasoconstriction in both hepatic arterial and portal venous system 
occurs at high doses (Greenway and Stark 1971; Richardson and Withrington 1981). 
Other endogenous agents such as glucagon also increases hepatic blood flow due 
to its potent vasodilatory action on the mesenteric vasculature and its relatively minor 
vasodilatory effect on the hepatic arterial system. Insulin, on the other hand, has no 
remarkable effect on hepatic blood flow (Greenway and Lautt 1989). Moreover, 
bradykinin, histamine, most prostaglandins, and gastrointestinal hormones (i.e. gastrin, 
secretin, cholecystokinin, and vasoactive intestinal peptide) are also hepatic arterial 
vasodilators. While bradykinin exhibits no notable effect on the portal venous system, 
histamine has been shown to cause hepatic venous constriction or outflow obstruction 
in the dog. Prostacyclin increases portal venous blood flow through its vasodilatory 
effect on the splanchnic vascular bed, whereas it has no significant effect on the 
hepatic arterial system. NO (i.e. endothelium-derived relaxing factor, EDRF) causes 
vasodilatation over both the pre-hepatic mesenteric vasculature and the hepatic arterial 
system, resulting in a net increase in hepatic vascular inflow. On the contrary, 
angiotensin reduces both hepatic arterial and portal venous blood flow (Greenway and 
Lautt 1989). Similarly, endothelin (i.e. endothelium-derived constricting factor, 
EDCF) not only causes systemic vasoconstriction (Miller et al. 1989), it also increases 
portal venous pressure (Tanaka et al. 1994; Charrueau et al. 2002), reduces hepatic 
perfusion (Kurihara et al. 1992) and decreases sinusoidal diameter (Okumura et al. 
1994; Zhang et al. 1994) (section 1.3.3.3, Fig. 1.5). Vasopressin decreases both portal 
venous flow and pressure through its vasodilator effect on the mesenteric vascular 
beds. Another molecule of interest is 5-Hydroxytryptamine which is believed to have a 
role to play in portal hypertension due to its predominant vasoconstricting property on 
the portal venous system (Mathie and Wheatley 2000). 
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In arteries, another vasoactive substance of interest is the endothelium-derived 
hyperpolarising factor (EDHF) (Edwards et al. 1996; Zygmunt et al. 1996; Hogestatt et 
al. 2000; Coleman et al. 2001). Its release from endothelial cells is stimulated by 
muscarinic agonists such as acetylcholine (Edwards et al. 1998). In the rat hepatic 
artery, EDHF has been identified as potassium which hyperpolarizes the smooth 
muscles by gating inward rectified potassium channels and by activating the sodium-
potassium adenosine triphosphatase (Na+-K+ ATPase) (Edwards et al. 1998; Beny and 
Schaad 2000). Evidence also shows that the action of EDHF involves the gap junction 
(Edwards et al. 1999). In addition to EDHF and NO, another study demonstrated that a 
relaxing factor(s) generated by cyclo-oxygenase (COX) also contributes to 
endothelium-dependent relaxation in the rat hepatic artery (Zygmunt et al. 1998). 
1.3.3.2 The relationship between portal venous and hepatic arterial blood flow 
It has been found that hepatic arterial blood flow increases in response to a 
decrease in portal venous flow. Indeed, the elevation in hepatic arterial inflow has 
been found to buffer up to 25% decrease in portal flow (Lautt 1985). Clinically, the 
increased hepatic arterial blood flow seen after portocaval shunt or superior mesenteric 
arterial ligation can increase hepatic arterial blood flow by almost 100%, but is unable 
to achieve complete compensation (Meyers and Jones 1990). The term "reciprocal 
hepatic blood flow response" was once proposed but found inappropriate as portal 
venous flow is not altered by changes in hepatic arterial flow (Lautt 1985). The fact 
that hepatic arterial blood flow is not affected by the metabolic demands of the liver 
has been established on the results of previous studies: (1) With the total hepatic flow 
remaining constant, decreasing hepatic oxygen supply by isovolemic haemodilution 
caused an oxygen-related vasodilatation of the intestine, a decrease in portal venous 
resistance and an increase in portal venous flow, but not an increase in hepatic arterial 
blood flow which actually showed a small reduction (Lautt 1977a). (2) By stimulating 
and inhibiting hepatic metabolism pharmacologically, no apparent change in hepatic 
arterial flow was observed. Instead, the hepatic oxygen demands were maintained by 
altering oxygen extraction (Lautt 1977b). (3) The bile salts, which have been found to 
stimulate hepatic metabolism, have also been reported to cause hepatic arterial 
vasodilatation. However, the vascular and metabolic responses of the liver to bile salt 
are independent. For example, infusion of high doses of taurocholate into the hepatic 
artery in the cat caused a significant arterial dilatation without a proportional increase 
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in bile flow (Lautt 1983). The results illustrated the independent effects of bile salts on 
arterial blood flow and hepatic metabolism which are not co-related. (4) Lactic 
acidosis in dogs caused an increase in portal blood flow but a decrease, rather than an 
increase, in hepatic arterial flow, resulting in a reduction in oxygen delivery to the 
liver and a significantly reduced hepatic venous oxygen levels. (5) Chronic alcohol 
exposure in rats led to an elevated oxygen demand by the liver but caused a 
vasoconstriction of the hepatic artery. (6) Anatomically, blood flows from the portal 
region with hepatic arteriole and portal venule to hepatic venule inside an acinus. This 
anatomic arrangement excludes the possibility of back diffusion of oxygen or any 
other vasoactive substances from the pericentral region (zone 3) to periportal region 
(zone 1) where the flow-determining resistance vessels are located (Lautt 1985). 
Hence, the conclusion is that portal blood flow is a major intrinsic regulator of hepatic 
arterial tone which is unaffected by hepatic metabolic demands. In this way, hepatic 
arterial blood flow changes so as to buffer the impact of portal flow alterations on total 
hepatic blood flow (Lautt 1983). 
Several hypotheses have been proposed to explain the phenomenon, including: 
(1) Myogenic mechanisms by which change in portal pressure would serve as the 
stimulus. (2) Neural mechanisms involving a reflex control. (3) Transport of 
vasoconstrictor substance(s) in the portal blood. (4) Entering of metabolic byproducts 
into sinusoidal blood. (5) Washout mechanism by which a vasodilator substance is 
washed out by altered portal flow which controls its local concentration in the area of 
the hepatic arterial resistance vessels. However, there is a lack of evidence to support 
those mechanisms except the last one (Lautt 1985). The vasoactive substance was later 
proposed to be adenosine which is a potent endogenous vasodilator (Lagerkranser et 
al. 1984; Lautt et al. 1984 ). As a result, Lautt first introduced the term "hepatic arterial 
buffer response" using the "washout hypothesis" in which altered portal blood flow 
washes away adenosine and therefore controls its local concentration in the area of the 
hepatic arterial resistance vessels, thereby controls the vascular tone (Lautt 1985). 
1.3.3.3 The regulation of hepatic microcirculation 
Species difference has been reported on the exact location of intrahepatic vascular 
resistance (IHVR). Although the results of the majority of animal studies showed that 
IHVR would appear to be located at the level of portal venules (i.e. pre-sinusoidal) 
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(Sherman et al. 1996), it was reported to be located at the level of the hepatic venules 
(i.e. post-sinusoidal) in cats and dogs under physiological conditions (Lautt et al. 
1986). However, shifting of IHVR to pre-sinusoidal has also been reported during 
neural stimulation (Lautt et al. 1987b). Indeed, studies showed that in the liver of 
humans, guinea pigs, cats, and tupaia, nerve endings are distributed all over the 
hepatic lobules mainly in the space of Disse and are RSC-related (Ueno and Tanikawa 
1997). There was in vitro evidence showing that HSC can contract through 
neurotransmitters such as substance P that exist in the nerve endings in human liver 
(Wang et al. 1994). In addition, another study using intravital fluorescence microscopy 
(IVFM) has shown a co-location between the sites of sinusoidal constriction and the 
vitamin A-associated autofluorescence of HSC on ET-1 challenge, suggesting that ET-
1 may mediate HSC contraction by acting on their ET receptors through an autocrine 
or paracrine mechanism (Zhang et al. 1994; Rockey and Weisiger 1996). It has later 
been shown that two types of ET receptors exist. Contraction of HSC through ET 
binding to endothelin A receptor (ET AR) on its surface seems to be related to the 
enhancement of intracellular Ca2+ and inositol phosphates (Kawada et al. 1993; Mathie 
and Wheatley 2000). In this way, HSC contractility may be similar to that of vascular 
smooth muscle cells due to the presence of cytoplasmic alpha-smooth muscle actin ( a-
actin) (Ueno and Tanikawa 1997). However, HSC have also been shown to contractile 
properties even before overt phenotypic transformation when the ( a-actin) was not 
detected in the vast majority of HSC (Clemens et al. 1997). On the other hand, ET 
binding to sinusoidal endothelial cell endothelin B receptor (ET 8 R) triggers NO 
release that brings about HSC relaxation (Bauer et al. 2000). Furthermore, 
prostaglandin E2, Iloprost, and adrenomedullin cause the elevation of c-AMP levels in 
HSC and relax the cells. In addition, HSC produce NO and inhibit contractility by an 
autocrine mechanism (Kawada et al. 1993; Rockey and Chung 1995). Another 
monoxide species, carbon monoxide (CO) generated by heme oxygenase, has also 
been proposed to be a HSC relaxant (Suematsu et al. 1996). Similar to NO, CO is also 
produced by three isoforms of the microsomal enzyme heme oxygenase (HO). While 
H0-1 is highly inducible and exists in sinusoidal endothelial cells and hepatocytes, 
H0-2 is constitutively expressed in hepatocytes. On the other hand, H0-3 is a poor 
heme catalyst and may have a role to play in heme binding (Pannen 2002). Indeed, it 
has been proposed that CO is more important than NO in the regulation of portal and 
sinusoidal resistance under physiological conditions (Suematsu et al. 1994; Suematsu 
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et al. 1995). Several factors are identified as inducers of CO release from H0-1 during 
hepatic IR. These include ROS, tissue ischaemia, increase in shear stress, heme release 
from necrotic cells, bacterial lipopolysaccharides (LPS), and proinflammatory 
cytokines (Pannen 2002). Hence, HSC seem to have an important role to play in the 
hepatic microcirculation by regulating sinusoidal contraction and relaxation. In the 
cirrhotic liver, intralobular innervation is decreased or absent, but ET-1 and NO are 
overexpressed, suggesting that HSC may play a key role in the sinusoidal 
microcirculation through these vasoactive substances rather than through intralobular 
innervation in liver cirrhosis (Ueno and Tanikawa 1997). The interactions among 
HSC, SEC, and various vasoactive substances in the regulation of hepatic 
microcirculation are summarized in figure 1.5. Hence, beside the up- or down-
regulation of those vasoactive agents, the responsiveness of the target cells, including 
their expression of specific receptors and the activation status, is another key factor in 
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Figure 1.5 Regulatory mechanisms of hepatic microcirculation 
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1.4 The effect of steatosis on hepatic circulation 
1.4.1 Hepatic steatosis and its clinical significance 
Steatosis is defined as the abnormal lipid deposition other than the adipose 
tissue. It has been shown to occur in the heart, pancreas, and skeletal muscle in which 
"lipotoxic" reactions occur leading to organ dysfunction (Unger and Zhou 2001). 
Liver steatosis is commonly known as fatty liver disease the aetiology of which 
includes alcohol consumption, obesity, diabetes, steroid abuse, pregnancy, and certain 
hepatotoxic chemicals (Howard and Billiar 1992). Obesity is so prevalent nowadays 
especially in the developed nations that obesity-induced hepatic steatosis has recently 
gained much momentum in the field of hepatology. The term non-alcoholic fatty liver 
disease (NAFLD) has been given for the condition that has been described as the 
"epidemic of the new millennium". Indeed, a recent large-scaled study suggested that 
hepatic steatosis may account for up to 69% of aminotransferase elevation in the US 
(Clark et al. 2003). It has been shown that not only does hepatic steatosis involve the 
deposition of triacylglycerol and cause hepatomegaly, it also gives rise to oxidative 
stress which is believed to be an important mediator for fibrogenesis (Parola and 
Robino 2001). Indeed, hepatic fibrosis has been reported to occur in up to 65% of 100 
morbidly obese patients in whom 4% was found to show histologic evidence of 
cirrhosis. The underlying mechanisms, however, remain unclear. Recent studies also 
suggested a role of TNF-a and gastrointestinal bacteria-induced signals in the 
pathogenesis of hepatic steatosis and type II diabetes mellitus (Li et al. 2002; Li et al. 
2003), although further studies are needed to elucidate the intricate molecular 
mechanism. The clinical significance, classification, and grading of the condition are 
further discussed in Chapter 3, 4, and 6 of this thesis. 
1.4.2 Hepatic haemodynamics in steatotic liver 
The impact of steatosis on hepatic haemodynamics and microcirculation is also a 
topic of interest. It is commonly believed that steatosis compromises hepatic 
circulation (Sato et al. 1986). While it has been reported that hepatic arterial blood 
flow showed no increase to compensate for the elevated liver mass and oxygen 
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demand from steatosis in an alcoholic fatty liver model (Bredfeldt et al. 1985), the 
hepatic blood flow in obesity-induced steatotic livers has not been reported. Using the 
genetically predisposed steatotic liver model of the obese Zucker rat (section 1.6.1), 
the gross hepatic haemodynamics and the in vivo tissue oxygenation status are 
assessed in Chapter 3 of this thesis. 
1.4.3 Impact of steatosis on hepatic microcirculation 
A significant reduction in hepatic microcirculation has also been demonstrated 
in human steatotic liver (Seifalian et al. 1997). In animals, the microcirculation of 
steatotic liver has also been widely studied both in vitro and in vivo. Reduction in 
sinusoidal volume and space of Disse was noted after steatosis induction with ethanol 
feeding for 12 weeks (Akamatsu et al. 1993). Narrowed, irregular sinusoids as a result 
of compression by fat-laden hepatocytes (Caraceni et al. 1999) with marked midzonal 
sinusoidal congestion (Hakamada et al. 1997) as well as enhanced Kupffer cell activity 
(Teramoto et al. 1993b) were noted in choline deficient rats with hepatic steatosis. An 
inverse relationship has also been reported between the degree of lipid infiltration and 
the drop in microcirculatory perfusion after high-cholesterol diet (Seifalian et al. 
1999). In addition, tortuous sinusoids, decreased regional blood flow and volume, as 
well as undetectable intersinusoidal flow have been demonstrated in the spontaneously 
mutated female obese Zucker rat (Sato et al. 1986). However, the clinical significance 
of the results from these studies is partially hampered by the use of different animal 
models of liver steatosis as different models may have varied hepatic microcirculatory 
patterns. Focusing on a genetically predisposed obesity model of spontaneous 
mutation, microscopic architecture of the steatotic liver and its alteration with 
increasing lipid deposition are studied in vivo in Chapter 4 and 6 of this thesis. 
1.4.4 Metabolic impact of hepatic steatosis 
Although the term non-alcoholic fatty liver disease (NAFLD) is widely used 
nowadays, there is still controversy about whether hepatic steatosis should be regarded 
as a disease of its own or merely the hepatic consequence of common metabolic 
disorders such as obesity, diabetes mellitus, and hyperlipidemia (Thaler 1980; 
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Angelico et al. 2003). However, the proposal that it is a harmless condition (Thaler 
1980) is no longer supported by recent evidence (Silverman et al. 1990; Parola and 
Robina 2001). It is now realized that the ever-increasing incidence of insulin-
resistance syndrome or so-called "syndrome X" (Reaven 1993) (which is defined by 
the U.S. National Institutes of Health according to the parameters of waist 
circumference, arterial blood pressure, and serum levels of glucose, high-density 
lipoprotein [HDL]-cholesterol as well as triglycerides) predisposes the liver to the 
gloomy condition (Marchesini et al. 2003). The remaining issue is the degree of 
systemic metabolic contribution to the aetiology of hepatic steatosis and the extent that 
a normal liver can contribute to the correction of the distorted metabolic conditions of 
obesity. To elucidate the issue, normal non-steatotic liver grafts are transplanted to 
obese recipients using genetically obese Zucker rats in Chapter 4 of this thesis. The 
impact of the procedure on both the liver graft and the metabolic status of the 
recipients are evaluated. 
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1.5 Ischaemia-reperfusion (1/R) injury of the liver 
1.5.1 The clinical significance of IR injury 
Ischaemia-reperfusion (IR) injury is encountered when an organ undergoes a 
shortage of blood supply (i.e. ischaemia) followed by restoration of blood flow (i.e. 
reperfusion). The situation can occur following an excessive loss of effective 
circulating volume followed by fluid resuscitation (e.g. haemorrhagic shock and 
severe thermal injury) or deliberately induced for therapeutic purposes such as the 
application of vascular exclusion technique (i.e. Pringle's maneuver) in major liver 
resections or during transplantation when transient cessation of blood supply to the 
liver occurs. It has now been widely recognized a significant contributor to clinical 
morbidity. A significant part of research in this thesis (Chapter 5 to Chapter 9) is 
focused on this topic. 
1.5.2 The mechanisms of hepatic IR injury (Fig. 1.6) 
1.5.2.1 Cellular elements 
Hepatic IR injury was considered to be monophasic damage brought about by 
reactive oxygen species (ROS) (Connor et al. 1992). However, current concept 
supports that hepatic IR injury is a biphasic process with different underlying 
mechanisms (Jaeschke 2000). The early phase, which occurs 0-4h post-IR, involves 
Kupffer cell activation that results in morphological changes (Caldwell-Kenkel et al. 
1991), priming (Liu et al. 1994), the release of ROS (Jaeschke and Farhood 1991) and 
proinflammatory cytokines such as TNF-a (Colletti et al. 1990) and IL-1 ~ (Suzuki and 
Toledo-Pereyra 1994). The sources of ROS have been proposed to be the xanthine 
oxidase pathway and mitochondria (section 1.5.2.4). Although initial accumulation of 
polymorphonuclear leukocytes (PMNs) begins as early as 30 to 60 min after 
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Figure 1.6 Cellular mechanisms of hepatic ischaemia-reperfusion (IR) injury 
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stage as anti-neutrophil antibody failed to protect against IR injury (Jaeschke et al. 
1992b) and myeloperoxidase activity could not be detected (Kawachi et al. 2000). 
However, in the late (or subacute) phase of reperfusion (i.e. 5-24h post-IR), PMNs 
have a pivotal role to play as reflected in the effectiveness of PMN functional 
blockade (Jaeschke et al. 1990) and prevention of PMN-induced oxidative stress with 
Mac-I antibody in alleviating IR injury (Jaeschke et al. 1993b). The fact that chemical 
inactivation of Kupffer cell also protects the liver from injury at the later stages of 
reperfusion implies that Kupffer cell-induced ROS and other inflammatory mediators 
formation as well as cell death (necrosis and apoptosis) may activate PMNs and 
predispose to the second stage damage. Generation of ROS (Jaeschke et al. 1992a) and 
inflammatory mediators such as leukotriene B4 (Hughes et al. 1992) from PMNs are 
the key events in the subacute phase of IR injury that is also characterized by more 
severe postischaemic injury and gross hepatocyte destruction (Jaeschke et al. 1990). In 
addition, a recent study further suggested that enhanced contractility of HSC after 
warm hepatic ischaemia contributes to persistent impairment in hepatic perfusion and 
mitochondrial respiration during reperfusion (Mizunuma et al. 2003). 
1.5.2.2 Adhesion molecules 
While sinusoidal accumulation of PMNs during inflammation appears to be 
independent of adhesion molecules (Jaeschke 2000), ~2 integrin/intercellular adhesion 
molecule- I (ICAM-1) interactions are necessary for PMN adhesion to the sinusoidal 
endothelium and also the subsequent transmigration (Essani et al. 1995). ~1 integrin 
and vascular cell adhesion molecule-I (VCAM-1) also appear to have a role to play in 
the process (Essani et al. 1997). On the other hand, P-selectin (Essani et al. 1998) and 
L-selectin (Lawson, Burns et al. 2000) are responsible for the initial PMN-venular 
endothelial cell interactions (e.g. rolling) that is followed by ~2 integrin/ICAM-1-
dependent adhesion (Vollmar et al. 1995). After extravasation, PMNs are adhered to 
the hepatocytes through the action of ~2 integrin and ICAM-1 (Nagendra et al. 1997). 
In the case of IR, TNF-a is released from the ischaemic liver and activates 
nuclear transcription factor-kappa B (NF-KB) (Teoh et al. 2003). As a result, the 
mRNA levels of ICAM-1, VCAM-1, P-selectin, and E-selectin are increased in 
hepatic endothelial cells, whereas both ICAM-1 mRNA and protein expression are 
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elevated in hepatocytes (Jaeschke 2000). The contribution of ICAM-1 to hepatic IR 
injury is well illustrated by the alleviated IR injury in !CAM-I-deficient mice (Yadav 
et al. 1998) and treatment with anti-ICAM-1 antibody (Farhood et al. 1995; Vollmar et 
al. 1995). Moreover, while blockade of Mac-I (CD llb) improves IR injury by 
blocking ROS formation by PMNs , an antibody against LFA-1 (CDlla) failed to 
offer protection. This may be due to damaged endothelium through which PMNs can 
come into direct contact with hepatocyte without recourse to LFA-1-dependent 
transmigration (Jaeschke 2000). The role of P-selectin in IR injury is more 
controversial (Jaeschke 2000). Although studies have shown a beneficial effect of 
applying anti-P-selectin antibody (Garcia-Criado et al. 1995; Singh et al. 1998) and 
using P-selectin deficiency mice (Yadav et al. 1999) in the process of hepatic IR, no 
well-defined scientific explanation can be given for the phenomen because: (1) P-
selectin is not expressed on sinusoidal endothelium, only on larger vessels like 
postsinusoidal venule (Essani et al. 1998); (2) No rolling of PMN occurs over 
sinusoids (Vollmar et al. 1994b); (3) The protective effect happens before PMN-
induced damage (Garcia-Criado et al. 1995). The possible explanation would be the 
blockade of P-selectin-dependent sinusoidal platelet adhesion which can cause direct 
injury and/or facilitate subsequent PMN adhesion (Jaeschke 2000; Sindram et al. 
2000). 
1.5.2.3 JR injury and mitochondria 
Ischaemia alone has been shown to inhibit the Na+/K+ pump, resulting in an 
increase in cytosolic Na+ which in turn causes an increase in cytosolic Ca2+. This then 
leads to an increase in mitochondrial Ca2+ and inner membrane permeability 
(Crompton 1999). Induction of hypoxia in isolated rat mitochondria was also found to 
impair ADP-stimulated respiration after reoxygenation. The impairment decreased 
with time of hypoxia and reoxygenation, suggesting that mitochondria play a 
pathogenic role in IR injury (Schild et al. 1997). Moreover, the decline in active 
mitochondrial respiration was found to be associated with oxidative damage to 
respiratory protein and lipid peroxidation (Schild et al. 1997). The results are 
consistent with those of another study that demonstrated a drop in antioxidant 
activities in rat subcellular organelles together with increased tissue damage on hepatic 
ischaemia and during reperfusion (Gupta et al. 1997). The improvement in respiration 
with antioxidant after hypoxia/reoxygenation further implied that oxidative stress 
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plays a part in IR injury to mitochondria (Schild et al. 1997). The role of ROS in IR 
injury will be discussed further in the next section (section 1.5.2.4). 
Mitochondria have also been found to have a pivotal role to play in the control 
of cell death under both physiological and pathophysiological conditions. A decrease 
in mitochondrial membrane potential, followed by mitochondrial uncoupling and 
generation of reactive oxygen species are believed to be the predisposing factor to 
apoptosis (i.e. programmed cell death) (Kroemer et al. 1995). Similarly, mitochondrial 
damage also appears to be a key early event in the progression to necrosis (Rosser and 
Gores 1995). Two pathways have been proposed: (1) Inhibition of oxidative 
phosphorylation without mitochondrial permeability transition (MPT) causes ATP 
depletion, ion dysregulation (e.g. mitochondrial free Ca2+) and enhanced degradative 
hydrolase activity. Also, ROS formation and lipid peroxidation can occur in the 
presence of oxygen. The resulting injury to the cytoskeleton and plasma membrane 
leads to plasma membrane bleb formation. These steps are reversible until further 
injury causes bleb rupture and cell lysis (Lemasters et al. 1987). (2) Mitochondrial 
damage with MPT results in irreversible damage and cell death (Rosser and Gores 
1995). It is now being increasingly realized that MPT is a common pathway to 
apoptosis, necrosis, and also autophagy (Lemasters et al. 1998). Therefore, although it 
is still controversial about the predominant mode of cell death (i.e. apoptosis vs. 
necrosis) in hepatic IR injury (Kohli et al. 1999a; Gujral et al. 2001), the change in 
mitochondrial permeability and membrane potential is still a reliable indicator of IR-
induced hepatocellular injury (Suematsu et al. 1992). The in vivo monitoring of 
mitochondrial membrane potential with rhodamine 123 is discussed in Chapter 5. 
1.5.2.4 Reactive oxygen species (ROS) 
Under physiological conditions, the production and removal of reactive oxygen 
species (ROS) in mitochondria are in a state of equilibrium maintained by an 
enzymatic system based on superoxide dismutase (SOD) and glutathione peroxidase 
(GPD). The former converts superoxide anions (02-•) into H20 2 which is then reduced 
to H20 by the latter (Jassem et al. 2002). It is proposed that physiological levels of free 
radicals play an important role as regulatory signalling molecules (Droge 2002). 
Depressed mitochondrial SOD activity has been demonstrated in both ischaemic and 
reperfused rat hearts (Arduini et al. 1988), indicating a diminished antioxidant defense 
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after IR injury. The excessive 0 2-. thus formed can combine with NO to form the 
cytotoxic, highly oxidant peroxynitrite anion (ONOO-) (Packer et al. 1996). In the 
presence of excessive ferrous ions that accumulate during ischaemia, H20 2 can be 
reduced to highly reactive hydroxyl radical (OH•) (Fenton reaction) which was found 
to be the predominant form (90%) of oxygen in myocardial mitochondria shortly after 
reperfusion and its levels decreased in intensity as the reperfusion progressed (Das et 
al. 1989). 
During ischaemia, xanthine dehydrogenase is converted into xanthine oxidase. 
The accumulation of hypoxanthine from the breakdown of ATP serves as a substrate 
for xanthine oxidase. The infiltration of activated PMNs is also believed to be another 
source of ROS during reperfusion (Atalla et al. 1985; McCord 1985). On the other 
hand, an important mitochondrial ROS origin is the "oxidative burst" that occurs when 
electrons escape from the mitochondrial electron transport chain as blood supply is 
restored and react directly with oxygen to form 0 2-. (Jassem et al. 2002). Indeed, it 
has been shown using isolated rat hepatocytes that mitochondria are a much more 
important source of 0 2-. during reoxygenation compared to the xanthine oxidase 
pathway (Caraceni et al. 1995). In addition, upregulation of inflammmatory cytokines 
such as TNF-a may occur during IR, resulting in mitochondrial ROS formation (Hines 
et al. 2003). Ceramide, which is a sphingolipid generated in the TNF-signalling 
pathway, has also been reported to mediate the TNF-induced ROS production in 
mitochondria (Garcia-Ruiz et al. 1997). Not only do ROS suppress mitochondrial 
respiration, they also cause damage to various molecules including lipids, protein, 
DNA, as well as the electron transport chain for oxidative phosphorylation. The 
damage may enhance further suppression in ATP synthesis, aggravation in electron 
leakage and further ROS formation (Zhang et al. 1990; Chen and Yu 1994), resulting 
in a vicious cycle. ROS generation during hepatic IR and its relation with NO will be 
further discussed in Chapter 9. 
1.5.2.5 Protease 
Despite the fact that ROS formation may cause considerable injury during 
hepatic IR, some authors claimed that ROS-induced lipid peroxidation cannot account 
for the extensive damage (Mathews et al. 1994). Moreover, there is a body of in vitro 
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evidence suggesting that PMN-induced hepatic IR injury is protease- rather than ROS-
mediated (Mavier et al. 1988; Harbrecht et al. 1993; Kim et al. 2002a) as PMNs can 
secrete several enzymes, such as myeloperoxidase and elastase from azurophil 
granules, following activation (Klempner et al. 1978; Weiss 1989). There is, however, 
a major discrepancy in the time of onset of PMN-mediated injury between the in vitro 
and the in vivo experimental settings (Jaeschke 2000). While PMN-induced injury has 
been demonstrated less than lh in vivo after PMN activation (Jaeschke et al. 1999), it 
took about l 2-15h for the in vitro damage to be evident (Ma vier et al. 1988; Harb rec ht 
et al. 1993). The major drawback of the in vivo experiments using activated PMNs is 
that the activated status of other hepatic cellular elements (e.g. hepatocytes and 
endothelial cells) cannot be sirnilated. Hence, the damage from adhesion molecules, 
including adherence-dependent ROS generation, cannot be reproduced (Jaeschke et al. 
1999). This probably can account for the effectiveness of antioxidant treatment against 
IR-injury only in vivo (Jaeschke 1991) but not in vitro (Mavier et al. 1988; Harbrecht 
et al. 1993). On the other hand, the possibility of ROS being co-factors in protease-
induced IR injury cannot be excluded (Weiss 1989; Jaeschke and Smith 1997). 
1.5.2.6 Inflammatory mediators 
1.5.2.6.1 Complement 
Although it was clear that Kupffer cell activation is the key event in the initial 
phase of hepatic IR injury, the identity of the exact mediators remains unknown 
(Jaeschke et al. 1993a). While the potent chemotactic mediator leukotriene B4 (LTB4) 
did not appear to be the candidate (Hughes et al. 1992), studies later showed that 
complement fits into the picture (Jaeschke et al. 1993a). Complement can be activated 
through release of subcellular membrane constituents (Pinckard et al. 1975) and ROS 
(von Zabern et al. 1987). By depleting complement with cobra venom factor and 
preventing complement activation with the soluble complement receptor type 1 
(sCRl), Jaeschke et al. showed that not only is complement involved in the induction 
of Kupffer cell-induced oxidative stress, it is also important in the priming of Kupffer 
cell and PMNs for further ROS generation and the promotion of PMN sequestration in 
the liver during reperfusion (Jaeschke et al. 1993a). The enhanced PMN accumulation 
during inflammation was later found to be due to the up-regulation of Mac-1 
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expression on PMNs (Witthaut et al. 1994). Accordingly, another study showed that 
sCRl treatment significantly improved hepatic microcirculation, reduced the number 
of adherent leukocytes, and decreased liver transaminases on reperfusion following 70 
min of warm hepatic ischaemia (Lehmann et al. 2001). 
1.5.2.6.2 Cytokines and chemokines 
Cytokines such as TNF-a and IL-1 are generated during hepatic IR (Colletti et 
al. 1990; Suzuki and Toledo-Pereyra 1994; Lichtman and Lemasters 1999). There is a 
body of evidence suggesting that TNF-a is a significant contributor to IR-induced 
liver injury (Peralta et al. 2002). TNF-a is known to induce cell death through 
apoptosis (Leist et al. 1995). Besides, pre-ischaemic administration of monoclonal 
mouse anti-TNF-a antibodies has been shown beneficial in alleviating postischemic 
hepatic injury and suppressing apoptotic activities in isolated rat livers (Ben-Ari et al. 
2002). On the other hand, studies also demonstrate a role of IL-1 in the induction of 
hepatic IR injury. Gene transfer of IL-1 receptor antagonist into the rat liver was found 
to be protective in terms of reduction in pro-inflammatory cytokines production and 
improved survival (Harada et al. 2002). Moreover, IL-1 receptor I-knockout (IL-lRI(-
/-)) mice showed significantly reduced PMN recruitment and NF-KB activation 
compared to the wild-type mice during IR (Kato et al. 2002). There is also evidence 
suggesting that IL-12 is required for the induction and development of hepatic IR 
injury. In mice treated with neutralizing antibody to IL-12 and in mice deficient in the 
IL-12 p40 gene, IR-induced increases in gamma interferon (IFN-y) and TNF-a were 
greatly reduced. Significant reductions in liver myeloperoxidase content and 
parameters of liver injury were also noted (Lentsch et al. 1999). Another clinical study 
showed that overproduction of acute reactant cytokines (interleukin-6 from the portal 
system and interleukin-8 from the systemic circulation) during hepatic IR relates 
positively with postoperative hepatocyte injury in humans (Kim et al. 2002b ). Several 
theories have been put forward to explain the phenomenon, including up-regulation of 
adhesion molecules such as ICAM (Essani et al. 1995; Colletti et al. 1998) and/or their 
receptors ( e.g. Mac-1) (Witthaut et al. 1994; Essani et al. 1995), induction of 
chemotactic factors for neutrophils such as CXC chemokines in hepatocytes (Thornton 
et al. 1990). The correlation between hepatic IR and cytokine release is now so well-
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established that cytokines such as TNF-a, IL-1 ~' and IL-6 have been accepted as 
clinical indicators for the degree of hepatic IR injury (Kim et al. 2002b ). 
On the other hand, other interleukins were found to be protective against hepatic 
IR injury. For example, IL-13 was found to suppress macrophage production of 
proinflammatory mediators and adenovirus-based IL-13 gene transfer was 
demonstrated to be cytoprotective against hepatic IR injury in the rat (Ke et al. 2003). 
In addition, pretreatment of liver grafts with IL-10 was shown to decrease post-
transplant transaminase levels in the pig (Donckier et al. 2003). Also, exogenous IL-10 
was found to protect against hepatic IR injury by suppressing NFKB activation and 
subsequent expression of proinflammatory mediators (Y oshidome et al. 1999). 
Another study showed that endogenous IL-10 is not an important regulator of the 
inflammatory response to hepatic IR, whereas endogenous IL-13 exerts protective 
effects on hepatocytes and hepatic endothelial cells against the insult (Kato et al. 
2003). 
Chemokines may be involved in myriad of tissue responses to injury such as the 
influx of leukocytes, and the modulation of a number of other critical biologic actions, 
including angiogenesis, neoplastic growth, myo-fibroblast activation, and the response 
to viral infections. Chemokine up-regulation in the liver may be induced by almost all 
types of injury, and there is often a clear relationship between the chemokine pattern 
activated by different types of injury and the predominant subclasses of leukocytes 
which infiltrate the liver (Ren et al. 2002). Previous studies have demonstrated the 
importance of CXC chemokine expression in hepatic IR injury, including macrophage 
inflammatory protein-2 (MIP-2) and cytokine-induced neutrophil chemoattractant 
(KC) which have been shown to be potently chemotactic for neutrophils in vitro and 
reported to be involved in neutrophil-dependent inflammatory tissue injury. MIP-2 
may be involved in the initial recruitment of neutrophils to the ischemic lobe, whereas 
KC may play a more generalized role in neutrophil recruitment (Lentsch et al. 1998). 
Indeed, another study showed that Bcl-2 overexpression which decreases post-IR 
MIP-2 levels or anti-MIP-2 pretreatment appears to be more effective than 
preconditioning or anti-TNF pretreatment against inflammatory responses, 
microcirculatory disorders, and subsequent hepatic IR injury (Peralta et al. 2002). A 
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major finding of that study is that the combination of preconditioning and Bcl-2 
overexpression (which reduced the increased TNF and MIP-2 levels after IR, 
respectively) as well as the combined anti-TNF and anti-MIP-2 pretreatment totally 
prevented IR-induced hepatic injury (Peralta et al. 2002), although further back-up 
studies are needed. Another chemokine of interest is IFN-y-induced hepatic epithelial 
neutrophil activating protein which was found to be an important mediator of the local 
neutrophil-dependent hepatic injury associated with hepatic IR (Colletti et al. 1996). 
Another intriguing chemokine is MIP-la which, instead of increasing during hepatic 
IR, showed an inverse relationship with the increase in post-IR PMN activities 
(Martinez-Mier et al. 2001). Its potential protective role in the process remains to be 
elucidated. Other CXC chemokines that fit into the picture are "monokine-induced by 
gamma interferon" (MIG) and "gamma-interferon-inducible protein" (IP-10). 
Pharmacologic doses of IFN-y in an in vivo model of hepatic IR injury was shown to 
elevate hepatic levels of IP-10 and MIG, decrease hepatic levels of MIP-2, reduce the 
number of Kupffer cells, and epithelial neutrophil-activating protein, resulting in a 
decrease in neutrophil-mediated hepatic injury (Ren et al. 2002). However, CXC 
chemokines are not as potent as TNF-a, IL-1, or C5a in neutrophil activation (Bajt et 
al. 2001). 
1.5.3 Ischaemic preconditioning 
Hepatic ischaemic preconditioning is the induction of a brief period of hepatic 
ischaemia before IR and is an inducible potent endogenous mechanism against 
subsequent IR injury. It has been suggested that preconditioning could inhibit the 
effects of different mediators involved in the microcirculatory dysfunction, including 
ET (Peralta et al. 1996), TNF-a (Peralta et al. 2002; Shinoda et al. 2002), and ROS 
(Cavalieri et al. 2002; Cutrn et al. 2002; Peralta et al. 2002). In the mouse, 
preconditioning periods of 5 and 10 minutes were found to be highly protective 
against IR injury (Teoh et al. 2002). It was found to be associated with activation of 
NF-KB (Funaki et al. 2002; Takahashi et al. 2002), p38 kinase (Carini et al. 2003), and 
cell cycle entry (Teoh et al. 2002). It has also been reported to protect livers from IR 
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injury by interfering with the increase in plasma TNF-a (Peralta et al. 2002), resulting 
in the attenuation of hepatic necrosis after continuous ischaemia and significantly 
reduced necrosis and apoptosis after intermittent ischemia (Funaki et al. 2002; Iwasaki 
et al. 2002). However, another study showed that hepatoprotective effects of 
preconditioning can actually be simulated by low-dose TNF-a injection that can prime 
hepatocytes to enter the cell cycle that enhances survival of the liver against IR injury 
(Teoh et al. 2003). The reduction in ROS formation after cold ischaernia by 
preconditioning was reported to be due to diminished xanthine/xanthine oxidase 
formation (Fernandez et al. 2002; Peralta et al. 2002). Studies also showed a protective 
role of NO (Watanabe et al. 2003) in alleviating hepatic microcirculatory and 
hepatocellular injury (Koti et al. 2002) possibly by activating p38 kinase through a 
guanylate cyclase/cGK-mediated pathway (Carini et al. 2003) and counteracting the 
action of ET (Peralta et al. 1996). 
1.5.4 IR injury and hepatic microcirculation 
Hepatic microcirculatory perfusion failure is a determinant of liver dysfunction 
in warm hepatic IR injury (Vollmar et al. 1994a). The severity of IR-induced 
microcirculatory disturbances is proportional to the duration of ischaemia (Chun et al. 
1994; Vollmar et al. 1994a). One of the most obvious findings in the hepatic 
rnicrovascular bed during IR is the heterogeneous perfusion pattern as cessation of 
sinusoidal perfusion occurs over certain focal areas and slowing of blood flow happens 
in other regions (Clemens et al. 1994). Several theories have been put forward to 
explain this phenomenon. Firstly, mechanical factors have been implicated early after 
reperfusion. Ischaernia-induced energy deficiency could lead to a failure in active 
transmembrane transport which in turn causes endothelial and Kupffer cell swelling 
due to intracellular edema (Vollmar et al. 1994a). Secondly, a disturbance in the 
delicate equilibrium between NO, ET and CO (Clemens et al. 1997; Inglott and 
Mathie 2000) also leads to sinusoidal narrowings through HSC contraction (Clemens 
et al. 1997) (section 1.3.3.3). This in turn enhances leukocyte-endothelial contacts and 
promotes leukostasis that further hampers sinusoidal blood flow although most 
sinusoids containing neutrophils are still conducting flow (Chun et al. 1994; Vollmar 
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et al. 1996a). As a result, the "no-reflow phenomenon" occurs, causing hypoxic cell 
injury (Koo et al. 1992; Chun et al. 1994). In combination with the release of 
proinflammatory cytokines and ROS, this leads to the ultimate consequence of cell 
death and parenchymal failure (Cutrn et al. 2002). The impact of hepatic IR on liver 
microcirculation and hepatocellular activities is investigated and discussed further in 
Chapter 5, 6, 7, and 9 of this thesis. 
1.5.5 Hepatic steatosis and IR injury 
Hepatic steatosis is a good example of microvascular distortion (section 1.4). It 
has been reported that the mechanisms of IR-induced injury are different in steatotic 
and normal non-steatotic liver (Selzner et al. 2000). Also, enhanced hepatic IR injury 
is well-documented in the literature (Koneru et al. 1995; Hakamada et al. 1997; Taneja 
et al. 1998). The mechanisms, however, remain speculative. Although previous studies 
did shed some light on the topic, the in vivo inspection of obesity-induced changes in 
hepatic microvasculature and monitoring of changes in metabolic activities have not 
been reported. Chapter 6 of this thesis is devoted to the in vivo study of steatotic liver 
during short-term hepatic IR and relevant discussion about the issue. 
1.5.6 Nitric oxide (NO) and hepatic IR injury 
NO was first identified as the endothelium-derived relaxing factor (EDRF) 
(Furchgott and Zawadzki 1980). Its vasodilatory property can also be applied to the 
hepatic microvascular bed. Although recent evidence suggested that NO may not be as 
important as CO in the maintenance of basal microvascular tone of the liver (Suematsu 
et al. 1994; Suematsu et al. 1995), the role of NO on hepatic IR is well-established 
(Inglott and Mathie 2000; Morisue et al. 2003). The significance of NO during hepatic 
IR in livers with distorted microvascular bed is discussed in Chapter 7 where the 
impact of NO blockade in hepatic steatosis during IR is investigated. However, since 
NO is produced through iNOS and eNOS in the liver (section 1.6.2.1), controversies 
arise regarding their contribution in hepatic IR injury. While it is commonly agreed 
that eNOS is essential in the maintenance of microcirculation during hepatic IR 
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(Kawachi et al. 2000), the role of iNOS is the bone of contention. Some authors 
proposed that it is detrimental in the IR process because it gives rise to the cytotoxic 
oxidant peroxynitrite that may combined with other ROS and cause hepatocellular 
damage (Hur et al. 1999; Morisue et al. 2003). Other authors found that iNOS-derived 
NO and peroxynitrite appear to be protective during hepatic IR (Hines et al. 2002; 
Inglott and Mathie 2000; Liu et al. 2000). On the other hand, some authors failed to 
identify the significance of iNOS in the hepatic IR process (Jaeschke et al. 1992b; 
Kawachi et al. 2000; Hines et al. 2001). In an attempt to gain an insight into the issue, 
wild-type, iNOS and eNOS gene knockout mice underwent hepatic IR with the degree 
of injury measured and compared in Chapter 9. Relevant discussion can also be found 
in Chapter 7 and 9 of this thesis. 
1.5. 7 The systemic impact of hepatic IR injury 
It is proposed that hepatic Kupffer cells and pulmonary alveolar macrophages 
together constitute a macrophage-axis involved in the regulation of regional and 
systemic inflammatory responses (Liu et al. 2001). This is supported by the fact that 
enhanced neutrophil infiltration as reflected in the increased myeloperoxidase (MPO) 
activities and histopathological changes were noted in the lung following hepatic IR 
(Martinez-Mier et al. 2001). There is a body of evidence suggesting that TNF-a is 
responsible for hepatic IR-induced pulmonary injury (Colletti and Green 2001; Peralta 
et al. 2002). One of the mechanisms proposed is TNF-induced up-regulation of P-
selectin (Peralta et al. 2001). Oxidative stress has also been shown to contribute to 
post-hepatic IR pulmonary damage (Fernandez et al. 2002; Weinbroum et al. 2002). In 
addition, a protective role of NO against hepatic IR-induced lung injury is implicated 
as reflected in an augmented pulmonary vascular permeability and superoxide 
generation in the lung tissue as well as an elevation in the production of TNF-a and 
IL-I~ from isolated rat pulmonary alveolar macrophages in vitro following NOS 
blockade with N(omega)-nitro-L-arginine methyl ester (L-NAME) (Liu et al. 2001). 
Accordingly, preconditioning has also been shown to attenuate hepatic IR-induced 
pulmonary injury through alleviating TNF-a (Peralta et al. 2002) and ROS (Fernandez 
et al. 2002; Peralta et al. 2002) release from the ischaemic liver. 
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1.6 The use of animal models for research in this thesis 
1.6.1 The obese Zucker rat (fa/fa) 
1.6.1.1 Introduction: The use animal models in obesity-related study 
Because of the prevalence of obesity and obesity-related complications (Health 
1998; McCullough 2002), there is an ever-increasing demand for obesity-related 
research both in vivo and in vitro. The use of animal models for in vivo study has the 
distinct advantage of the possibility of monitoring the systemic pathophysiological 
changes on a long-term basis. The most common animal models for the study of 
obesity are 1) spontaneous mutation models, including the yellow obese mice (AY, A vy, 
Aiy) which develop obesity due to dominant mutations at the Agouti locus (Herberg 
and Coleman 1977; Moussa and Claycombe 1999), the obese (ob) mice which are 
leptin-deficient, the KK mice, the New Zealand obese (NZO) mice, the diabetes (db) 
mice (Herberg and Coleman 1977), and the obese or "fatty" (fa/fa) Zucker rats 
(Zucker and Zucker 1961). The db mouse and the obese Zucker rat have defective 
leptin receptors and are leptin-resistant although they have higher than normal serum 
leptin levels (Chua et al. 1996a); 2) genetically modified animals. This group consists 
of a series of mice with increased hepatic lipogenesis, including the A-bZIP/F, aP2-
Diptheria Toxin, AP2-SREBP-1C, fat-specific CEBPa knockout, pancreas-specific-
IGF-II, PEPCK-SREBP-la, and the Stat 5B knockout mice (Koteish and Diehl 2001); 
3) nutritional obesity models, including the induction of a surgical/chemical lesion 
over the ventromedial hypothalamic "satiety center" with resulting hyperphagia and 
feeding certain high-fat diets in rats (Tschop and Heiman 2001). These models of 
nutritional obesity, unlike the genetic ones, show no marked abnormalities in lipid 
metabolism (Zucker and Zucker 1961). Here we focus our research on the obese 
Zucker rat that acquires obesity on a genetic basis and has a body size suitable for 
various operations and physiological measurements. In this thesis, this animal model is 
used to study the hepatic haemodynamics (Chapter 3), tissue oxygenation (Chapter 3), 
metabolic/microcirculatory impact of transplantation (Chapter 4), IR injury (Chapter 
6), and the role of NO in obesity (Chapter 7). 
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1.6.1.2 The origin of the "Zucker" rat 
The obese Zucker rat was first reported by Zucker and Zucker in 1961 after their 
discovery of a spontaneous mutation in a cross between the Merck Stock M and 
Sherman rats (Zucker and Zucker 1961; Bray 1976). They designated the mutation as 
"fatty" which, after breeding experiments, appeared to be due to a single recessive 
gene. They chose the symbol fa for the fat allele and Fa for the normal such that those 
carrying 2 fatty genes (fa/fa) are obese and their littermates with one or 2 normal 
alleles (Fa/fa or Fa/Fa) are normal in appearance and body weight (Zucker and 
Zucker 1962) (Fig. 1.7). 
1.6.1.3 The genetic basis of obesity in the obese Zucker rat 
The identical behavioral and metabolic phenotype of the diabetes (db/db) mice 
and fatty (fa/fa) Zucker rats led researchers to propose that db and fa are mutations in 
homologous genes. The proposal was later proven with mapping and the fa recessive 
gene was identified on chromosome 5 (Truett et al. 1991; Chua et al. 1996b). After 
successful cloning of the ob gene and the discovery of its encoding the OB protein 
(leptin) (Zhang et al. 1994), the finding of a high level of OB protein in the db/db mice 
and fa/fa rats led to the hypothesis that the db gene might actually encode a receptor 
for OB (Coleman 1973). The hypothesis was finally proven by Chua. et al. (1996) 
who, after mapping and mutation analysis, demonstrated that the db, fa, and the gene 
encoding the receptor for OB protein ( Obr or Lepr) are the same gene. The ob gene is 
highly expressed in mature adipocytes but not in other tissues in the obese Zucker rats 
(Ogawa et al. 1995). The OB protein of the obese Zucker rat is composed of 167 
amino acids, the sequence of which is 96% and 83% homologous to those of the 
mouse and human OB proteins, respectively (Zhang et al. 1994; Ogawa et al. 1995). 
The mutation in obese Zucker rat has later been found to be a missense mutation with 
an A to C conversion at nucleotide position 806 in the leptin receptor mRNA causing a 
praline substitution for glutamine at position 269 (Chua et al. 1996b; Iida et al. 1996; 
Takaya et al. 1996). 
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Figure 1. 7 Phenotypes of Zucker rat siblings 
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1.6.1.4 Reproduction 
It has been reported that the sex organs of the male obese Zucker rats are either 
normal in size and appearance or highly atrophic (Zucker and Zucker 1962; Deb and 
Martin 1975). Restricted feeding during the period 6 to 20 weeks has been proposed 
beneficial to male sex organ development in the obese animals (Zucker and Zucker 
1962). The concentrations of androgen receptors are also reduced in prostate and liver 
of the obese male Zucker rats (Bannister and Whitaker 1985). In addition, plasma 
testosterone levels are lower in 20-week-old obese males compared to the lean rats. 
The obese male Zucker rats also show abnormal sexual performance that does 
not improve with exogenous testosterone treatment (Withyachumnarnkul and 
Edmonds 1982) or diet restriction (Edmonds and Withyachumnarnkul 1980) and are 
only occasionally fertile (Zucker and Zucker 1962). On the other hand, the female 
obese rats present with an underdeveloped uterus ( <50% of normal in weight) and are 
uniformly sterile (Zucker and Zucker 1962). Ovarian weight in the obese Zucker rats, 
however, is either lower (Bray 1969) or higher (Zucker and Zucker 1962) than that of 
their lean littermates. Although the concentrations of luteinizing hormone (LH) and 
follicle-stimulating hormone (FSH) are increased in the obese Zucker rats (Bray et al. 
1973), delayed vaginal bleeding, irregular estrus cycles (7-13 days in obese vs. 4 days 
in lean), impaired ability to induce pseudopregnancy and impaired sexual behavior 
have been noted (Zucker and Zucker 1961; Saiduddin et al. 1973; Whitaker et al. 
1983; Whitaker and Robinson 1989; Bivens and Olster 1997). In contrast, the 
achievement of pseudopregnant state and decidual response following stimulation in 
the obese Zucker rats comparable to the responses in the lean rats, suggesting that the 
possibility of implantation in the obese animals could not be excluded (Chelich and 
Edmonds 1986). Successful pregnancy in the obese female Zucker rat, however, has 
not been reported. As for the changes in gonadotropin levels, the mid-afternoon surge 
of LH during pro-estrus is reduced and the timing is less consistent in the obese rats 
(Whitaker and Robinson 1989). The results of a recent study also suggested that a 
leptin signal is required for the maintenance of a normal pulsatile pattern of LH 
secretion in the obese Zucker rat (Todd et al. 2003). However, the maximum 
concentrations of FSH and prolactin of the obese animals also decline more slowly 
during estrus (Whitaker and Robinson 1989). Moreover, the progesterone 
concentrations have been reported to be higher during most of the estrous cycle 
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(Whitaker and Robinson 1989), although the concentrations of estradiol were found to 
remain normal during pro-estrus (Whitaker et al. 1983). On the other hand, the 
concentration of estradiol receptors was found to be lower both in the uteri (Saiduddin 
and Zassenhaus 1979) and in the preoptic area (Whitaker and Robinson 1989) of the 
obese rats compared to the lean rats. However, the response of the uterus to exogenous 
estradiol showed no impairment in one study (Bray et al. 1976). Therefore, 
abnormalities may exist both in the response of peripheral target tissue to gonadal 
hormones and in the feedback of ovarian hormones to their central target sites in the 
hypothalamus in obese Zucker rats (Whitaker and Robinson 1989). Those 
abnormalities in reproductive hormones and estradiol receptors may contribute to the 
infertility of the obese female Zucker rats although the exact mechanisms remain 
unclear (Whitaker and Robinson 1989). As a result, only phenotypically normal 
heterozygous breeding pairs can be used for breeding with a 25% possibility of 
producing obese offspring (Zucker and Zucker 1961; Zucker and Zucker 1962). 
1.6.1.5 Growth and development 
Developmentally, the obese phenotype can be distinguished from normal as 
early as 23 days after birth and is quite prominent by 5 weeks when visible and 
palpable differences in body fat content and in body shape can be perceived (Zucker 
and Zucker 1962; Bray 1976; Truett et al. 2000). No sex differences in serum lipid 
profiles are observed in the lean and obese groups although the males tend to be 
heavier than the females in both groups (Zucker and Zucker 1961; Powley and Morton 
1976). Growth and food intake both show a prominent increase in the obese rats but 
not in the heterozygous or lean homozygotes (Zucker and Zucker 1961). Hyperphagia 
seems to play an important part in weight gain in the early weeks of the obese rats 
when there is little evidence for a significant decrease in physical activity (Deb et al. 
1976). There are several theories to explain hyperphagia in the obese Zucker rat. It has 
been proposed that neuropeptide Y, which normally stimulates food intake and is 
inhibited by leptin and insulin, is hyperactive in the obese rat due to its leptin 
resistance (Williams et al. 2001). Furthermore, opioid receptor stimulation (Marin-
Bivens and Olster 1999), blunted ventromedial nucleus serotonergic activity (Routh et 
al. 1994), NO (Stricker-Krongrad et al. 1996), and the differential expression of 
dopaminergic receptors in the hypothalamus have also been reported to contribute to 
hyperphagia in the obese animals (Fetissov et al. 2002). The effect of gene-dosing 
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between the Fa/fa and Fa/Fa rats is not discernible unless a high fat diet is given, when 
the heterozygous rats show a greater tendency towards overweight than their lean 
homozygous littermates (Zucker and Zucker 1962). Obese Zucker rats weigh on the 
average 52% more than their lean littermates. This difference is mainly due to the very 
high lipid accumulation in the whole body of fa/fa rats (Zucker 1972). Evidence of 
body fat mobilization has been observed in the obese Zucker rats as they used up their 
entire body lipid storage and succumbed after 51 days of total starvation, whereas their 
lean littermates, with a limited storage of body fat, died after 8 days (Zucker and 
Zucker 1962). The fat content and amount of food also have an effect on their life 
span; While high fat diet has been shown to shorten the average life span of the obese 
Zucker rat, food restriction has been found to increase its life span (Zucker and Zucker 
1962; Johnson et al. 1997). Recent evidence also showed that surgical removal of 
visceral fat could reduce insulin resistance and diabetes development in the aging 
Zucker rats (Gabriely et al. 2002). Moreover, a decrease in bone mineral density has 
been reported in the obese Zucker rat (Mathey et al. 2002). Also, the skin of the obese 
rats has been found to be more vulnerable to injury, although no evidence of impaired 
healing was noted (Zucker and Zucker 1962). 
1.6.1.6 Carbohydrate metabolism 
The use of obese Zucker rat as a model of human type II diabetes mellitus is 
mainly on the basis of its increased peripheral insulin resistance and the resulting 
hyperinsulinemia that occurs as early as 3 to 4 weeks after birth. Hyperinsulinemia in 
the obese animals has also been reported to be influenced by the quantity of 
carbohydrate in the diet and by litter size (Zucker and Antoniades 1972; Bach 1977). 
Insulin concentration in the pancreas of the obese Zucker rat is increased (Lemonnier 
et al. 1974) and glucose-induced insulin release from isolated islets is also enhanced 
(Stern et al. 1972; Schade and Eaton 1975). This is consistent with the findings of 
increased size and number of pancreatic islets (York et al. 1972; Shino et al. 1973) and 
also with an enlarged pancreas with normal conformation in the obese Zucker rat 
(Zucker and Zucker 1962). Another important contributory factor to hyperinsulinemia 
in the obese Zucker rat would appear to be parasympathetic activity-mediated increase 
in islet blood flow (Atef et al. 1992). The insulin levels can only be normalized by 
total starvation (Zucker and Antoniades 1972) or reducing food intake by 25 % (York 
and Bray 1973). Circulating concentrations of glucagon are reduced (Eaton et al. 1976; 
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Bhathena et al. 1987) despite the fact that the pancreatic glucagon levels are normal 
(Eaton et al. 1976). No significant difference in glucose tolerance after intraperitoneal 
glucose administration has been found in lean and obese Zucker rats at 5 and 50 week 
of age (Zucker and Antoniades 1972). In the literature, the reported blood glucose 
levels in the obese Zucker rats are, however, highly variable. While some authors 
report that the obese Zucker rats have higher blood glucose than the lean rats (York 
and Bray 1973; Lemonnier et al. 1974; Bach 1977; Triscari et al. 1979), others found 
no significant differences between the two groups (Zucker and Zucker 1961; Zucker 
and Antoniades 1972; Shino et al. 1973; Lemonnier et al. 1974) or even lower glucose 
levels in the obese animals (York et al. 1972). Glucose-6-phosphatase activity is 
increased in the obese animal (Taketomi et al. 1975), whereas the activity of fructose-
6-diphosphatase is either increased (Taketomi et al. 1975) or unchanged (Martin 
1974). No significant intergroup difference was noted in the level of acetyl-CoA in the 
liver (Bach 1977). The levels of pyruvate, however, is higher in the obese Zucker rat 
compared to the lean rat both in the blood and in the liver (Bach 1977). The degree of 
ketonemia in the obese Zucker rats is more controversial; while one study showed 
ketonemia in 9-week-old obese rats (Bach 1977), other authors reported a slight 
hypoketonemia in 5-month-old obese animals as compared with the leans (Malewiak 
et al. 1977). Another study showed that glucose is the main source of muscle energy 
during exercise and recovery in the lean Zucker rats. However, while the obese Zucker 
rats also utilize glucose during exercise, they depend more on lipid for energy during 
recovery (Ardevol et al. 1997). 
1.6.1.7 Lipid metabolism 
Serum lactescence (milky appearance) is universal in obese Zucker rats. A study 
on younger obese rats showed detectable hyperlipidemia by 39 days of age, although 
not sufficient to produce visible lactescence which becomes prominent only by 73 
days (Zucker 1965). The lactescence persists for up to 18 hours during fasting (Zucker 
and Zucker 1961). One of the earliest abnormalities discernible in the obese Zucker 
rats is an elevated serum lipoprotein levels (Zucker and Zucker 1962; Barry and Bray 
1969). Lipoprotein levels increase with age (York et al. 1972). One study has shown 
that 9-week-old obese rats show no sign of hyperchylomicronemia that is evident in 
12-month old animals (Bach 1977). The majority of the increase is in the low density 
lipoprotein fraction with a higher percentage of triglyceride (78%) than in the 
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corresponding lipoproteins from the lean animals (60%) (Bray 1976). Production of 
very low density lipoproteins (VLDL) by the perfused liver of the obese rat is twice 
that of livers from the lean animals (Schonfeld 1974). Serum low density lipoproteins 
(LDL) and high density lipoproteins (HDL) are twofold higher in the obese rats. 
Cholesterol levels have also been found to reach the adult levels more rapidly in the 
obese rats than the other lipid components (Zucker and Zucker 1962). Total fatty acids 
have been reported by Zucker and Zucker to be about 10 times higher in the obese 
animals, whereas the cholesterol and phosphatides are about 4 times higher (Zucker 
and Zucker 1961). Other studies have reported a 5- to 8-fold higher plasma 
triglyceride level and a 2-fold increase in plasma cholesterol and free fatty acids levels 
in the obese Zucker rats, respectively (Bray 1976; Bach 1977). The finding that the 
activity of lipoprotein lipase from adipose tissue is also increased indicates that both 
production and removal rates for lipoproteins are enhanced in the obese Zucker rats 
(Schonfeld 1974). Moreover, it has long been noticed that the increase in body fat per 
gram of food intake is higher in the obese rats than in normal animals suggesting an 
increased efficiency for food utilization (Bray et al. 1973; Zucker 1975). Indeed, it has 
been revealed that the obese Zucker rats not only demonstrate increased release of 
very low density lipoproteins (Schonfeld and Pfleger 1983), but also show increased 
activities of key lipogenic enzymes (Berke and Kaplan 1983), elevated lipid 
esterification and lipogenesis (Azain 1983), increased adipocyte hypertrophy (Bray 
1969) and hyperplasia (Johnson et al. 1971; Abadie et al. 2001). The degree of 
adipocyte hypertrophy varies with the sites of adipose cell depot ( subcutaneous > 
retroperitoneal > gonadal ) (Johnson et al. 1971). The number of adipocytes in the 
obese Zucker rats also depends on age and adipose cell depot (Johnson et al. 1971; 
Stern and Greenwood 1974). Unlike the lean rats in their adulthood, the obese rats can 
still increase the number of adipocytes in mid-adulthood (Johnson et al. 1971). 
Another interesting finding has been the sex difference in the development of 
perigenital adipose tissue with the female Zucker rats showing a 2.3-fold increase in 
the number of parametrial adipose cells compared to their lean littermates, while there 
were significantly fewer epididymal adipose cells in the male obese rats than in the 
lean counterparts (Lemonnier 1971). Blood flow has been reported to be reduced by 
more than 50% in all depots of adipose tissue of the obese Zucker rat per unit cell 
surface area. However, when cell number alone is taken into account, blood flow is 
decreased in all depots except the mesenteric depot of the obese Zucker rat. This 
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picture is compatible with the reported interdepot variation in metabolic activities 
(West et al. 1987). Lipogenesis in adipose tissue of the obese rats declines with age 
with fatty acid synthesis highest in young obese rats (5- to 7-week old) but 
subsequently falls to a lower level by 4 to 6 months of age (York and Bray 1973; York 
and Bray 1973; Martin and Lamprey 1975). In addition to hyperinsulinemia, impaired 
glucagon activity as manifested by decreased glucagon binding to target tissues has 
also been proposed to be an important contributor to the hyperlipemia and obesity in 
obese Zucker rats (Bhathena et al. 1987). The impaired fatty acid oxidation observed 
in the whole liver of the obese Zucker rat has been proposed to be due to the 
diminished transport of fatty acids across the mitochondrial inner membrane via 
carnitine palmitoyltransferase I. The decreased mitochondrial content per unit wet 
weight of liver in the obese animals has also been reported to aggravate the condition 
(Clouet et al. 1986). Another interesting finding is that, in the presence of an elevated 
free fatty acid concentration, the pancreatic islet cells of prediabetic obese Zucker rats 
have a higher lipogenic capacity than the lean controls. This has been suggested by 
some as a possible predisposing factor for their subsequent development of diabetes 
(Lee et al. 1997). Ceramide, which is a nonoxidative metabolic product of long-chain 
fatty acids and a mediator in apoptosis, has been proposed to be a potent contributor to 
~ cell dysfunction. Free fatty acid-induced ~ cell apoptosis is 7-fold higher in the 
obese rat possibly leading to the development of diabetes (Shimabukuro et al. 1998). 
Recent theories also suggested that the nonfunctional leptin receptors in obese Zucker 
rats deprive them of the protective effect of leptin which normally oxidizes excess 
fatty acids and prevents their deposition in nonadipose tissue ( or "steatosis") such as 
the skeletal muscle, heart, and pancreas, resulting in insulin-resistance, myocardial, 
and ~ cell dysfunction, respectively (Unger and Zhou 2001). Similar effect of 
lipotoxicity in the liver, however, has not been reported. These "lipotoxic diseases" 
also involve NF-KB-induced NO production which leads to peroxynitrite formation 
and apoptosis (Unger and Orci 2001). To elucidate the role of NO in steatotic liver, 
hepatic haemodynamics and microcirculation are studied after NOS blockade in 
Chapter 7. In addition, to investigate the importance of a normal liver in the regulation 
of lipid metabolism in obesity, the alterations in plasma lipid profile following 
transplantation of normal non-steatotic liver grafts to obese recipients is also studied in 
Chapter 4. 
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1.6.1.8 Cardiovascular function 
Data on blood pressure in obese Zucker rat are somewhat inconsistent (Paulson 
and Tahiliani 1992). While the majority of authors showed a mild elevation in arterial 
blood pressure in the obese animals of approximately 20 mmHg (Paradise et al. 1985; 
Kurtz et al. 1989; Bickel et al. 2001), others have found no significant difference from 
lean animals (West et al. 1987; Morgan et al. 1995). Even after high sodium diet, 
modest (Morgan et al. 1995) or no (Pawloski et al. 1992) increase in mean arterial 
blood pressure is found in obese animals. The divergence in results probably stems 
from the use of different animal colonies (Paulson and Tahiliani 1992) and, especially 
the age of the animals (Cox and Kikta 1992). In fact, the obese Zucker rats have been 
found to be hypotensive relative to their lean littermates at the age of 6-15 weeks and 
only after the age of 24 weeks do the obese rats begin to show a significantly higher 
blood pressure (Cox and Kikta 1992). To date, the obese Zucker rat has been generally 
accepted as a model of obesity-induced hypertension (Sowers et al. 1991; Van 
Zwieten et al. 1996). There have been several theories for the elevated arterial pressure 
in the obese Zucker rat. Firstly, it has been proposed that the insulin-resistant state 
leads to reduced membrane Ca2+-ATPase activity leading to an increased intracellular 
calcium concentration, a marked impairment in vascular smooth muscle Ca2+ efflux, 
and subsequently an increase in total peripheral resistance (Levy et al. 1989; Sowers et 
al. 1991). Secondly, enhanced pressor sensitivity to vasoconstrictor compounds such 
as angiotensin II and norepinephrine in the obese Zucker rat may also contribute to the 
hypertension (Cox and Kikta 1992; Zemel et al. 1992; Alonso-Galicia et al. 1996). 
Finally, the increase in the renal alpha(l)-subunit of Na-K-ATPase, the thiazide-
sensitive Na-Cl cotransporter, and the beta-subunit of the epithelial sodium channel 
(ENaC) may increase sodium retention and thereby play a role in obesity-related 
hypertension (Bickel et al. 2001). Although juvenile obese rats (9 weeks) have 
enhanced cardiac contractility (Segel et al. 1980), older animals around 20 weeks 
(Zhou et al. 2000) and 50 weeks of age (Paradise et al. 1985) have reduced 
contractility (Segel et al. 1980), left ventricular hypertrophy, and cardiac dilatation. 
Hence, the cardiac function in the obese Zucker rat seems to be age-dependent 
(Paulson and Tahiliani 1992). Cardiac steatosis has been reported to have a significant 
impact on the cardiac function of obese Zucker rat. The cardiac triacylglycerol content 
in 14 week old animals was found to be almost 3 times higher than normal (Zhou et al. 
2000). The cardiac deposition of the nonoxidative metabolic products of long-chain 
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fatty acids, ceramide, has been proposed to be an important contributor to NO-
mediated lipotoxicity and lipoapoptosis that lead to impaired cardiac function in the 
obese Zucker rats. Reduction in cardiac lipid deposition has been shown to reduce 
ceramide content, prevent apoptosis and restore cardiac function (Zhou et al. 2000; 
Unger and Orci 2001). 
One interesting finding is that, unlike human obesity, the obese Zucker rats show 
no increase in cardiac output (Crandall and Cervoni 1987; West et al. 1987). In terms 
of organ perfusion, blood flow to the organ systems has been reported to show no 
significant difference between the lean and obese Zucker rat when the organ weight is 
not taken into account. However, blood flow to the triceps surae muscle, epididymis, 
and testis per gram of tissue was found to be elevated (West et al. 1987). 
Obese Zucker rats have impaired NO-dependent arteriolar dilation in skeletal 
muscle which has been attributed to an increased vascular oxidant (Frisbee and Stepp 
2001). However, NO-dependent dilation is normal in the intestinal arterioles of the 
obese animals (Bohlen and Lash 1995). Furthermore, impairments in agonist-
stimulated, endothelium-dependent vaodilation and NO signalling are implicated in 
the pro-oxidant insult believed to provoke the onset of type II diabetes mellitus in the 
obese animal (Laight et al. 2000). Skeletal muscle insulin resistance in the obese 
Zucker rat has also been found to impair the insulin-induced increase in femoral 
arterial blood flow and skeletal muscle capillary recruitment (Wallis et al. 2002). In 
addition, the decrease in capillary recruitment after lower limb ischemia in the obese 
rat would appear to be due to a persistent vasoconstriction mediated by serotonin 
(Janiak et al. 2002). Hence, an increased sensitivity to vasoconstrictors and a 
diminished vasodilating action of NO due to its scavenging by reactive oxygen species 
seem to be the key mechanisms of vascular dysfunction in the obese Zucker rat. On 
the other hand, consistent results were obtained from two studies on the response of 
thoracic aorta from obese Zucker rat to acetylcholine and nitroprusside, showing that 
there is an enhanced vasodilatory response of the aorta from young ( 12 weeks) Zucker 
rats to acetylcholine compared to the lean animal. The same response, however, 
cannot be elicited in the obese rats older than 24 weeks (Cox and Kikta 1992; Sexl et 
al. 1995). The inhibition of the response by pretreatment with NO-synthase inhibitors 
suggested an increased NO release to acetylcholine in the young obese rats and offered 
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a plausible explanation for their lower blood pressure compared to their lean 
littermates (Cox and Kikta 1992; Sexl et al. 1995). Impaired insulin-induced vascular 
smooth muscle glucose transport has also been noted in the aorta of the obese Zucker 
rat (Banz et al. 1996). 
1.6.1.9 Hepatic circulation and metabolism 
The liver of the obese Zucker rat is 86% heavier than in nonobese controls, and 
that its relative size is significantly greater (Bach 1977). The main cause of greater 
liver weight is the higher lipid content (Bach 1977). It has been reported that there is 
as much as 69% more lipid per gram of liver weight in the obese Zucker rat (Bach 
1977). Indeed, the liver and the heart are the two major organs with increased weight 
in the obese Zucker rat (West et al. 1987). The liver of the obese Zucker rat also bears 
striking histological resemblance to human obesity-induced liver steatosis. Not only 
does it show an increase in the degree of lipid deposition from zone 1 to zone 3 of an 
acinus, it also demonstrates the pattern of macrovesicular and microvesicular fatty 
change noted in human hepatic steatosis (Burt et al. 1998). The fact that portal 
inflammation noted in the choline-methionine deficient rat model of fatty liver is 
absent in the obese Zucker rat makes the latter more suitable for the study of obesity-
induced Ii ver steatosis (Hakamada et al. 1997). Metabolically, no significant difference 
in oxygen consumption or oxidative capacity of hepatocytes from young male obese 
and nonobese Zucker rats in vitro has been found (Wardlaw and Kaplan 1986). There 
is an increase in hepatic glycogen levels in the obese Zucker rats compared to the lean 
rats (Bach 1977; Triscari et al. 1979). The hepatic blood flow is remarkably decreased 
in the steatotic liver of the obese Zucker rat (Sato et al. 1986). In terms of hepatic 
microcirculation, tortuous sinusoids, the absence of intersinusoidal sinusoids and a 
decrease in hepatic vascular bed have also been reported (Sato et al. 1986). The 
clinical significance of liver steatosis also includes increased susceptibility to 
ischemia/reperfusion (IR) injury and the unsuitability of its use as a donor graft in liver 
transplantation. While enhanced vulnerability to IR injury is well-documented for the 
obese Zucker rat liver (Taneja et al. 1998), there is still controversy about the latter 
issue (Fishbein et al. 1997; Urena et al. 1999). One of the major drawbacks in the use 
of the steatotic liver from obese Zucker rat is in the study of liver cirrhosis. As it has 
been reported that leptin is an important mediator in fibrosis (Ikejima et al. 2002; 




various fibrogenic agents and potentially produce false-negative results not applicable 
to clinical conditions. 
1.6.2 The nitric oxide synthase (NOS) gene knockout mice 
1.6.2.1 Background: Nitric oxide and its biological properties 
In 1977, Murad et al. first reported that NO activated guanylate cyclase which 
could convert GTP into cGMP. Contrary to popular belief, he also proposed that 
cGMP brought about smooth muscle relaxation (Arnold et al. 1977). In 1980, 
following Furchgott's description of an endothelium-derived relaxing factor (EDRF) 
which mediates blood vessel relaxation by acetylcoline (Furchgott and Zawadzki 
1980), much research focused on identifying the nature of the molecule which was 
finally confirmed by Ignarro to be NO (Ignarro et al. 1987). As a result of these 
important discoveries, these three scholars were awarded the Nobel Prize of 
Physiology in 1998 (Reference to http://www.almaz.com/nobel/). 
NO is a reactive and highly unstable radical with a half-life of less than 5 sec. It 
is a readily diffusible gas synthesized in mammalian cells from L-arginine by a family 
of three NO synthases (NOS) which are neuronal NOS (nNOS), inducible NOS 
(iNOS) and endothelial NOS (eNOS) (Michel and Feron 1997; Mashimo and Goyal 
1999). The biosynthesis of NO from the catabolism of L-arginine is a multistep 
process that involves the five electron oxidation of nitrogen. The process is catalyzed 
by NOS which is a cytochrome P 450-type of enzyme with a heme complex which is 
believed to be the active site for its reactivity. This reaction is largely the same as 
other monoxygenase-type reactions that involve an initial two-electron oxidation that 
is aided by one molecule of NADPH to form the unstable intermediary N-hydrox L-
arginine (Fig. 1.8). It is believed that this is rapidly catalyzed again by NOS, and 0.5 
molecules of NADPH per reaction act as a cofactor for the addition of a second 
oxygen molecule to result in a three-electron transfer and the generation of L-citrulline 
and NO (Stamler and Feelisch 1996). It has recently been found that there is 
competition between NOS and the enzyme arginase which catalyzes the formation of 
ornithine and urea from arginine. The nomenclature of the NOS isoforms reflected the 
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origins of their first discoveries. Both nNOS and eNOS were thought to be 
constitutively present and thus were also known as "cNOS". However, later studies 
revealed that both eNOS and nNOS may also be induced under different physiological 
or pathological conditions (e.g., haemodynamic shear stress or nerve injury) 
(Forstermann et al. 1998). On the other hand, inducible or iNOS may function as a 
"constitutive" enzyme under physiological conditions in some cells (Guo et al. 1995). 
As for the sources of the enzymes, an important level of nNOS actually exists in 
skeletal muscle. The same situation applies to iNOS and eNOS. The former occurs not 
only in macrophages but also in hepatocytes, chondrocytes, endothelial cells and 
fibroblasts, while the latter can be found in blood platelets, the bronchial tree, cardiac 
myocytes, and pyramidal cells of hippocampus of the brain (Snyder 1995). To add to 
the confusion, the human genes for the NOS isoforms are officially categorized in the 
order of their isolation and characterization; thus, the human genes encoding nNOS, 
iNOS, and eNOS are termed NOS 1, NOS 2, and NOS 3, respectively (Michel and 
Feron 1997). 
The NOS isoforms share several common biochemical features. Their overall 
amino acid sequence identity is approximately 55%. Also, they have similar overall 
catalytic scheme (i.e. 5-e-oxidation of the terminal guanido nitrogen of L-arginine; 
involving cosubstrates e.g. 0 2, NADPH and numerous redox cofactors). Finally, for all 
isoforms, NO synthesis depends on the enzyme's binding to calmodulin despite the 
fact that iNOS appears to be able to bind with extremely high affinity even at resting 
intracellular calcium ion concentration (at the range of nanomolar). The NOSs have 
their specific tissue specificity. For example, nNOS expression in neurons and skeletal 
muscle is different due to tissue-specific splicing of nNOS mRNA, resulting in the 
production of structurally distinct protein molecules. Similarly, the association of 
eNOS with different isoforms in endothelial cells and cardiac myocytes results in the 
production of NO with different biological consequences (Alexander 1998). 
Due to its short half-life (i.e. less than 5 seconds), NO mainly acts within the 
cells in which it is synthesized or in interactions with nearby cells and molecules. It 
may be stabilized or degraded through interacting with diverse intra- or extracellular 
chemical moieties. The biological role and chemical fate may also be affected by the 








































The reaction involves five-electron oxidation of nitrogen: Two-electron oxidation with one molecule of NADPH forms the 
unstable intermediary N°-hydroxy-L-Arginine. The reaction is rapidly catalyzed again by NOS, with 0.5 molecules of NADPH 
per reaction acting as a cofactor for the addition of a second oxygen molecule to result in a three-electron transfer and the 
generation of L-citrulline and NO. 
1.6.2.2 Development of the nitric oxide synthase gene knockout mice and its 
pathophysiolo gical significance 
The use of various specific NOS inhibitors in animals to elucidate the role of 
each NOS is limited by the specificity, bioavailability and the difficulty in long-term 
administration of the drugs. Also, because of complex and overlapping expression 
patterns (Marletta 1994; Nathan and Xie 1994), the particular NOS isoform involved 
in many processes is not clear. In fact, NO generated by separate isoforms may have 
different roles and potentially opposing effects (Iadecola 1997). As a result, specific 
deletion or "knockout" of genes in whole animals has been developed to generate mice 
lacking nNOS, iNOS, and eNOS (designated nNOS-/-, iNOS-/-, and eNOS-/-, 
respectively) (Mashimo and Goyal 1999). Since the use of NOS knockout mice in this 
thesis focuses on the role of different NOS isoforms in hepatic ischaemia-reperfusion 
(IR) injury (Chapter 9), only iNOS-/- and eNOS-/- mice are used as experimental 
groups because nNOS has not be reported to have a significant role to play in the liver. 
The molecular basis for the development of iNOS-/- and eNOS-/- mice and the 
procedures for genotyping are described in section 8.1 of this thesis. 
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1.7 Nitric oxide in the cardiovascular system 
Since the ground-breaking discoveries concerning NO as a signalling molecule in 
the cardiovascular system less than two decades ago, many studies have focused on the 
role of this intriguing molecule in the regulation of systemic and local 
haemodynamics. Instead of merely being the "endothelium-derived relaxing factor 
(EDRF)" as it was first identified, NO has now been found to have a much more 
complicated role to play in the regulation of cardiac function. It also has a variety of 
physiological impacts on the peripheral vascular system. The use of different NOS 
gene knockout mice and NOS blockers has shed considerable light on the role of 
different NOS isoforms in the cardiovascular system. The systemic and hepatic 
haemodynamics of the iNOS and eNOS gene knockout mice are further studied in 
Chapter 9 of this thesis. 
1.7.1 Nitric oxide and systemic haemodynamics 
NO donors have long been known to cause relaxation of vascular smooth muscle 
(Mashimo and Goyal 1999). In the cardiovascular system, endothelial NO is important 
for the regulation of vascular tone, systolic and diastolic cardiac function, vascular 
proliferative responses to injury, platelet aggregation, and hemostasis (Huang 2000). 
eNOS knockout mice have been reported to be hypertensive (Huang et al. 1995; Kojda 
et al. 1999; Yang et al. 1999) and mice with transgenic overexpression of eNOS are 
hypotensive (Ohashi et al. 1998). The hypertension in eNOS-/- mice was believed to 
be solely due to systemic vasoconstriction as a result of the lack of tonic vasodilatory 
effect from eNOS-mediated NO formation. Indeed, isolated aortic rings from eNOS 
knockouts failed to relax to acetylcholine (Ach) indicating the absence of endothelium-
dependent vasodilation (Huang et al. 1995; Kojda et al. 1999). Also, pharmacological 
blockade of NO activities in eNOS-/- mice causes no further increase in blood pressure 
(Kojda et al. 1999). A study using aorta from wild type (WT) and eNOS-/- mice 
showed that there is increased sensitivity of vessels to NO donor from eNOS-/-
animals in which soluble guanylate cyclase (sGC) was found to be the site of 
upregulation in the sGC - cGMP signalling pathway (Hussain et al. 1999). Although 
the blood pressure is elevated in eNOS-/- mice, left ventricular (L V) chamber 
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dimension, basal L V pressure, maximal rate of L V force development, shortening 
fraction and ejection fraction (indicators of L V contractility), and cardiac output are 
similar in WT and eNOS-/- mice (Yang et al. 1999; Gyurko et al. 2000; Godecke et al. 
2001). However, the heart rate is significantly lower in the eNOS-/- mice compared to 
the WT as is observed in WT animals being given NO blockers (Yang et al. 1999). 
Baseline ventricular relaxation is found to be normal in eNOS-/- mice but is impaired 
in WT mice after NOS inhibition. However, cGMP levels in the left ventricle are 
similar in both groups of animals. On the other hand, the expression of atrial 
natriuretic peptide (ANP), which is another physiological regulator of cGMP and 
exerts a chronic hypotensive effect via a decrease in total peripheral resistance (TPR) 
(Melo et al. 1998), was found to be markedly upregulated in the eNOS-/- mice 
(Gyurko et al. 2000). These indicate that LV function in eNOS-/- mice is well 
compensated. 
eNOS immunostaining has been found to be located over the macro- and 
microvascular endothelium throughout the myocardium in WT mice and is absent in 
eNOS-/- mice (Gyurko et al. 2000) and eNOS expression in cardiac myocytes has been 
reported to account for 20% of total cardiac eNOS (Godecke et al. 2001). In an in vitro 
study of the rat, isolated ventricular myocytes with decreased eNOS activity exhibited 
increased inotropism to beta-adrenergic agonist isoproterenol (Belhassen et al. 1996). 
The same finding was noted in another in vivo study using eNOS-/- mice which 
showed an increased left ventricular baseline contractility towards isoproterenol as 
compared with the WT mice. The beta-adrenergic receptor binding, however, was not 
significantly different in the two groups of animals (Gyurko et al. 2000). The results, 
however, are in contrast to those of another in vitro study which showed an increase in 
beta-adrenergic receptor density by 50% in eNOS-/- hearts (Godecke et al. 2001). 
Moreover, while LVP was enhanced in eNOS-/- hearts by another beta-adrenergic 
agonist, dobutamine, the L-type Ca2+ currents (ICa,L) in isolated cardiomyocytes of 
WT and eNOS-/- hearts showed no differences after beta-adrenergic stimulation. The 
results suggested that endothelium-derived NO is important in mediating the whole-
organ effects (Godecke et al. 2001). However, the contractile effects of dobutamine 
could be inhibited almost completely by ACh or adenosine but the extent of the anti-
adrenergic effect of both compounds was identical in WT and eNOS-/- hearts, 




adenosine (Godecke et al. 2001). Other papers in the literature have demonstrated 
negative inotropic (Finkel et al. 1992) and chronotropic (Romeo et al. 1992) effects of 
NO on cardiomyocytes (Murohara et al. 1998; Yogo et al. 2000). In addition, 
bradykinin is known to stimulate NO production in skeletal muscle, heart and kidney. 
It has been shown that although bradykinin caused no decrease in oxygen consumption 
in the hearts from eNOS-/- mice, a significant decrease in myocardial oxygen 
consumption was noted when the hearts of the eNOS-/- mutants were co-incubated 
with canine coronary microvessels and the effect was abolished by L-NAME. The 
results then suggest that coronary microvessels can regulate cardiac oxygen 
consumption through a NO dependent mechanism (Pittis et al. 2000). 
On the other hand, eNOS may also be involved in establishing the baroreceptor set 
point (Huang et al. 1995). Indeed, it has been reported using eNOS gene-transfected 
rats that eNOS also has a role to play in the brain in the control of blood pressure and 
the sympathetic nervous system as overexpression of eNOS in the nucleus tractus 
solitarii decreases blood pressure, heart rate, and sympathetic nerve activity in the 
conscious animals (Sakai et al. 2000). Moreover, NO and NOS inhibitors have been 
shown to affect baroreceptor responses (da Silva et al. 1994; Scrogin et al. 1994; 
Matsuda et al. 1995). eNOS has also been reported to be responsible for the blood 
pressure buffering effect of endogenous NO as reflected in the enhanced blood 
pressure variability in eNOS knockout mice (Stauss et al. 1999). 
Moreover, studies using eNOS-/- mice have also revealed a role of eNOS-derived 
NO in modulating pulmonary vascular tone and in attenuating the development of 
chronic hypoxic pulmonary hypertension (Fagan et al. 2000). An interesting study 
showed that hypoxic mice developed severe pulmonary hypertension with a right 
ventricular systolic pressure up to 60 mmHg as compared with 27 mmHg in normoxic 
mice. Using quantitative reverse-transcription PCR, expressions of eNOS and 
inducible NOS (iNOS) in the lung were found to increase 1.5-fold and 3.5-fold, 
respectively. In addition, the level of lung eNOS protein was increased, neuronal NOS 
(nNOS) protein was unchanged, and iNOS was below the limit of detection. 
Immunohistochemistry demonstrated no change in lung iNOS or nNOS staining in 
either central or peripheral areas, but suggested increased eNOS in the periphery 
- 57 -
\ 
following hypoxia. The results suggest that in mice, hypoxia is associated with 
increases in lung eNOS, possibly in iNOS, but not in nNOS (Fagan et al. 2001). 
NO from iNOS also plays a role in vasodilation, particularly in pathological states, 
and is responsible for hypotension during severe inflammatory conditions (Mashimo 
and Goyal 1999). Better cardiac performance 7 hours after endotoxin challenge in 
iNOS knockout mice as compared with the WT also implies that NO produced through 
NOS2 is required for the development of systolic and diastolic dysfunction in murine 
sepsis (Ullrich et al. 2000). However, since the set point for systemic blood pressure is 
regulated through interaction of cardiac, neuronal, humoral and vascular mechanisms, 
NO may also have a role to play in the renin-angiotensin system and autonomic 
nervous system. Indeed, a functional feedback balance has been proposed to exist 
between both angiotensin II and NO. For example, the impairment in NO-dependent 
vascular relaxation in diabetes and atherosclerosis can be restored by decreasing the 
synthesis and/or blocking the action of angiotensin II (Raij 2001). On the other hand, 
lack of NO production from eNOS has also been implicated in the development of 
cardiac abnormality such as bicuspid aortic valve (Lee et al. 2000b ). However, absence 
of NO release from eNOS has been shown not to be the single most important factor 
for the development of long-term complications of hypertension such as cardiac 
hypertrophy (Yang et al. 1999) and reduced left ventricular function (Kuhlencordt et 
al. 2001b). Furthermore, NO from eNOS is implicated in the protection of the heart 
against infarction (Jones and Lefer 2000). NO derived from eNOS has also been 
shown to participate in the protective effect of angiotensin-converting enzyme 
inhibitors against myocardial infarction (Yang et al. 1999). Indeed, impaired 
cardioprotective effects of NO has been implicated in the causation of myocardial 
infarction in which the missense Glu298Asp variant of the endothelial nitric oxide 
synthase (eNOS) gene has been identified a risk factor (Shimasaki et al. 1998). 
NO from nNOS has also been implicated in the regulation of systemic 
haemodynamics. A study using isolated atrial preparations with an intact right vagus 
nerve from WT (nNOS+/+) and nNOS-/- mice showed that the rate of decline in HR 
during vagal nerve stimulation was slower in nNOS-/- compared with nNOS+/+ atria 
in vitro and selective nNOS inhibition attenuated the decrease in HR in nNOS+/+ atria 
but had no effect on nNOS-/- atria. However, the NO donor sodium nitroprusside 
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significantly enhanced the magnitude of the vagal-induced bradycardia in all atria, 
showing the downstream intracellular pathways activated by NO were intact. The 
results suggested that neuronal NO facilitates vagally induced bradycardia via a 
presynaptic modulation of presynaptic modulation of neurotransmission (Choate et al. 
2001). The results are in consistent with those of another study which demonstrated 
that chronic oral L-NAME treatment induced bradycardia in both control and eNOS-/-
mice, suggesting that both eNOS and other isoforms of NOS might be involved in 
heart rate control (Kojda et al. 1999). Another study has shown that a cardiac muscle 
nNOS isoform is located on sarcoplasmic reticulum (SR) of cardiac myocytes, where it 
may respond to intracellular Ca2+ concentration and modulate SR Ca2+ ion active 
transport in the heart. The isoform was reported to be larger than the brain NOS and 
inhibit SR Ca2+ uptake (Xu et al. 1999). 
I. 7.2 Nitric oxide and the vascular system 
Similar to their vulnerability to myocardial infarction, eNOS mutant mice have 
been shown to develop larger brain infarcts and exhibit a more pronounced 
haemodynamic effect of vascular occlusion when subjected to focal ischaemia (Huang 
1999). Accordingly, another study using iNOS-/- mice in a chronic cardiac rejection 
model showed that NO from iNOS is important in the prevention of transplant 
arteriosclerosis by suppressing neointimal smooth muscle cell accumulation (Koglin et 
al. 1998). Later, another group showed that eNOS also plays a protective role in 
allografts against atherosclerosis. Besides, in eNOS-deficient allografts, early 
overexpression of iNOS is capable of preventing the development of allograft 
arteriosclerosis. It has therefore been proposed that in allografts with dysfunctional 
vascular endothelium and impaired eNOS activity as a result of ischaemia or native 
arteriosclerotic disease, iNOS gene therapy may serve to improve their long-term 
survival and function (Lee et al. 2000a). 
A study using apolipoprotein E (apoE)/eNOS-double knockout (DKO) and apoE-
knockout (KO) control animals showed that, after 16 weeks of high cholesterol diet, 
apoE/eNOS-DKO mice showed significant increases in atherosclerotic lesion area of 
93.6% and 59.2% compared with apoE-KO mice. All apoE/eNOS-DKO animals 
studied developed peripheral coronary arteriosclerosis, associated with perivascular 
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and myocardial fibrosis, whereas none of the apoE-KO mice did. Also, increased left 
ventricular wall thickness and decreased fractional shortening were also noted in the 
DKO animals. Male DKO animals also developed atherosclerotic abdominal 
aneurysms and aortic dissection. The results imply that hypertrophy and reduced left 
ventricular function cannot be explained by increased blood pressure alone, because 
eNOS-KO animals do not develop these complications (Kuhlencordt et al. 2001b). 
Another relevant study using apoE/iNOS-DKO and apoE (-/-)/iNOS (+/+) mice on a 
high fat diet revealed that there was a 30-50% reduction in atherosclerotic lesion area 
in the aortic root at 16 weeks in the former compared with the latter. The former also 
showed significant reductions of 45-70% in aortic cholesterol level at 22 week. The 
results indicate that iNOS contributes to the size of atherosclerotic lesions in apoE-
deficient mice, possibly through a direct effect at the site of the lesion (Detmers et al. 
2000). The antiatherosclerotic effects of high-density lipoprotein (HDL) cholesterol 
and HDL apolipoproteins ApoA-I have also been attributed to NO derived from 
eNOS; in an in vitro study, it was demonstrated that HDL activates eNOS via SR-BI 
through a process that requires ApoA-I binding (Yuhanna et al. 2001). Inducible nitric 
oxide synthase (iNOS) is expressed by leukocytes and smooth muscle cells in 
atherosclerotic lesions. By using apoE/iNOS-double knockout (dKO) and apoE-
knockout (KO) control mice, a study showed that genetic deficiency of iNOS 
decreases diet-induced atherosclerosis and lowers plasma levels of lipoperoxides, a 
marker for oxidative stress, in apoE-KO animals, suggesting that a reduction in iNOS-
mediated oxidative stress could partly explain protection from lesion formation in dKO 
animals (Kuhlencordt et al. 2001a). 
NO has also been found to modulate vascular growth and repair. By studying the 
chronic morphological changes (i.e. neointimal formation and reduction of cross-
sectional vascular area (constrictive remodeling)) of the left common carotid artery 
after its being ligated in the WT, eNOS-/- and iNOS-/- mice for 4 weeks, it was shown 
that different NOS isoforms exerted different vasculoprotective effects caused by 
blood flow disruption in vivo: NO derived from eNOS inhibits neointimal formation, 
whereas NO derived from iNOS suppresses the development of constrictive 
remodeling (Y ogo et al. 2000). Another study, however, demonstrated that mechanical 
vascular injury in vivo and in vitro induces iNOS expression and that lack of iNOS 
expression attenuates neointima formation after perivascular arterial injury, suggesting 
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that iNOS expression after vascular injury may promote neointima formation (Chyu et 
al. 1999). Furthermore, NO from eNOS has also been reported to be important in 
angiogenesis after ischaemic injury of hindlimbs in both rodent and murine models. It 
was found that not only did oral L-arginine supplementation improve angiogenesis 
after tissue ischaemia, an impaired angiogenesis in eNOS-/- mice was also noted after 
the ischaemic insult versus WT controls. Also, the failure in improvement in 
angiogenesis in the eNOS-/- mice after vascular endothelial growth factor (VEGF) 
administration suggests that eNOS acts downstream from VEGF (Murohara et al. 
1998). 
NO also has a role to play in the regulation of renal haemodynamics. In the rat, 
nNOS expression was detected in the renal cortex and eNOS expression was noted 
only in the inner medulla (Kumar et al. 2003), whereas iNOS seems to exist in two 
distinct fractions: (1) The "tubular" fraction was reported to be present even in sham-
operated rats, and (2) The "interstitial" fraction which was observed only in the 
inflammatory portions of the post-partial nephrectorny kidney (Fujihara et al. 2002). 
Constitutive isoforms of NOS (i.e. nNOS and eNOS) have been identified in the 
juxtaglomerular apparatus in which NO attenuates the efficacy of renal blood flow and 
decreases the sensitivity of the tubuloglomerular feedback by inhibiting Ca++ influx 
mainly in the afferent arteriole (Kramp 2000). NOS inhibition with L-NAME has been 
found to increase renal vascular resistances and decrease the glomerular filtration 
coefficient (Gabbai 2001). eNOS-derived NO in particular appears to be important in 
the maintenance of normal renal blood flow as L-NAME has been reported to decrease 
renal, especially medullary (Wickman et al. 2001), blood flow in the wild-type mice 
but not in the eNOS-/- mutants (Beierwaltes et al. 2002). On the other hand, NO may 
have opposing effects on renin secretion depending on the source of NO (Kramp 
2000). A body of evidence suggests that high levels of iNOS-derived NO may inhibit 
eNOS activity, resulting in renal vasoconstriction and reduced glomerular filtration 
rate (Gabbai 2001). Alterations in NOS expression have also been implicated in 
pathological conditions such as hypertension in which diminished expression of 
constitutive NOS isoforms (i.e. nNOS and eNOS) with reduced renal blood flow was 
noted using the spontaneously hypertensive rat model (Kumar et al. 2003). Similarly, 
reduced eNOS protein was reported to be associated with a reduction in medullary 
blood flow in rats with renovascular hypertension (Wickman et al. 2001). Up-
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regulation of eNOS in renal microvasculature has also been suggested to contribute to 
the preglomerular and postglomerular vasodilation as well as increased glomerular 
capillary pressure characteristic of early diabetes (De Vriese et al. 2001). 
1. 7.3 Summary 
In brief, the currently known functions of NO in the cardiovascular system 
include: ( 1) Regulation of systemic blood pressure via the sGC - cGMP signalling 
pathway, central nervous system, modification of baroreceptor response and 
interaction with angiotensin II; (2) Facilitation of vagal-induced bradycardia via a 
presynaptic modulation of neurotransmission; (3) Negative inotropic and chronotropic 
effects on cardiomyocytes; (4) Regulation of myocardial oxygen consumption. (5) 
Modulation of vasomotion; (6) Inhibition of platelet aggregation (i.e. antithrombotic); 
(7) Inhibition of adhesion molecule expression (i.e. anti-inflammatory); (8) Anti-
atherosclerotic through its anti-oxidative properties; and (9) Modulation of 
angiogenesis through its regulation of intimal and smooth muscle proliferation. 
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1.8 Theme development of this thesis 
1.8.1 Objectives of the research in this thesis 
Although extensive research has been undertaken worldwide on the prevalent 
pathological condition of obesity-related hepatic steatosis (i.e. non-alcoholic fatty liver 
disease) that has reached an epidemic level, there are still some key questions 
remained unanswered: 
1. How does obesity affect hepatic circulation? Does those changes in hepatic 
haemodynamics affect the basic cellular needs ( e.g. oxygenation) of the organ? 
2. Exactly what causes changes in hepatic perfusion in the fatty liver? Are there any 
alterations in hepatic microvascular structure that we can identify in vivo? 
3. Although hepatic steatosis has been accepted as a disease, there are still questions 
about the primary or secondary nature of the condition. While the steatotic liver is 
considered not ideal as donor graft for transplantation, are obese patients suitable to 
act as recipients with their underlying metabolic disorders? Would those disorders be 
improved with a normal non-steatotic liver? 
4. Is obesity-related steatotic liver more susceptible to the clinical condition of warm 
ischaemia-reperfusion (IR) injury? If so, any early in vivo alterations in subcellular 
activities that can be detected? 
5. Does nitric oxide (NO), which is one of the key molecules in vascular tone regulation, 
have a role to play in the steatotic liver? Is it protective against or detrimental to the IR 
process in hepatic steatosis? 
6. If NO does have a role to play in IR injury, what are the contributions of the eNOS 
and iNOS isoforms to the process? 
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The aims of the work presented in this thesis are: 
(i) To gain an insight into the impact of hepatic steatosis on hepatic haemodynamics and 
microcirculation as well as the effect of the distorted hepatic microcirculation in 
steatotic liver on tissue oxygenation (Chapter 3). 
(ii) To study the significance of systemic metabolic environment m the aetiology of 
hepatic steatosis and the metabolic impact of a normal non-steatotic liver on the obese 
recipient (Chapter 4). 
(iii) To explore the clinical significance of hepatic steatosis in warm ischaemia-reperfusion 
injury (Chapter 6). 
(iv) To examine the role of the vasoactive free radical, NO, in hepatic haemodynamics and 
microcirculation of the steatotic liver under normal conditions and during IR (Chapter 
7). 
(v) To investigate the role of different NOS isoforms in the liver in hepatic IR injury by 
using iNOS and eNOS gene knockout mice (Chapter 9). 
1.8.2 Layout of this thesis 
The first part of the thesis focuses on the study of hepatic haemodynamic 
alterations in the steatotic liver and its impact on tissue oxygenation. Secondly, the 
effect of systemic metabolic conditions on the etiology of hepatic steatosis was 
examined by transplanting normal non-steatotic liver grafts into obese recipients and 
following the changes in liver histology and plasma lipid profile for up to 3 months. 
Thirdly, to probe deeper into the clinical significance of hepatic steatosis in 
transplantation, ischaemia-reperfusion injury was induced in the steatotic liver and the 
changes in hepatic microcirculation, hepatocellular function and integrity were 
investigated after validating the in vivo use of the key fluorescent markers for hepatic 
study. Finally, to gain insight into the mechanism of enhanced vulnerability of the 
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steatotic liver to IR injury, the role of the vasoactive molecule, NO, was explored by 
systemic administration of the NOS blocker, N(omega)-nitro-L-arginine methyl ester 
(L-NAME), and following the changes m hepatic haemodynamics and 
microcirculation before and after IR. All of the above research were performed on 
male Zucker rats. However, the question remained as to the role of different NOS 
isoforms in the IR process. As a result, hepatic IR injury was induced on wild-type, 
iNOS and eNOS gene knockout mice and the changes in hepatic haemodynamics and 
microcirculatory perfusion were compared. 
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2.1 The application of intravital fluorescence microscopy to the study 
of hepatic microcirculation 
2.1.1 Basic Principles 
The observation of in vivo biological preparations using fluorescence 
microscopy is based on the detection of a known emission fluorescence wavelength 
from the tissue itself (i.e. autofluorescence) or from a fluorescent dye after its uptake 
by a particular tissue following its excitation by a specific wavelength of the light 
source. Hence, an exploitation of the excitation/emission wavelength of commercially 
available fluorescence dyes and their tissue uptake properties allows the visualization 
of specific tissues of interest by utilizing different excitation/emission filter sets (Fig. 
2.1). With the advance in optical and digital technologies, the imagines can now be 
captured with enhanced precision and analyzed with improved accuracy. 
2.1.2 The intravital fluorescence microscope (IVFM) system for hepatic 
microcirculatory study 
A schematic presentation of the intravital fluorescence microscope image 
capturing and analyzing system is shown in Fig. 2.2. An anaesthetized animal is 
placed under a Zeiss Axiotech 100 HD microscope (Carl Zeiss Inc, Germany). The left 
lobe of liver is epi-illuminated with a HBO-lOOW mercury lamp (Carl Zeiss AttoArc, 
Germany) through an excitation filter of appropriate wavelength. The image from the 
microscope is projected onto a low light charge-coupled device (CCD) camera (Kappa-
CF 8/1 FMC, Messtechnik GmbH, Germany), recorded on videotape by a high 
resolution video recorder (Panasonic-model AG-7355; Japan), and displayed on a 
Sony TV monitor (PVM-20M7MDE, Japan). A video timer is superimposed on the 
TV monitor (VTG-33, FOR-A Ltd, Japan), thereby facilitating subsequent off-line 
frame-by-frame analysis of video-recorded images. Low magnification xlO objective 
(W xl0/0.30, Zeiss, Germany) and water immersion objectives of x20 (W x20/0.50), 
x40(W x40/0.75) x63 (W x63/0.90) and xlOO (W xl00/1.0) can be used in the 
microscopic procedure depending on specific study parameters (Fig. 2.3). Three 










Figure 2.1 Observation of three different measurement parameters over the 
same microscopic field by shifting filters of different excitation/emission 
wavelength. 
A. Observation of mitochondrial membrane potential using Rh 123 
B. Measurement of leukocyte adherence using Rh6G 
C. Quantitation of viable hepatocyte nucleus using bisbenzimide H33342 
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Figure 2.3 Objectives of different magnifications 
A: xlO; assessment of general lobular perfusion 
B: x20; measurement of fluorescent intensity, functional sinusoidal density, 
leukocyte adhesion, and hepatocyte nucleus density 
C: x63; measurement of hepatic cord width, sinusoidal diameter, and hepatocyte 
nucleus density 
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560 nm/>580 nm and 330-390 nm/>430 nm can be chosen for the detection of 
autofluorescence or fluorescence from different fluorochromes after specific cellular 
uptake. The excitation/emission wavelengths of hepatic autofluorescence, all the 
fluorochromes used in the subsequent studies and their origins are listed in Table 2.1. 
The actual laboratory setting of the IVFM system is shown in Fig. 2.4. 
2.1.3 Animal preparation for intravitalfluorescence microscopy 
All surgical procedures were performed under general anaesthesia. The animals 
are placed in the supine position with the body temperature maintained at 37°C using a 
thermoregulated heating pad. Blood vessel catheterization is necessary for the 
administration of fluorochromes and collection of blood samples. A laparotomy is 
performed by an upper midline incision plus a left side sub-costal extension. The 
ligaments over the left side of the liver are dissected and the left lobe liver is 
mobilized. The animal is then placed on its left side on a specially designed 
microscope platform (Fig. 2.5). The left liver lobe is gently exteriorized and its lower 
surface is turned facing upwards. The lobe is then placed under the intravital 
fluorescence microscope. The exposed liver surface is covered with a glass coverslip 
to prevent drying and injury and is adjusted horizontal to the microscope to guarantee 
an adequate homogeneous focus level for the microscopic procedure. 
2.1.4 Off-line microcirculatory analysis 
2.1.4.1 Hardware and software 
The off-line microcirculation analysis workstation is shown in Fig. 2.6. Video-
recorded images are exported to a Sony Trinitron video monitor (PVM-20M2MDA, 
Japan), and to a G3 Macintosh computer with the NIH image 1.62 software via a high 
performance image frame-grabber PCI board (Model 1.2, Neotech Inc, London, 
England) for storage, analysis, and for desktop publishing (Sony colour video printer 
Model UP-1200AEPM). Spatial calibration of the computer-NIH image system is 
performed using a microscope length calibration kit (accurate to 10 µm) (Carl Zeiss 
Inc., Germany). Density calibration is accomplished with the Kodak photographic step 
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Dosage Manufacturer References fluorochrome wavelength 
Vitamin-A associated Hepatic 330-390 nm/>430 nm - - (Suematsu et al. 
autoflurescence stellate cell 1993) 
NAD(P)H Mitochondria 330-390 nm/>430 nm - - (Schuchmann et al. 
autoflurescence 2001) 
Rhodamine 123 (Rh123) Mitochondria 450-490 nm/>520 nm 1 µmol/kg Molecular probes* (Suematsu et al. 
1992) 
Rhodamine 60 (Rh6G) Leukocyte 528 nm/547 nm 0.1 µmol/kg Sigma# (Baatz et al. 1995) 
Bisbenzimide H33342 Hepatocyte 346 nm/460 nm 2 µmol/kg Sigma (Vollmar et al. 
(Bis) nucleus 1998b) 
2', 7' -dichlorofluorescin Reactive 490 nm/530 nm 0.3 µmol/kg Molecular probes (Motoyama et al. 
diacetate (H2DCFDA) oxygen species 1998) 
Fluorescein FITC-labeled 492 nm/518 nm 4mg/ml RBC Sigma (Zimmerhackl et al. 
isothiocyanate (FITC) erythrocyte suspension for 1983) 
incubation 
* Molecular Probes, Leiden, The Netherlands 







Figure 2.4 The intravital fluorescence microscope workstation 
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1. Zeiss Axiotech 100 HD microscope 
2. Filter block 
3. Mercury lamp (HB0-100W) cast 
4. Low light charge-coupled device (CCD) camera (Kappa-CF 8/1 FMC) 
5. Light intensity controller (Carl Zeiss AttoArc) 
6. Camera controller (Kappa) 
7. Video timer (VTG-33, FOR-A Ltd) 
8. TV monitor (Sony PVM-20 M? MOE) 
9. High resolution video recorder (Panasonic-model AG-7355) 
10. Remote controller for video recorder (Panasonic AG-A600) 
11 . Microphone for oral recording 
12. Computer 
13. Maclab/8 analog digital instrument 
14. On-line printer 
15. Normal saline for use with water immersion objectives 
.. 
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Figure 2.5 Animal preparation for IVFM examination 
1. Mouse in supine position 
2. Tracheostomy tube 
3. Catheter inside carotid artery 
4. Wet gauze swabs covering all 
exposed tissue surface 
5. Left lobe liver under glass coverslip 
6. Rectal temperature probe 
7. Heating pad in water-proof cover 
8 
8. Stage of adjustable height 
9. Plasticine disc 
10. Adjustable arms 
11 . Magnetic stud for maintaining 
stage position 
12. Metallic tray 
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Figure 2.6 The off-line analysis workstation 
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1. Sony Trinitron video monitor 
2. G3 Macintosh computer 
3. Computer monitor 
4. Panasonic high resolution 
video cassette recorder 
5. Sony color video printer 
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7. Remote controller for video recorder 
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tablet no. 2 (Eastmann Kodak, New York, and U.S.A.) according to the NIH Image 
recommendations. 
2.1.4.2 Measurement parameters 
A summary of the general IVFM off-line analysis methodology is shown in Fig. 
2.7 A-F. In the imagines acquired with water immersion objective (20x), a 200x200 
µm2 frame is used to include all 3 functional zones of an acinus (Rappaport 1987) for 
quantitative analysis of fluorescence intensity (Fig. 2.7B), hepatocyte nucleus density 
(Fig. 2.7C), and leukocyte adherence (Fig. 2.7D). Five to eight microscopic fields are 
chosen at random at each specific time point. Measurements are taken with the centre 
of the frame over each acinus. Quantification of leukocyte adherence to endothelial 
lining of sinusoids is performed by counting the number of adherent leukocytes per 
area observed (200x200 µm2) (Rorie et al. 1997). A leukocyte is defined as adhering if 
it remains stationary for 20 s (Menger et al. 1991). Hepatic cord density and functional 
sinusoidal density are determined by a 200 µm raster line drawn perpendicular to the 
sinusoids and counting the number of hepatic cords and of perfused sinusoids included 
during an observation period of 1 min (Clemens et al. 1985). Both parameters are 
expressed as n/200 µm (Fig. 2.7 A). Using NIH image, the total grey values associated 
with hepatocellular fluorescence within the defined measurement area (200 x 200 µm2) 
are determined and the hepatocellular fluorescence intensity (optical density, OD) is 
automatically calculated once a density calibration is applied to the analysis system 
(Suematsu et al. 1992). Hepatocyte nuclei density (n/40,000 µm2) is determined by 
calculating the number of bisbenzimide fluorescence positive-associated hepatocyte 
nucleus sites within the defined area (200 x 200 µm2) using the cell-counting software 
("Cell counting macro" available from the NIH image web site) (Zhang et al. 2000). 
Hepatic cord width (i.e. width of hepatocytes) and sinusoidal diameters are measured 
using imagines acquired with the x 63 objective after bisbenzimide administration 
(Fig. 2.7E). Ten fields are chosen at random in each animal and in excess of 10 




Figure 2. 7 A & B General IVFM off-line analysis methodology (I) 
A. 200Jtm raster line for measuring hepatic cord density and functional 
sinusoidal density after Rhl23 administration 
B. 200pm x 200pm square for measuring Rhl23 fluorescence intensity 




Figure 2.7C & D General IVFM off-line analysis methodology (II) 
C. 200pm x 200pm square for counting viable hepatocytes following 
bisbenzimide H33342 administration 
D. 200pm x 200pm square for quantitating leukocyte adherence after 
Rh6G administration (Note: timer reading over right upper corner) 
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Figure 2.7E & F General IVFM off-line analysis methodology (Ill) 
E. Measurement of hepatic cord width (x) and sinusoidal diameter (y) under 
high magnification after bisbenzimide H33342 administration 
F. Calculation of RBC velocity by measuring distance travelled and time 
eclipsed using FITC-labelled RBCs and background staining with Rhl23 
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Sinusoidal erythrocyte velocity is assessed with fluorescein isothiocyanate 
(FITC)-labelled RBCs that are prepared using a modification of the technique 
described by Zimmerhackl et al (Zimmerhackl et al. 1983). Briefly, RBCs in 
heparinized whole blood 5-7 ml from a donor animal are washed three times with 
Alsever's buffer (20.5 g glucose, 8.0 g citric acid trisodium salt, 0.55 g citric acid, 
3.766 g NaCl per litre solution; pH 6.2) and once with bicine-saline buffer (3.264 g 
bicine, 0.399 g NaOH, 7.288 g sodium chloride per litre solution; pH 8.3). The washed 
RBCs are resuspended 1:1 in bicine-saline buffer and added to dissolved FITC (4mg 
FITC/ml RBC suspension dissolved in 0.1ml N,N-dimethylformamide). After 
incubation for 3h at room temperature, erythrocytes are washed five times by repeated 
suspension in bicine-saline buffer and centrifugation (1,400 rpm for 10 min). 
Following resuspension in 0.9% saline to a hematocrit around 50 and addition of 
citrate-phosphate-dextrose ( 1.4: 10), RBCs are stored at 4 °C and used within 5 days. 
After introduction into the hepatic microcirculation, labelled RBCs are observed with 
excitation/emission filters of wavelengths 450-490 nm/>520 nm under a x20 
objective. With the readings from the superimposed timer (Fig. 2.7F, right upper 
corner), the RBC velocity can be calculated after measuring the traveled distance from 







2.2 The assessment of hepatic microcirculatory perfusion using laser-
Doppler flowmetry 
2.2.1 History 
The application of laser Doppler flowmetry (LDF) in the study of 
microcirculation dated back to the 1970s when it was first used to measure the retinal 
blood flow in the rabbit (Riva et al. 1972). Since the power of the laser used in the 
study was high (lOmW), LDF was not used in human retina until two years later after 
modification of the system to produce a power of 18 µW (Tanaka et al. 1974). The 
technique was then widely used in the study of a variety of transparent tissues, 
including web of frog (Koyama et al. 1975), mesentery of mouse (Born et al. 1978), 
hamster cheek pouch (Einav et al. 1975), human skin (Holloway and Watkins 1977; 
Johnson et al. 1984) and testicular blood flow (Damber et al. 1982). The technique 
was then utilized in the study of visceral perfusion, including pancreas (Hosotani et al. 
1985), renal (Hansell and Ulfendahl 1986), intestinal mucosal (Shepherd and Riedel 
1985) and liver (Arvidsson et al. 1988; Almond and Wheatley 1992) blood flow. 
2.2.2 Basic principles 
The measurement of RBC velocity with laser Doppler flowmetry is based on the 
detection of a frequency shift of the backscattered light after moving RBCs are hit by 
an incident collimated laser beam according to the Doppler effect (Fig. 2.8). When a 
laser beam hits a tissue, the backscattered light consists of the portion from static 
tissue matrix, which has not been Doppler shifted, and also that portion with a broad 
spectrum of frequencies from interactions with moving RBC. The Doppler shift (~f) 
thus produced can be expressed in the equation: 
~f oc v · cos8 
where v is RBC velocity, 8 is the angle between the incident laser beam and 







Figure 2.8 Principle of hepatic microvascular blood flow measurement with laser 
Doppler flowmetry 
x: Backscattered light from "static" element (e.g. hepatocytes) showing no significant 
difference in frequency compared with the incident laser beam 
y: Backscattered light from "dynamic" element (e.g. RBCs) showing frequency shift 








direction of blood flow with the RBC travelling towards the laser source and scattering 
light directly backwards. However, two factors complicate the measurement. Firstly, 
instead of being parallel tubes running in the same direction, the microcirculation 
consists of an intricate and interlinked network ramifying in all directions. Secondly, 
RBC is an irregular structure that travels in the bloodstream with every possible 
orientation. It also has a magnitude larger than the wavelength of light and a refractive 
index close to that of tissue. According to the Rayleigh-Debye theory of isotropic 
sphere scattering, a large portion of incident light is actually scattered in a forward 
direction, resulting in a lower average frequency shift of light compared to 
backscattering (Tenland 1982). As a result, the generation of an output signal (Vout) 
from an array of backscattered light of different frequencies is calculated as follows 
(Nilsson et al. 1980a): 
V out = ( ko f o 00 mP( m)d {J)) 
Where P( m) is the power spectral density of the photodector signal and ko is a constant. 
Therefore, an output signal can be generated that is linearly related to the flux of red 
cells, i.e. the red cell density times velocity in a specific tissue volume, irrespective of 
how the RBC flux is obtained (Tenland 1982). 
2.2.3 The equipment 
The basic structure of a laser Doppler flowmeter consists of a probe, optic fibres, 
and the instrument itself (Fig. 2.9). The probe is responsible for transmitting out a 
collimated laser beam and the collection of backscattered light from RBC with two 
identical optic fibres that transmit the light to independent photo-detectors in the 
instrument. The detected light signals are then processed through normalizing, 
frequency-filtering, difference, noise suppression, squaring and low pass filtering so 
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The Perimed Periflux PF4001 flowmeter (Jarfalle, Sweden) was used in all the 
subsequent studies (Fig. 2.10). This device generates a laser beam from a 2 mW 
helium neon laser operating at 632.8 nm. The calibration of the machine is achieved 
by using a motility standard of calibrated 2 µm latex spheres that produce a standard 
deflection on a chart recorder of 2.5 V, or 250 PU (Almond and Wheatley 1992). The 
output signals are then exported to a bridge amplifier (ADinstruments Pty Ltd., Castle 
Hill, NSW, Australia) where the signals are amplified and digitized. The data are 
recorded and later analyzed with the MacLab software (ADinstrument, version 3.5.4) 
using a Macintosh computer (Power Macintosh 7200/120) . 
;.;~7·+u ... ftli,•. llb:O:c ~ , 
1 I. - - f.·;. , 
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Figure 2.10 Laser Doppler flowmeter 
2.2.4 The application of LDF to the study of hepatic microcirculation 
The liver is an ideal organ for LDF application because it consists of a dense 
homogenous sinusoidal network under a transparent liver capsule that permits laser 
penetration (Fig. 2.8). In contrast with the measurement of LDF signals from the skin, 
the measurement of hepatic LDF signals, however, requires a laparotomy and direct 
contact between the liver surface and the laser probe through a self-adhesive probe 




















1 ~a0suesrepro~~ \/ .. .' · • 
3. Self-adhesive probe 
holder 
4. Mid-line laparotomy 
5. Left lobe liver 
6. Optic fibres 
7. Retractor 
(made from paper clip) 
8. Adhesive tape 
9. Fixation pin . . • .· 
10. Wet gauz~ s~abs c~vering exposed t!ssue : : . : ~: 
Figure 2.11 Animal preparation for hepatic laser Doppler flowmetry 
measurement 
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The LDF signals have previously been shown to correlate well with the changes 
in whole liver perfusion despite the small interrogative area under study (Wheatley et 
al. 1993; Wheatley et al. 1993). Moreover, LDF signals have also been found to 
exhibit strong correlations between portal venous and hepatic arterial blood flows 
(Arvidsson et al. 1988; Kotzampassi et al. 1998) as well as total hepatic blood flow 
(Almond and Wheatley 1992). A linear relationship has been demonstrated between 
the LDF signals, red blood cell (RBC) velocity and RBC concentration for a RBC 
velocity up to 4mm/s and a RBC volume fractions up to 1.5% (Almond and Wheatley 
1992). The blood flow in the sinusoids, compared to other microvessels, has been 
reported to have an important influence on the LPF signals because of their relatively 
high contribution to the total vascular compartment at the liver surface (Tawadrous 
2001). LDF is now a well-established technique that has been widely used in the study 
of hepatic microcirculation in animal models (Wheatley and Zhao 1993; Seifalian et 
al. 1999) and also in human (Seifalian et al. 1997) . 
2.2.5 Merit and limitations 
The LDF technique has the distinct advantage of giving continuous, stable and 
linear real-time measurements of the flux of erythrocyte in the outermost layer of 
tissue with a high degree of spatial resolution (Tenland 1982; Tawadrous et al. 2001) . 
It is also relatively non-invasive and does not interfere with the delicate microvascular 
system under study (Nilsson et al. 1980b ). The ease of operation and the applicability 
of the technique through a transparent medium (e.g. glass coverslip) also facilitate its 
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use in the study of biological systems. However, a linear relationship between RBC 
flux and LDF signals cannot be established for a high RBC volume fraction which 
causes frequent multiple scattering in more than one moving cell (Tenland 1982). 
Also, because the technique operates on the assumption that red-cell volume fraction 
remaines constant, certain tissues with variable red-cell volume fractions are not 
suitable for LPF study (Vongsavan and Matthews 1993a). In addition, the utilization 
of differential channel technique in photo-detection does not completely eliminate the 
noise that interferes with the signal output. Another problem is the lack of calibration 
in conventional units (Wheatley et al. 1993) and the unit for measurement (i.e. PU) is 
arbitrary. The problem involved in signal calibration is the difficulty in identifying the 
precise microvascular bed interrogated by the laser light (Tawadrous et al. 2001). 
Further variables are introduced by the fact that the distribution of tissue blood flow 
varies in different layers under different conditions (Kuznetsova et al. 1998) and the 
sensitivity of LPF instruments is affected by the distance between the probe tip and the 




2.3 Measurement of vascular blood flow using ultrasound flowmetry 
2.3.1. Principles 
The first ultrasound flowmeter was made in U.S.A by Franklin et al. in 1966 and 
it operated on the ultrasound transit-time method. Unlike the Doppler principle that 
measures the frequency shift, the reflected sound from one moving target makes 
possible the measurement of the time difference over a given distance between the 
upstream and downstream sound waves. Similar to the laser-Doppler flowmeter, the 
first ultrasound flowmeter depended on velocity measurement of a point over a flow-
section and required an additional assessment of the inner diameter of the vessel to 
determine the flow volume (Transonic-Systems 1993). 
The basic concept of a conventional transit-time flowmeter is illustrated in Fig. 
2.12. A confined ultrasound beam passes through a blood vessel. Changes in "transit 
time" (i.e. time it takes for the wave of ultrasound to travel from transducer 1, TR 1, to 
transducer 2, TR 2) is then determined. The difference between the upstream and 
downstream transit time is a measure of flow volume. The transit time varies with the 
mid-stream flow velocity in the confined region and the distance that blood travels in 
the vessel within that time interval. 
Figure 2.12 Schematic presentation of a conventional ultrasound flowmeter 
Sensor @J Body 
~~~ ,d.,,,"..._/ )e~~~~, ~~~ 
TR2 
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TR 1: Transducer 1 
TR 2: Transducer 2 
d: Distance the sound wave travels 
inside blood vessel 
v: Velocity of blood flow 
v 0: Augmented velocity of sound wave 
















2.3.2. The ultrasound flowmeter 
The ultrasound flowmeter used in the subsequent studies is shown in Fig. 2.13 . 
A 
Figure 2.13 The hardware of ultrasound flowmetry 
A. The ultrasound flowmeter 
B. The two probes used in hepatic circulation studies: 
Model l.5RB76: measurement of portal venous blood flow in the rat; 
Model 0.5VB405: measurement of hepatic arterial blood flow in the rat and portal 





Based on the principle mentioned above, the probe of the modified ultrasound 
flowmeter now consists of two adjacent sensor windows and a metallic acoustic 
reflector between which lies the blood vessel. The upstream transducer first sends out 
a sound impulse that passes through the blood vessel and the surrounding tissue. The 
impulse then reaches the downstream transducer where the sound impulse is converted 
into a starting signal which is then amplified and sent to a phase detector. The sound 
velocity is elevated as it travels downstream, resulting in shortening of transit time of 
the arriving impulses. The starting signal and the reference signal from a rhythm 
generator form a phase difference that is recorded and saved (Fig. 2.14 ). 
The next cycle is just an exchange in function between the sound wave sender 
and signal converter. The sound wave travelling from the downstream transducer, 
which now acts as the sound wave sender, to the upstream transducer (i.e. signal 
converter). Travelling upstream causes a delay in transit time. The resulting phase shift 
is then subtracted from the first one to give the flow volume independent of the 
measurements of the blood vessel (Drost 1980). The electronic detector is so sensitive 
that the time difference in measuring a flow rate up to 25rnl/min is as small as one 
picosecond. 
Many flowmeters require a certain angle between the incident direction of the 
probe and the blood vessel (i.e. the vector of flow). Such a measurement is sensitive to 
changes in the probe direction and disturbances in laminar flows, for example, 
secondary flows and wavy flow patterns arising from bending course of blood vessel. 
The problem is solved by the design of the Transonic flowmeter probe which offers a 
double capturing of a reflected sound wave. The vector sum of the two measurements 
corresponds to the axial flow components. This technique makes the flow 
measurement independent of the flow profile and the incident angle of the probe 
(Transonic-systems 1993). As flow sensitivity is optimized for a specific range of 
vessel diameters, accurate blood flow measurement for blood vessel of different size 
requires different probes (Transonic-systems 1997). The two probes used in the 
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Figure 2.14 Principle of flow volume calculation in an ultrasound flowmeter 
..A.. -Ii. 
Subtraction I Flow volume I 
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2.4 The measurement and recording of systemic haemodynamic 
parameters 
2.4.1 Introduction 
The monitoring of systemic haemodynamic parameters in small animals, 
including systemic arterial blood pressure and heart rate, can either be noninvasive or 
invasive. The noninvasive option includes plethysmographic and 
photoplethysmographic measurement of heart rate and blood pressure through tail 
arteries. A warming restrainer is usually required to keep the animal warm to get a 
dilated and pulsatile tail artery to achieve this purpose. On the other hand, the invasive 
procedure involves the surgical placement of an arterial catheter into the animal. The 
monitoring is either acute or chronic. For chronic measurement, the femoral artery is 
usually chosen. The carotid artery is good for acute measurement but not 
recommended on a chronic basis because the occlusion of one of the carotid arteries 
causes compromise of cerebral blood flow that generally results in some morbidity to 
the animal (Transonic-Systems 1997). After cannulation, the catheter is connected to a 
pressure transducer where the pressure signals are transformed into electrical ones 
which can then be digitized, recorded and later analysed in a computer. 
2.4.2 The catheters 
Catheters of appropriate size for different animals can be made by placing a 
metallic wire inside and fusion of different segments of polyethylene tubes using a hot 
air gun (Heissluftgeblase Typ Hot-Jet «S», 230V- 50/60 Hz 2A 460W, Leister CH-
6056 Kagiswil, Switzerland). For instance, catheters for arterial and venous 
cannulation of an adult rat can be made by fusing a polyethylene tube of inner 
diameter (ID) 0.58mm and outer diameter (OD) 0.96mm (Critchley Tyco Electronics 
Pty Ltd., Silverwater, Australia) to another segment of polyethylene tube with ID 
0.28mm and OD 0.61mm. While the wider end can be connected to a blunted 23G 
needle for blood withdrawal and/or drug administration, the finer end greatly increases 
the ease of vessel cannulation (Fig. 2.15A). On the other hand, because of the small 





















prior tappering of the tip of the polyethylene tube (ID/OD 0.20/0.50mm) by placing a 
metallic wire of diameter 0.2mm inside and gently stretching the catheters over the hot 
air gun (Fig. 2.15B). 
Figure 2.15 Self-made catheters for blood vessel cannulation in (A) rat, and 
(B) mouse. 
2.4.3 Cannulation 
The general technique in vascular catheterisation is shown in Fig. 2.16. Briefly, 
traction is applied distally through a thread around the vessel. The tip of a bent needle 
(usually 25G or 30G, depending on the size of the vessel) is gently introduced 
proximally into the lumen of the vessel. Thereafter, a slight traction is applied to the 
needle upwards to open up the puncture site through which a saline-filled catheter is 
inserted. After advancement of the catheter further along the vessel, the patency of the 
catheter is checked through the return of blood into the catheter after applying a slight 
negative pressure to the syringe. The catheter is then secured in place by ligating the 






















Figure 2.16 Vascular cannulation technique 
2.4.4 The transducers 
Pressure transducers (UFI, model 1050, CA, USA) are used in the subsequent 
studies for transforming pressure signals into electrical ones with a sensitivity of 5 
µVNolt excitation/mmHg and an accuracy <+/- 1.5% or +/-1 mmHg 
(http://www.ufiservingscience.com/DS 1050 I .html) . 
2.4.5 Data recording and analysing 
Two systems, namely the analog and digital systems, are available in our 
laboratory for haemodynamic recordings. An analog signal is a continuous one without 
minimum discrete difference between adjacent points. The digital one, on the other 
hand, is quantised into discrete levels over a discrete time interval (ADinstruments 
1991). Previous studies in our laboratory using the analog and digital system show no 
significant difference in terms of sensitivity and accuracy between the two in 
haemodynamic measurements. In the subsequent studies, the digital system is used in 
























by a bridge amplifier (ADinstruments Pty Ltd., Castle Hill, NSW, Australia), the 
signals are recorded and later analysed with the MacLab software (ADinstrument, 
version 3.5.4) using a Macintosh computer (Power Macintosh 7200/120) (Fig. 2.17). 
Figure 2.17 The digital system for haemodynamic data recording and analysis 
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2.5 Hepatic surgical procedures 
2.5.1 Induction of partial hepatic ischaemia-reperfusion (IR) injury 
The induction of partial hepatic IR in the subsequent studies includes the 
complete occlusion of blood flow in and out of the left lobe liver of the animal (Fig. 
2.18A). Different techniques are adopted for the rat (Chapter 6) and the mouse 
(Chapter 9) due to their different body sizes. For all animals, a bolus of heparin (20 
U/kg, intravenously) is administered before vessel occlusion to prevent potential 
thrombus formation in the ischaemic liver lobe due to hemostasis. 
2.5.1.1 Rat 
The left lobe liver is dissected free from the attaching ligaments. Hepatic 
ischemia is induced by obstructing the vessels by placing a 4-0 silk loop around the 
hilar region of the left liver lobe. The free ends of the suture are then passed through a 
2.5 cm segment of polyethylene tube (ID 1.4 mm; Critchley Electrical Products Pty 
Ltd, Auburn, NSW, Australia) (Fig. 2.18B). The tube is then gently advanced over the 
sutures onto the hilum and fixed in place with a hemostat. Absence of blood flow to 
the left lobe is then confirmed by laser-Doppler flowmetry (LDF) or intravital 
fluorescence microscopic (IVFM) examination. Reperfusion starts when the hemostat 
is released. 
2.5.1.2 Mouse 
For preciseness of the operation, all procedures are carried out under an 
operative microscope. Similar to the procedures for the rat, the ligaments around the 
left lobe liver are dissected. However, due to the fragility of the liver parenchyma in 
the mouse, a non-traumatic vascular clamp (S&T, Ref/Art. 00325, Switzerland) is 
applied to the hilar region of the left lobe liver (Fig. 2.18C). Absence of blood flow is 





Figure 2.18 Induction of partial hepatic ischaernia 
A. Anatomy of the rat liver (Note: Arrow indicates the site of vascular occlusion) 
B. Hepatic ischaemia induction in the rat using silk loop 




2.5.2 Orthotopic liver transplantation in the rat 
2.5.2.1 Surgical procedures 
All surgical procedures are performed under ether anaesthesia using aseptic 
techniques under an operation microscope. For all ligations, 6-0 silk suture is used 
throughout. OLT with graft rearterialization is performed using previously described 
technique (Zhang and Wheatley 1996; Zhang et al. 2000) in which the sleeve 
anastomosis technique for the hepatic artery (HA) reconstruction is employed. 
2.5.2.2 Donor operation 
A midline laparotomy is performed and extended to the lateral abdomen below 
the thorax on both sides. The liver is freed from its ligaments. The left infraphrenic 
vein, the pyloric vein and the gastroduodenal artery (GDA) are cauterized using a 
bipolar coagulator (Elektrotom B 50, Martin, Germany) and divided. A single ligation 
around the right suprarenal vessels is made and later cut. The common HA is dissected 
from its origin to the bifurcation. A piece of Venflon tubing (O.D. 1.0 mm, 20G, 5mm 
long) is inserted into the lumen of the bile duct as close to the liver as possible and 
secured in place. Preparation of the abdominal aorta and the celiac trunk together with 
its two branches, the left gastric artery and the splenic artery is unnecessary in this 
model. The liver is perfused with 40ml cold (4°C) University of Winconsin (UW) 
solution via the PV using a perfusor VI pump (B. Braun, Melsungen, Germany) with 
the perfusate leaving the liver via the infrahepatic IVC (Fig. 2.19A). Following 
occlusion of the common HA and IVC with vascular clamps, the graft is removed and 
stored in cold UW solution at 4 °C before implantation for no more than 2 hours. 
2.5.2.3 Recipient operation 
After a long midline laparotomy, all the ligaments are dissected and divided as 
before. The right suprarenal vessels are doubly ligated and divided. The proper HA is 
dissected from its origin to the right HA. Before the proper HA is cut adjacent to the 
right HA, the common HA and the GDA are temporally occluded using a length of 6-0 
silk. The liver is removed after the infrahepatic IVC, the PV and the suprahepatic IVC 
are clamped. The donor liver graft is then placed in orthotopic position in the recipient. 





Figure 2.19A & B Procedures of orthotopic liver transplantation in the rat (I) 
A. Donor liver perfusion with 4 °C UW solution through portal vein (PV) before graft 
harvesting 
B. Portal vein anastomosis with cuff method during liver implantation (Note that cuff 








Figure 2.19C & D Procedures of orthotopic liver transplantation in the rat (II) 
C. Suprahepatic IVC anastomosis with continuous running suture 
D. Completion of portal vein (PV), infrahepatic IVC, and bile duct (BD) anastomoses 
inferior vena cava (IVC) anastomoses (Fig. 2.19B ), whereas the suprahepatic IVC was 
reconnected with a running suture (8-0 Prolene, Ethicon) (Fig. 2.19C). The PV is 
firstly reconnected followed by the suprahepatic IVC anastomosis . The PV blood flow 
is then re-established. Thereafter the infrahepatic IVC is reconnected. 
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2.5.2.4 Rearterialization of liver graft 
Graft rearterialization is performed with the aid of an operating microscope (x16 
magnification). The lumen of both the donor's common and the recipient's proper HA 
are thoroughly irrigated with saline solution before the loose adventitia is gently 
removed from both vessels. The vessel ends are then placed within a few mm of each 
other. The procedures are summarized in Fig. 2.20. The first suture (9-0 Praline) is 
then made in the posterior wall of the recipient's proper HA taking care not to 
penetrate the vessel lumen. The donor common HA is picked up close to its end and 
the vessel wall pierced with the needle (inside to outside). The suture is then left until 
the second suture had been placed. The second suture is also placed in the posterior 
wall of both vessels at a point about one-third of the vessel's circumference from the 
first suture. The two sutures are then tied, joining the side of the recipient's vessel to 
the end of the donor's vessel. The overlapping recipient's end is placed above the 
junction of the vessels. The recipient's proper HA is gently tucked into the lumen of 
the donor's common HA using microforceps. The third suture is then placed in the 
same way as the previous two but in the anterior wall of the vessel and at the point 
bisecting the first 2 sutures. The final step is to tie the third suture. Special care is 
necessary to ensure that the sleeve is straight before the HA blood flow is re-
established. After completion of the HA reconstruction, the bile duct is anastomosed 
with an intraluminal stent as previously described (Zhang, et al. 2000) (Fig. 2.19D). 
The abdomen is closed with a running suture of absorbable material (4-0 Vicryl) after 
the abdominal cavity is checked for hemostasis and irrigated with normal saline. 
2.5.2.5 Postoperative care 
After operation, the rats are kept in single cages for 7 days at room temperature 
and given free access to tap water and fed standard pellet diet. Temgesic (0.05mg/kg 
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Figure 2.20 Liver graft rearterialisation in transplantation with sleeve 
anastomosis technique 
CHA: Common hepatic artery 
PHA: Proper hepatic artery 
1, 2, 3: Sequence of suture placement 
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2.6 The Griess reaction 
The role of nitric oxide in the cardiovascular system has been well established 
(section 1.7). Since NO is a highly unstable radical (section 1.6.2.1), keeping tract of 
its metabolic footprints is especially important in the monitoring of the activity of the 
molecule. Although NO-specific electrodes and chemiluminescence are now available 
for the direct measurement of NO activity, quantitation of the stable end-products of 
NO metabolism, nitrite (N02-) and nitrate (N03), has been accepted as a rapid, simple, 
effective, and relatively inexpensive way of assessing NO production. The biological 
reactions of NO are summarized as follows (Titheradge 1998): 
(1) 2NO + 02 ~ 2N02 
2N02~N204 
N204 + 20ff ~ N02- + N03- + H20 
(2) N02 + NO ~ N203 
N203 + 20ff ~ 2N02- + H20 
In Chapter 9 of this thesis, nitrite concentration is determined as an estimation of 
NO production. It involves a stoichiometric diazotization reaction using the Griess 



































2.7 General considerations in the choice of animals for study in this 
thesis 
Unlike the ordinary laboratory rat strains (e.g. Lewis, Sprague-Dawley or 
Wistars) which can survive and continue to gain weight up to 2 years of age, the 
average life span of the obese Zucker rats is less than a year (mean=323 days) (Zucker 
and Zucker 1962). The body weight of 12 male lean and 12 male obese Zucker rats 
were followed at our laboratory in the course of our experiments for a period of 1 year 
and the growth curves are shown in Fig. 2.22. The mean peak body weight was at 
35.58 and 42.86 weeks of age for the lean and obese Zucker rats, respectively. 
Thereafter, they began to lose weight and succumbed. Death of the obese Zucker rats 
are often, but not always, preceded by a body weight loss (Zucker and Zucker 1962) 
that may be partly explained by a decrease in lipogenesis with age (Bray 1976). In this 
thesis, Zucker rats younger than 30 weeks of age were used to avoid age-induced 
interference with their physiological parameters . 
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Figure 2.22 Growth curves of lean and obese Zucker rats 
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Chapter 3 ________ _ 
NAD(P)H Autofluorescence and Blood Flow in 
the Steatotic Liver of the Obese Zucker Rat 
3.1 Jntroduction 
3.2 Materials and Methods 
3. 2.1 Experimental protocol 
3.2.2 Animals 
3.2.3 Surgical procedures 
3.2.4 lntravital fluorescence microscopy 
3.2.5 Off-line fluorescence analysis 
3.2.6 Hepatic haemodynamics measurement 
3.2.7 Hepatic microcirculatory peifusion (HMP) 
3.2.8 Statistical analysis 
3.3 Results 
3.3.1 Mean arterial blood pressure 
3.3.2 Hepatic blood flow 
3.3.3 Hepatic vascular resistance 
3.3.4 NAD(P)H autofluorescence intensity on UV epi-illumination 
3.4 Discussion 
3.1 Introduction 
Obesity is a prevalent condition in the western world (McCullough 2002). Of 
those morbidly obese patients, 90 per cent were reported to show histological 
abnormalities of the liver and one third to have steatosis involving more than 50 per 
cent of hepatocytes (Clain and Lefkowitch 1987). The majority of patients also show 
histological evidence of hepatic fibrosis even in the absence of diabetes (Silverman et 
al. 1990). Although deterioration in hepatocyte integrity in human liver steatosis has 
been well recognized (Assy et al. 2000), the precise mechanism remains unclear. 
The haemodynamics and cellular function of liver steatosis has received some 
attention. The appearance of narrow and tortuous sinusoids in the steatotic liver of 
choline and methionine deficient Sprague-Dawley rats has been reported (Teramoto et 
al. 1993b). In addition, Seifalian et al. noted a decrease in HMP in obese human 
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subjects (Seifalian et al. 1997) and revealed a progressive decrease in hepatic 
rnicrocirculatory perfusion (HMP) with increasing degree of steatosis in a cholesterol-
fed rabbit model (Seifalian et al. 1999). Portal venous pressure was found to be 
elevated in the choline deficient rat (Wada et al. 1974) but not in the obese Zucker rat 
(Selzner et al. 2000). Moreover, no significant difference has been found in sinusoidal 
erythrocyte flow velocity between the lean and obese Zucker rats (Sato et al. 1986). 
An in vitro study using isolated hepatocytes revealed neither significant difference in 
oxygen consumption nor oxidative capacity between the lean and obese Zucker rats 
(Wardlaw and Kaplan 1986). On the other hand, steatosis has been reported to be 
associated with mitochondrial dysfunction and decreased intracellular energy levels 
(Fromenty and Pessayre 1997). This is consistent with the proposal that a restriction in 
the access of blood solutes to the hepatocytes causes an impairment in liver function 
irrespective of the metabolic capacity of hepatocytes (Villeneuve et al. 1996). The 
change in architecture of the hepatic microvascular bed, therefore, has a significant 
impact on the microcirculatory perfusion and metabolic status of the steatotic liver. 
To establish if steatosis causes changes to liver blood flow and HMP, we measured 
hepatic haemodynarnics and laser-Doppler signals in the obese and lean Zucker rats. 
In addition, to investigate the in vivo redox status of the steatotic liver of the obese 
Zucker rat, we recorded and analyzed the autofluorescence from reduced nicotinamide 
adenine dinucleotide (phosphate) (NAD(P)H) in the liver which is an indicator of the 
oxidation-reduction states of the respiratory carriers (Ince et al. 1992). 
Nicotinamide adenine dinucleotide (NAD+) (Fig. 3. lA) is a major electron acceptor 
in the oxidation of fuel molecules such as glucose and fatty acids. During substrate 
oxidation, the nicotinarnide ring of NAD+ accepts one hydrogen ion and two electrons. 
The reduced non-fluorescent form of this carrier is fluorescent NADH (Fig. 3. lB) 
which is now an energy-rich molecule because it contains a pair of electrons with a 
high transfer potential. These electrons are then transferred to the ultimate electron 
acceptor in aerobic organisms, 0 2, by means of an electron transport chain, or 
respiratory assemblies, located in the inner membrane of mitochondria, resulting in the 
generation of a large amount of free energy for ATP formation. Provided that there is 
no shortage of substrate and phosphate availability, NAD(P)H is an indicator of 
cellular oxygen (Chance et al. 1962; Vollmar et al. 1998a) because an interruption of 
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oxidative phosphorylation due to inadequate oxygen supply is associated with a 
prompt increase in tissue NAD(P)H levels as reflected by a corresponding increase in 
its optical fluorescence (Ince et al. 1992; Burkhardt et al. 1998). 
Specific objectives of the current study were (i) to establish to what extent 
hepatic arterial (HABF) and portal venous blood flow (PVBF) were altered in the 
steatotic liver of the obese Zucker rat, and (ii) to test the hypothesis that reduced total 
hepatic blood flow (THBF) would cause a reduction in blood flow in the hepatic 
rnicrocirculation (i.e. hepatic rnicrocirculatory perfusion, HMP) leading to alterations 
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Figure 3.1 Nicotinamide adenine dinucleotide: 
oxidized (NAD+) and reduced (NADH) forms 
A. Structure of the nonfluorescent oxidised form (NAD1 
R=H in NAD+ 
R=POf in NADP+ 
*Reactive site of NAD+ over its nicotinamide ring 
B. Change in fluorescence intensity through interconversion 
of the oxidised and reduced forms 
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3.2 Materials and Methods 
3.2.1 Experimental protocol 
Under general anaesthesia, both the lean and obese groups were subjected to 
intravital fluorescence microscopic (IVMF) examination of the autofluorescence from 
left lobe liver on ultraviolet light (UV) epi-illumination. After image recording for 1 
min over 5-8 widely separated microscopic fields (i.e. to minimize the photobleaching 
effect of UV exposure on adjacent fields), 20 min were given for the recovery of 
possible reduction in NAD(P)H autofluorescence before the second IVFM 
examination. Thereafter, the animals underwent right carotid artery cannulation for 
arterial blood pressure measurement which was followed by a series of hepatic 
haemodynamic studies including portal venous blood flow (PVBF), hepatic arterial 
blood flow, portal venous pressure, and hepatic microcirculatory perfusion (HMP) 
measurement. The animals were finally sacrificed and their livers were weighed (Fig. 
3.2). 
3.2.2 Animals 
Male Obese Zucker rats (25-30 weeks of age, n=7) with mean body weight 
778.1±49.6 g and age-matched lean controls with mean body weight 464.3± 7.3 g 
(n=7) were used in this study. The whole experiment was conducted with the approval 
of the Otago University Animal Ethics Committee. All animals were housed with 
controlled 12 hr light/dark cycles with free access to water and standard laboratory 
diet. 
3.2.3 Surgical procedures 
All surgical procedures were performed under chloralhydrate anaesthesia (36 
mg/kg body weight intraperitoneal). The details of animal preparation for intravital 
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Figure 3.2 Experimental protocol for hepatic NAD(P)H and haemodynamics study in the Zucker rat 
IVFM: lntravital fluorescence microscopy 
MAP: Mean arterial blood pressure 
PVBF: Portal venous blood flow 
HABF: Hepatic arterial blood flow 
PVP: Portal venous pressure 
HMP: Hepatic microcirculatory perfusion 
LDF: Laser Doppler flowmetry 
3.2.4 Intravital fluorescence microscopy (IVFM) 
IVFM was performed as previously described in section 2.1.2. A x20 water 
immersion objective (W x20/0.5, Zeiss, Germany) was used in the microscopic 
procedure (Fig. 2.3B). A filter set with excitation/emission wavelengths 330-390 
nm/>430 nm was used for the detection of autofluorescence from NAD(P)H upon UV 
epi-illumination (Table 2.1). Five to eight microscopic fields were chosen at random 
for each animal. The observation and recording lasted for one minute. Images were 
recorded again after 20 min to allow full recovery of NAD(P)H autofluorescence 
(Kurose et al. 1993). 
3.2.5 Off-line fluorescence analysis 
The equipment and methods for off-line analysis were outlined in section 2.1.4. 
Fluorescence intensity measurement was performed by computer-assisted 
densitometric gray level determination as previously described (Vollmar et al. 1996b; 
Burkhardt et al. 1998). After being captured and digitized at one-second intervals, the 
images were opened with NIH Image and a 200x200 µm2 frame was used to include 
all 3 functional zones of an acinus for the NAD(P)H autofluorescence analysis (Fig. 
2.7B). The fluorescence intensities of the images were plotted against time. Linear 
regression analysis was then performed for the values between the twentieth to sixtieth 
second of UV epi-illumination to eliminate the interference from hepatic stellate cell 
(HSC) vitamin A-associated autofluorescence during the first 20 seconds of the 
recording as described by Burkhardt et al (Burkhardt et al. 1998). The values of 
NAD(P)H autofluorescence intensity were obtained for those images recorded after 20 
min of recovery from prior UV exposure and compared with those of linear regression 
analysis to ensure the consistency of the results. 
3.2.6 Hepatic haemodynamics measurement 
A cannula (Fig. 2.15A) was inserted into the right carotid artery for systemic 
arterial pressure measurement. The portal vein and hepatic artery of the animal were 
then meticulously dissected to avoid direct touching of the vessels. Two ultrasonic 
probes (Model 1.5RB76 and model 0.5VB405, Transonic Systems Inc., NY, USA) 
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(Fig. 2.13B), which were connected to a small animal blood flow meter (Model T206, 
Transonic Systems Inc., NY, USA) (Fig. 2.13A), were placed around the portal vein 
and hepatic artery for the continuous measurement of PVBF and HABF, respectively. 
Portal pressure measurement was performed by placing a 23-gauge needle with an 
attached polyethylene catheter (ID 0.58 mm, Critchley Electrical Products Pty Ltd., 
Silverwater, NSW, Australia) into the portal vein. The systemic arterial and portal 
venous pressures were transmitted to pressure transducers (UFI, model 1050, CA, 
USA). The blood flow and pressure signals were then exported to a bridge amplifier 
(ADinstruments Pty Ltd., Castle Hill, NSW, Australia) where the signals were 
amplified and digitized. The data were recorded and later analyzed with the MacLab 
software (ADinstrument, version 3.5.4) using a Macintosh computer (Power 
Macintosh 7200/120) (Fig. 2.17). 
3.2.7 Hepatic microcirculatory perfusion (HMP) 
HMP was measured by laser Doppler flowmetry (LDF) using a Perimed Periflux 
PF4001 flowmeter (Jarfalle, Sweden) (Fig. 2.10) as described in section 2.2.3. A 
microprobe (PF415: 1) was placed on the surface of the median lobe of the livers with 
a self-adhesive probe holder and the signal was obtained at 300 Hz using a time 
constant of 0.03s (section 2.2.4). The LDF signal was then digitized with MacLab 
software (ADinstrument, version 3.5.4) and expressed in arbitrary perfusion units 
(PU) (section 2.2.3). The animals were sacrificed at the end of all the measurements 
and the livers were harvested and weighed. Liver weights were 17.1±0.7 g and 
29.6±0.6 g for the lean and obese groups, respectively (P<0.0001). 
3.2.8 Statistical analysis 
Units used for blood flow and resistance measurements were ml·min-1-g-1 tissue 
and mmHg-mr1-min, respectively. The linear regression analysis was performed with 
the StatView software (version 4.0). All data were expressed as mean±SEM. Where 
appropriate, the Student t test was used for analysis of the data. For all other data, 




3.3.1 Mean arterial blood pressure 
The obese Zucker rats had a significantly higher mean arterial blood pressure 
(122.2±3.7 mmHg) than the lean rats (106.2±3.7 mmHg) (P<0.05). 
3.3.2 Hepatic blood flow 
PVBF per unit liver weight was significantly lower in the obese (0.54±0.03 
ml·min-1·t1) than in the lean animals (0.87±0.02 ml·min-1·g-1) (P<0.0001) (Fig. 3.3A), 
whereas there was no significant difference in HABF per unit liver weight between the 
obese (0.05±0.007 ml·min-1·g-1) and the lean (0.05±0.009 ml·min-1·g-1) rats (Fig. 3.3B). 
The obese Zucker rats also showed a prominent reduction in total hepatic blood flow 
(THBF) per unit liver weight (0.59±0.03 ml·min-1·g-1) as compared with their lean 
littermates (0.92±0.03 ml·min-1·t1) (P<0.0001) (Fig. 3.3C). The LDF signal from the 
liver of the obese rats (96±18 PU) was 33.3% lower than that of the lean rats (144±12 
PU) (P<0.05) (Fig. 3.3D). 
3.3.3 Hepatic vascular resistance 
Portal venous pressure was not significantly elevated in the obese Zucker rats 
(9.0±1.0 mmHg) compared to that of the lean controls (7.9±0.5 mmHg). There was 
also no significant difference in portal vascular resistance (PVR) between the obese 
(0.57±0.07 mmHg·mr1,min) and lean (0.54±0.04 mmHg·ml-1·min) animals (Fig. 
3.4A). However, hepatic arterial resistance (HAR) was 38.7% lower in the obese 
group (83.1±9.1 mmHg·mr1·min) than in the lean group (135.5±15.8 mmHg·mr1,min) 
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Figure 3.3 (A) Portal venous blood flow, (B) Hepatic arterial blood flow, and (C) 
Total hepatic blood flow per unit of liver weight in the lean and obese Zucker 
rats. (D) Hepatic microcirculatory perfusion measured with laser Doppler 
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Figure 3.4 (A) Portal venous resistance and (B) Hepatic arterial resistance in the 
lean and obese Zucker rats. * P<0.05 vs. lean group. 
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3.3.4 NAD(P)H autofluorescence intensity on UV epi-illumination 
Typical hepatic microfluorographs for the lean and obese Zucker rats are shown 
in Fig. 3.5. In Fig. 3.5A and 3.5C are shown images of non-steatotic liver from the 
lean rat and steatotic liver from the obese rat taken after 1 second of UV exposure. In 
these images, the positions of the HSC within the hepatic microvasculature are clearly 
visible as bright spots which are vitamin-A derived autofluorescence. After 
approximately 20 seconds, the HSC disappear due to the rapid photobleaching of their 
vitamin A stores (Fig. 3.5B and 3.5D). The remaining fluorescence coming from the 
tissue is due to NAD(P)H autofluorescence (Burkhardt et al., 1998). Autofluorescence 
intensity was plotted against time for both groups (Fig. 3.6A). A significant difference 
between the two groups was noted from the eighth second of UV exposure on 
(P<0.05). Retrograde analysis of the values from the twentieth to the sixtieth second 
was performed on the two groups, giving the baseline NAD(P)H fluorescence intensity 
of 0.14 aU and 0.16 aU for the lean and obese group, respectively. There was no 
significant fluctuation in fluorescence intensity between the twentieth and sixtieth 
second of UV epi-illumination in either group. After 20 min of recovery from prior 
UV exposure, the fluorescence intensities in both groups were unchanged ( obese: 
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Figure 3.5 Hepatic microfluorographs showing vitamin A-associated autofluorescence from HSC and 
background fluorescence intensity of NAD(P)H during the first second of ultraviolent light (UV) 
epi-illumination in (A) lean, and (C) obese Zucker rats. (B) and (D) are corresponding microfluorographs 
showing NAD(P)H autofluorescence after 20 seconds of UV epi-illumination and photobleaching of HSC 
vitamin A-derived autofluorescence for the Jean and obese Zucker rats, respectively. Note the brighter 
background in the obese rats and progressive increase in fluorescence intensity from zone l to zone 3 of 
an acinus as tissue oxygen decreases. 
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Figure 3.6 (A) Diminution of hepatic autofluorescence on ultraviolent epi-
illumination. Results of linear regression analysis shown through interceptions on 
Y-axis. (B) NAD(P)H fluorescence intensity recorded after 1 minute of UV 
exposure followed by 20 minutes of recovery. *P<0.05 vs. lean group. 
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3.4 Discussion 
Morphologically, hepatic steatosis has been classified into the macro- and 
microvesicular types both of which have been shown to occur in the obese Zucker rat. 
Altered hepatic metabolism of free fatty acids has also been reported in the obese 
animals (Fukuda et al. 1982). 
In this study, there was a significant reduction in both PVBF and THBF per unit 
liver weight in the steatotic liver of the obese Zucker rats. On the other hand, the 
hepatic arterial resistance in the obese animals is markedly decreased, resulting in no 
significant difference in HABF per unit liver weight between the lean and the obese 
animals. It has been reported that there was no evidence of a compensatory increase in 
HABF in chronically ethanol-fed rats despite an elevated hepatic oxygen demand 
(Bredfeldt et al. 1985). However, clinically, an increase in oxygen extraction to 
maintain oxygen consumption was found in nonalcoholic but not in the alcoholic fatty 
liver (Kasahara et al. 1988). This is consistent with the previous finding that there is an 
increased hepatic oxygen extraction in the obese Zucker rat which has a nonalcoholic 
fatty liver (Sato et al. 1986). Based on the results of this study, one might propose that 
the maintenance of regional HABF in the obese Zucker rat may represent a 
compensatory mechanism to meet the oxygen requirement for the steatotic liver in the 
face of a greatly reduced THBF. However, there is strong evidence to suggest that 
HABF is not controlled by hepatic parenchymal cell metabolism but by the hepatic 
arterial buffer response whereby a fall in PVBF is compensated for in part by a rise in 
HABF by a mechanism believed to involve adenosine (Lautt 1985). The significant 
reduction in HAR in obese rat may indicate that the hepatic arterial buffer response 
still operates in the steatotic liver. Recently, Richter and co-workers reported that the 
HABF not only maintained THBF following a reduction in PVBF but also served to 
maintain tissue oxygenation and NAD(P)H fluorescence (Richter et al. 2001). 
Clinically, the impact of obesity on HABF and tissue oxygenation remains to be 
elucidated. 
NADH, which is a key element in energy transfer from the tricarboxylic acid 
cycle to the respiratory chain during aerobic metabolism, was first reported by Chance 
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et al (Chance et al. 1962) to be an indicator of the mitochondrial redox state and 
cellular oxygen levels due to its fluorescent properties. Since the measured 
autofluorescence originates from both mitochondrial and cytosolic NADH and 
NAD(P)H, as their fluorescence spectra overlap, it is referred to as NAD(P)H 
(Schuchmann et al. 2001). A body of evidence has shown that the NAD(P)H 
fluorescent signal is predominantly mitochondrial in origin rather than cytoplasmic 
(O'Connor 1977; Chance et al. 1979). Because of the distinct physiological advantage 
of monitoring tissue mitochondrial redox state and hence the oxygenation status, it has 
been used to investigate hepatic tissue oxygenation both in vitro (Minor et al. 1998) 
and in vivo (Vollmar et al. 1998a). In addition, excellent correlation was noted 
between pyridine nucleotide fluorescence intensity and mitochondrial phosphorylative 
activity in rat liver (Tokunaga et al. 1988). It has also been used as an indicator of 
mitochondrial metabolic functions in the rat central nervous system (Schuchmann et 
al. 2001). Clinically, mitochondria have been proposed to play an important role in 
steatohepatitis in which ultrastructural mitochondrial lesions and impairment in 
respiratory complexes have been reported (Pessayre et al. 2001). 
The increase in NAD(P)H fluorescence may represent a failure of hepatic 
arterial buffer response to meet the increased oxygen demand of the steatotic liver. In 
addition, NADH, which is also a product of hepatic oxidation of ethanol to 
acetaldehyde via alcohol dehydrogenase (Lieber 1997), has been found to inhibit fatty 
acid beta-oxidation and enhance its esterification to triglyceride and to partly account 
for alcohol-induced hepatic steatotic change in human subjects (Eaton et al. 1997). 
Therefore, whether the increase in NADH levels in the steatotic liver due to the 
interruption of oxidative phosphorylation from hypoxia also enhances further lipid 
deposition in hepatocytes and perpetuates a vicious cycle remains to be elucidated (see 
Chapter 10). Moreover, increased NADH within the cytosol and mitochondria leads to 
an increased NADH/NAD+ redox potential which has been reported to trigger various 
associated metabolic disorders (Peters and Preedy 1998). The most notable effect is 
the inactivation of xanthine dehydrogenase, resulting in a shift of purine oxidation to 
the free radical generating enzyme xanthine oxidase (Lieber 1997; Mantle and Preedy 
1999). Hence, the finding of increased tissue NAD(P)H in the steatotic liver of the 
obese Zucker rat in this study also raises the possibility of increased free radical 
production which has been proposed to be an important initiating factor of fibrosis in 
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steatotic liver (Parola and Robino 2001). The results of this study are also consistent 
with those of previous studies which support the idea of an altered hepatic lipid 
metabolism rather than an increased adipocyte proliferation as a primary cause of 
obesity in the obese Zucker rat (Johnson and Goldstein 1981). 
In conclusion, the current study shows that steatosis of the liver in the obese 
Zucker rat leads to a reduction in THBF, primarily due to a fall in PVBF. In addition, 
in the face of a PVBF reduction, there is a drop in HAR that, however, cannot 
completely compensate for the reduction in tissue perfusion and oxygenation. The 
results also suggest that the marked reduction in THBF in the obese Zucker rat leads to 
a change in hepatocyte mitochondrial redox status which may participate in a vicious 
cycle leading to further lipid deposition and free radical formation. 
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Chapter4 
The Metabolic and Microcirculatory Impact of 
Orthotopic Liver Transplantation on the Obese 
Zucker Rat 
4.1 Introduction 
4.2 Materials and Methods 
4.2.1 Experimental protocol 
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4.2.3 Orthotopic liver transplantation 
4.2.4 lntravitalfluorescence microscopy (lVFM) 
4.2.5 Off-line microcirculatory analysis 
4.2.6 Hepatic microcirculatory peifusion (HMP) 
4.2. 7 Liver biopsies and histologic analysis 
4.2.8 Plasma lipid profile analysis 
4.2.9 Statistical analysis 
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4.3.1 Anhepatic phase, survival and complications 
4.3.2 Body weight changes 
4.3.3 Liver/body weight ratio 
4.3.4 Morphological analysis 
4.3.5 Hepatic microcirculation 
4.3.6 Plasma triglyceride level 
4.3. 7 Plasma cholesterol level 
4.3.8 Plasma high density lipoprotein-cholesterol level 
4.4 Discussion 
4.1 Introduction 
Although the decrease in hepatic perfusion per unit weight of steatotic liver may 
be a potential contributory factor to hepatic lipid deposition (Chapter 3), the 
development of hepatic steatosis may also be a primary event brought about by an 
altered intrinsic metabolism of hepatocytes (Fukuda et al. 1982) and/or secondary to 
the systemic metabolic influences of obesity (Thaler 1980). 
Nevertheless, reports in the literature on the outcome of liver transplantation 
(OLT) in obese and diabetic patients are few (Kim et al. 1996). While much emphasis 
has been placed on the use of steatotic liver grafts in clinical liver transplantation, the 
- 123 -
suitability of OLT as a therapy in obese recipients has not been widely discussed. One 
possible reason for this may be the relatively rare occurrence of steatohepatitic 
cirrhosis and other indications such as major liver trauma for OLT in this patient 
population. However, a study on liver biopsies of a series of 100 morbidly obese 
patients showed that up to 4% had histologic evidence of cirrhosis (Silverman et al. 
1990). Moreover, obesity is a prevalent condition in the western world (McCullough 
2002). It has been reported that about 90 per cent of morbidly obese patients show 
histologic abnormalities of the liver and one third of those have steatosis involving 
more than 50 per cent of hepatocytes (Clain and Lefkowitch 1987). Non-alcoholic 
hepatic steatosis or fatty liver has been classified by some as a disease that can be 
divided into four histologic groups: 1. uncomplicated fatty liver or hepatic steatosis; 2. 
fatty hepatitis or steatohepatitis (NASH), which is a slowly progressive fatty liver with 
inflammation, has been noted in 36% of patients with morbid obesity (Silverman et al. 
1990); 3. fatty liver with fibrosis, which can present as central venous, sinusoidal, 
bridging and/or portal fibrosis, has been reported to occur in up to 65% of morbidly 
obese patients (Silverman et al. 1990); and 4. cirrhosis, which may also present with 
hepatocellular carcinoma. Another rare but often fatal subfulminant course of NASH 
with submassive hepatic necrosis has also been recognized (Clain and Lefkowitch 
1987; Ludwig et al. 1997). However, other authors proposed that steatosis is not a 
disease but is just a benign symptom of disturbed lipid metabolism and that it is the 
underlying cause of the steatosis, and not the fat accumulation per se, that produces 
the cirrhosis (Thaler 1980). Such a theory is supported by the report that although 
there was a significant incidence of poor early graft function with the use of steatotic 
liver grafts, this did not affect transplant outcome and the steatotic condition of the 
graft is reversible (Fishbein et al. 1997). A lack of evidence for nutritional deficiency-
induced cirrhosis in man also supports that viewpoint (Thaler 1980). Also, recurrence 
of obesity-induced hepatic steatotic cirrhosis has been reported in clinical OLT (Kim 
et al. 1996; Carson et al. 1997; Czaja 1997). Recently, using leptin-deficient ob/ob 
mice, it has been demonstrated that liver hyperplasia is evident at the earliest stage of 
non-alcoholic fatty liver disease (Yang et al. 2001). These findings support the concept 
that obesity-related metabolic abnormalities, rather than cirrhosis, initiate the hepatic 
neoplastic process during obesity. All these findings have shifted the focus from the 
graft itself to recipient suitability for optimal transplant outcome. 
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To evaluate the extent of recipient metabolic influence on the etiology of hepatic 
steatosis in terms of microcirculatory and morphological change and to investigate the 
regulatory role of liver in obesity, normal non-steatotic liver grafts from lean Zucker 
rats were transplanted to their age-matched obese littermates. The transplanted animals 
were followed up to three months for their changes in plasma lipid profile, body 
weight, liver histology, hepatic microvasculature and perfusion. Key questions 
addressed were ( 1) does the presence of the non-steatotic graft in the obese rat 
improve lipid metabolism? and (2) does the non-steatotic graft become steatotic with 
time leading to the return of deranged metabolism in the recipient? Measurement of 
hepatic microcirculatory perfusion (HMP) with laser Doppler flowmetry (LDF) and in 
vivo observation of the liver grafts using intravital fluorescence microscopy (IVFM) at 
3 months after transplantation were also performed to measure changes in hepatic cord 
width, sinusoidal diameter and hepatocyte nucleus density. Morphological analysis of 
the liver graft biopsies at different time points after transplantation was also performed 
to assess, among other things, the extent and progression of steatotic change and 
glycogen deposition after transplantation. 
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4.2 Materials and Methods 
4.2.1 Experimental protocol 
Under general anaesthesia, the liver grafts from lean Zucker rats were 
transplanted to age-matched obese rats in the experimental group, whereas the lean 
and obese control groups underwent only laparotomy. Just before operation, baseline 
plasma lipid profile measurement, liver biopsy of the liver graft, and measurement of 
hepatic microcirculatory perfusion (HMP) were carried out on all animals (Fig. 4.1). 
Postoperatively, measurement of body weight change was performed weekly, while 
plasma lipid measurement and liver biopsy were carried out on a monthly basis till the 
end of the third postoperative month when intravital fluorescence microscopic (IVFM) 
examination of the liver and HMP measurement were also performed. The animals 
were then sacrificed and their liver were weighed. The liver specimens were sent to an 
independent pathologist, Professor Arthur Zimmermann, University of Berne, 
Switzerland, for the assessment of steatotic change and glycogen deposition. 
4.2.2 Animals 
Male obese Zucker rats (n=9) aged 12-16 weeks and weighing between 450 to 
550g were used as liver graft recipients with their age-matched lean littermates 
weighing between 280-360g (male, n=9) as liver donors. Another group of age-
matched male obese Zucker rats (n=6) and male lean Zucker rats (n=6) underwent 
laparotomy alone and served as the controls. The whole experiment was conducted in 
accordance with the Care and Use of Laboratory Animals (NIH publication 86-23, 
revised 1985) and with the approval of the Otago University Animal Ethics 
Committee. All animals were housed with controlled 12 hr light/dark cycles with free 
access to water and standard laboratory diet. Animals were fasted for 6 hours before 
operation and blood sampling. Weekly values of body weight were obtained 
throughout the experiment. 
4.2.3 Orthotopic liver transplantation 
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Figure 4. 1 Experimental protocol for post-transplant study in the obese Zucker rat 
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OLT: Orthotopic liver transplantation 
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4.2.4 Intravital fluorescence microscopy (IVFM) 
IVFM examination of the liver was performed at three months after operations 
in the manner previously described in section 2.1. A water immersion objective of x63 
(Wx63/0.90, Carl Zeiss Inc, Gottingen, Germany) was used in the microscopic 
procedure (Fig. 2.3C). A bolus of bisbenzimide (2 µmol/kg body weight, Sigma 
Chemical Co., St. Louis, MO, USA) was administered intravenously for the 
identification of viable hepatocyte nuclei (Vollmar et al. 1998b) (Fig. 2.7C), 
measurement of hepatic cord width and sinusoidal diameter (Fig. 2.7E). A filter set 
with excitation/emission wavelengths 330-390 nm/>430 nm was used for fluorescence 
detection (Table 2.1 ). 
4.2.5 Off-line microcirculatory analysis 
The setting for off-line analysis was described in section 2.1.4. Hepatocyte 
nucleus density was determined by counting the number of bisbenzimide-associated 
fluorescent hepatocyte nucleus sites within each high-powered field (HPF, which 
refers to a single NIH image captured with the x63 objective) using cell-counting 
software ("Cell counting macro") (Zhang et al. 2000). Hepatic cord width and 
sinusoidal diameter were obtained by choosing 10 fields at random in each animal and 
in excess of 10 measurements were made in each field. All measurements were 
performed on digitized images. 
4.2.6 Hepatic microcirculatory perfusion (HMP) 
HMP was measured by laser Doppler flowmetry (section 2.2) at 3 months after 
operation. The signal was obtained at 300 Hz using a time constant of 0.03s. The LDF 
signal was then digitized with MacLab software (AD Instrument, version 3.5.4) and 
expressed in arbitrary perfusion units (PU). 
4.2. 7 Liver biopsies and histologic analysis 
Liver biopsies were harvested at the time of operation and then monthly using a 
minimally invasive mini-laparotomy with the animals under ether anaesthesia. 
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Haemostasis was achieved with electrocauterization. Tissue samples were divided into 
two groups: Group 1 tissue was fixed in 10% buffered formalin, embedded in paraffin 
and processed for hematoxylin-eosin (HE) staining. Group 2 tissue was fixed in 
absolute alcohol for periodic acid-Schiff (PAS) reagent staining and glycogen 
analysis. Specimens were compared in a blind fashion by one investigator (AZ) and 
were assessed for the extent of macro-/microvesicular fatty changes and glycogen 
depostion. The grading systems were as follows: macrovesicular fatty change (MAFC) 
(0: none, 1: few single hepatocyte with MAFC, 2: small clusters of hepatocytes with 
MAFC, less than 5% of section involved, 3: larger clusters, 5-10% of section involved, 
4: more than 10% involved); microvesicular fatty change (MIFC) (0: none, 1: few 
cells involved, not easily detectable, 2: easily detectable, 3: easily detectable, 
massive); glycogen-staining (0: no glycogen staining or glycogen staining in few 
scattered hepatocytes, 1: slight PAS-positive granular staining, 2: moderate staining, 3: 
marked staining). 
4.2.8 Plasma lipid profile analysis 
Fasting blood samples were obtained monthly after transplantation by the 
ophthalmic venous plexus blood collection technique and placed in heparinized tubes. 
Plasma was separated by centrifugation and kept at -80 °C until measurement. 
Triglyceride, cholesterol, and high density lipoprotein cholesterol levels were 
determined using an Hitachi 911 analyser (Hitachi, Tokyo, Japan). 
4.2.9 Statistical analysis 
All data were expressed as mean±SEM. Where appropriate, the Student t test 
was used for analysis of the data. For all other data, repeated measure analysis of 




4.3.1 Anhepatic phase, survival and complications 
Of the nine OLT performed, one animal died on postoperative day (POD) 1, 
giving an overall survival of 89%. The mortality was most probably due to the 
prolonged anhepatic phase (30 min in this particular operation). Wound infection with 
dehiscence was noted in 1 transplanted animal (11 % ) on POD 9. The rest of the 
transplant group and the sham groups were healthy throughout and remained free of 
major complications. 
4.3.2 Body weight changes 
Significant differences in body weight changes after operation were noted in the 
lean and obese sham-operated and OLT animals throughout the 3-month study period 
(Fig. 4.2A). All three groups showed a slight decrease in body weight at one week 
after operation. Thereafter, a steady rise in body weight was noted in the lean and 
obese sham-operated animals. In the OLT group, body weight did not rise post-
operatively and from 6 weeks on it was significantly lower than in the obese sham 
group. By the end of the experimentation, the body weight of the OLT and sham-
operated lean controls were not significantly different. 
4.3.3 Liver/body weight ratio 
The lean Zucker rats had a liver/body weight ratio of 3.25±0.1 % at the end of the 
experiment. The liver of the obese sham-operated rats was significantly enlarged as 
compared with the lean animals with a liver/body weight ratio of 3.79±0.18% 
(P<0.05). A higher liver/body weight ratio was found in the OLT animals 
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Figure 4.2 (A) Changes in body weight in the transplanted and sham-operated 
Zucker rat. OLT: orthotopic liver transplantation group. (B) Liver/body weight 
ratio in the transplanted and control Zucker rats. * P<0.05 vs. obese group at the 
same time point. #P<0.05 vs. lean control group. 
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4.3.4 Morphological analysis 
No evidence of fatty change was noted in the lean donor livers before 
transplantation. In addition, biopsies from the lean sham-operated controls taken 
throughout the experimentation period were all normal (Fig. 4.3A). Biopsies from the 
obese controls showed diffused and marked microvesicular fatty change (MIFC) 
(mean grading 2.7±1.2) and slight to moderate macrovesicular fatty change (MAFC) 
(mean grading 1.7±0.3) (Fig. 4.3B). Morphological analysis of the livers from the 
transplanted group showed no evidence of steatotic change up to two months after 
OLT (Table 4.1). However, remarkable MIFC with an average grading of 2.7±0.3 was 
noted 3 months after transplantation (Fig. 4.3C). Interestingly, no significant MAFC 
was noted throughout the whole post-transplant course. Moreover, either no glycogen 
deposition or glycogen in a few scattered hepatocytes was noted in liver sections from 
lean controls and biopsies of donor liver grafts before OLT (grade 0) (Fig. 4.4A), 
whereas moderate to marked glycogen deposition was seen in the native livers of the 
obese recipients and also in biopsies from obese controls throughout the course of 
study (mean grading 1.3±0.3) (Fig. 4.4B). The OLT group showed slight PAS-positive 
granular staining one month postoperatively (mean grading 0.7±0.5) (Table 4.1). 
However, moderate to marked glycogen deposition was noted in the second and third 
month after transplantation (mean grading 1.9±0.2 and 2±0.1, respectively) (Fig. 




Figure 4.3 Representative liver sections processed by hematoxylin and eosin 
stain. (A) Absence of notable steatotic change in donor livers on the day of 
transplantation. (B) Micro- (black arrow) and macrovesicular fatty change (white 
arrow) in native livers of recipient obese Zucker rats. (C) Moderate to marked 





Figure 4.4 Staining of liver sections with periodic acid-Schiff reagent, showing 
(A) Absence of glycogen deposition in lean sham-operated Zucker rats. (B) 
Moderate to marked glycogen deposition in obese controls (black arrow). (C) 
Moderate to marked staining of glycogen granules in liver grafts 3 months after 
transplantation (black arrow). 
- 134 -
"' 
Table 4.1 Semi-quantitative analysis of morphological features in livers of lean/obese 
control Zucker rats and in liver grafts after lean to obese transplantation at four 
different time points. 
Lean Obese OLT (Lean to obese) 
OM lM 
MAFC grading 0.2±0.2 1.7±0.3* 0±0 0±0 
MIFC grading 0±0 2.7±1.2* 0±0 0±0 
Glycogen grading 0±0 1.3±0.3* 0±0 0.7±0.5* 
OLT: orthotopic liver transplantation group (i.e. obese recipients), 
MAFC: macrovesicular fatty change, 
MIFC: microvesicular fatty change, 










4.3.5 Hepatic microcirculation 
Hepatic microcirculatory perfusion was significantly lower in the sham-obese 
than the sham-lean group (P<0.001, Table 4.2). HMP in the OLT group was 
intermediate between and significantly different from the 2 control groups. NFM 
investigation revealed that the hepatic cord width was significantly wider in the obese 
than in the lean animals (P<0.001, Table 4.2). The hepatic cord in the OLT group 
(17.0±0.3 µm) was also narrower than that in the obese control group (23.1± 0.7 µm) 
(P<0.05) but was not significantly different from the lean controls (15.9±0.4 µm). No 
significant differences in sinusoidal diameter among the three groups were found 
(Table 2). Hepatocyte nucleus density in the OLT group (51.4±1.3/HPF) was 
significantly lower than in the lean controls (59.6± 1.2/HPF) (P<0.01) but was still 
higher than in the obese controls (38.8± 1.2) (P<0.005) (Table 4.2) (Fig. 4.5). 
4.3.6 Plasma triglyceride level 
The plasma triglyceride level in the OLT group dropped dramatically one month 
post-OLT from 6.8±0.5 to 2.1±0.3 mmol/L (P<0.0001) and did not change 
significantly thereafter (Fig. 4.6A). The triglyceride levels in this group at 1, 2, and 3 
month after OLT were significantly different from those of their obese sham-operated 
littermates at the same time points but not from those of the lean controls. The obese 
sham-operated animals maintained a significantly higher plasma triglyceride level than 
their lean sham-operated counterparts. Both sham-operated groups showed no 
significant fluctuation in plasma triglyceride levels throughout the course of the 
experiment. 
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Table 4.2 Microcirculatory features and HMP of livers in transplanted and 
control Zucker rats 3 months after operations. 
Lean Obese OLT 
Hepatic cord width (µm) 15.9±0.4 23.1±0.7* 17.0±0.3# 
Sinusoidal diameter (µm) 9.9±0.7 9.8±0.9 9.9±0.2 
Hepatocyte nucleus density (n/HPF) 59.6±1.2 38.8±1.2* 51.4±1.3*# 
HMP (PU) 220.6±10.5 113.3±5.0* 137 .2±2.6*# 
Values expressed as mean±SEM, OLT: orthotopic liver transplantation group. 
HPF: high-powered field. 
HMP: hepatic microcirculatory perfusion. 
PU: perfusion unit. 
* P<0.05 vs. lean group, 





Figure 4.5 Representative microfluorographs showing bisbenzimide-stained 
hepatocyte nuclei which appear as bright spots (arrow) and hepatic cords in high-
powered fields. (A) Lean controls. (B) Transplanted group. (C) Obese controls. 
(S: sinusoids. The bars in the lower right corner in each microfluorograph 
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Figure 4.6 Changes in (A) plasma triglyceride level, (B) plasma cholesterol level, 
and (C) plasma high density lipoprotein-cholesterol level before operations and 
during a 3-month postoperative period. *P<0.05 vs. baseline of the same group. 




4.3. 7 Plasma cholesterol level 
Plasma cholesterol levels were significantly higher in the obese sham group than 
in the lean controls throughout the experiment. In the sham-operated lean animals, 
there was a small but significant increase compared to their baseline levels (3.32±0.28 
mmol/L) in the fourth and twelfth post-operative weeks (i.e. 4.6±0.65 and 4.96±0.29 
mmol/L, respectively) . In the obese controls, cholesterol rose from 5.78±0.58 mmol/L 
pre-operatively to 8.84±0.92 and 8.97±1.37 mmol/L by post-operative weeks 8 and12, 
respectively. In the OLT animals, the levels were markedly higher than those of the 
lean controls at the beginning of the experiment (5.58±0.2 mmol/L) but were 
significantly lower than those of the obese sham group at one month after OLT 
(4.58±0.44 mmol/L). Thereafter, the levels rose significantly by postoperative weeks 8 
and 12 to levels of 8.1±0.97 and 9.86±1.3 mmol/L, respectively. A significant 
difference (P<0.05) was noted between the OLT and the lean controls by the twelfth 
week after OLT (Fig. 4.6B). 
4.3.8 Plasma high density lipoprotein-cholesterol level 
The plasma HDL-C levels were higher in the lean than in the obese controls 
throughout the course of the experiment (P<0.05). In the OLT group, the plasma 
HDL-C levels were initially low (0.6±0.03mmol/L). However, from week 4 post-OLT, 







The liver has long been known as the organ responsible for carbohydrate, protein 
and lipid homeostasis. It is also the major organ for cholesterol and lipoprotein 
metabolism. Obesity has been reported to have an adverse effect on the liver, as 
reflected clinically in elevated serum liver enzymes, hepatomegaly and hepatic fatty 
parenchymal changes (Van Steenbergen and Lanckmans 1995). Obesity-induced non-
alcoholic hepatic steatosis, steatotic hepatitis and fibrosis have also been reported 
(Clain and Lefkowitch 1987). 
In this study, the obese Zucker rat was used as a genetically-predisposed model 
of an obese recipient to study the metabolic consequences and changes in hepatic 
microcirculation following implantation of normal non-steatotic liver grafts. The 
major difference between the transplanted and sham-operated animals in this 
experimental setting is the denervated liver grafts in the former. However, a body of 
evidence has shown that hepatic denervation has no notable impact both on hepatic 
haemodynamics (Wheatley et al. 1993) and metabolic functions including 
aminopyrine and galactose breakdown (Wheatley et al. 1993), oxygen uptake (Lautt 
1977b ), glucose metabolism (Perseghin et al. 1997), and glycogen synthesis (Schneiter 
et al. 2000) . 
In this study, the increased "fat tolerance" as reflected in the progressive 
increase in plasma levels of HDL-C may explain the reduced body weight gain in the 
OLT group, as it enabled the animals to rapidly catabolize ingested triglyceride 
(Patsch and Patsch 1984). The plateau in body weight gain in the OLT group probably 
represented a slowdown in fat deposition as reflected in the dramatic decrease in 
plasma triglyceride levels after OLT. The significantly elevated liver/body weight 
ratio in the OLT group as compared with the lean controls indicated an increase in 
liver mass in the transplanted animals probably due to lipid deposition that was 
prominent in histologic sections (Fig. 4.5C). In addition, the reduced body weight in 
the OLT animals may also have contributed to the result. These results indicate that 







animals. The same phenomenon has also been observed in the obese controls as 
compared with their lean littermates (Fig. 4.2B). 
Consistent with the results of previous studies, elevated plasma triglyceride and 
cholesterol levels were noted in the sham-operated obese Zucker rats compared to the 
lean controls throughout the course of this study (Zucker 1965; Bach 1977). Age has 
also been reported to have a significant impact on the plasma lipid profile of the 
Zucker rat. In a study by Zucker et al., an analytically detectable hyperlipidaemia was 
noted as early as 39 days in the obese rat but it was not sufficient to produce visible 
plasma lactescence until day 73 (Zucker 1965). On the other hand, another report 
showed a decrease in serum triglyceride levels as the obese Zucker rats aged (Liszka et 
al. 1998). In the current study, there was no significant fluctuation in plasma 
triglyceride levels in the adult obese and lean sham-operated animals throughout the 
course of the experiment. However, an increase in plasma cholesterol levels was noted 
by post-operative week 8 and 12 in the obese controls and post-operative week 4 and 
12 in the lean controls, respectively. The results were not surprising as the 
heterozygous lean Zucker rats (Fa/fa) have been reported to have a greater tendency 
towards overweight than the homozygotes (Fa/Fa) and may also exhibit small 
elevations in plasma cholesterol and fatty acids (Zucker 1965). Interestingly, a 
significant drop in plasma triglyceride and a difference in plasma cholesterol levels 
between the OLT and obese controls were noted one month after transplantation. With 
the introduction of a non-steatotic liver graft, this improvement in the plasma lipid 
profile probably reflects a temporary correction in the defective hepatic lipid 
metabolism of the obese Zucker rat. The retarded body weight gain in the OLT group 
may also contribute to the subsequent reduced plasma triglyceride levels, as lipectomy 
of up to 10% body weight has been reported to cause a marked decrease in serum 
triglyceride levels in the obese Zucker rat (Liszka et al. 1998). The hyperinsulinaernia-
insulin resistant state may be an important factor accounting for the subsequent rise in 
plasma cholesterol levels in the OLT group in this study (Alarrayed et al. 1992). In 
contrast to an early study which demonstrated a twofold increase in serum high 
density lipoproteins in the obese Zucker rat (Schonfeld 1974), significantly lower 
HDL-C levels were noted in the sham-operated obese rats as compared with their lean 
littermates. After transplantation, however, there was a significant increase in HDL-C 
levels which is indicative of increased "fat tolerance" in the OLT animals (Patsch and 
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Patsch 1984). On the other hand, a parallel clinical study on 622 liver transplants 
revealed only eight cases with diagnosed pretransplant NASH. Of the eight patients, 
up to 6 developed recurrent steatosis. Three of those 6 patients even showed severe 
steatosis involving 80% of the liver tissue and hepatocyte degeneration diagnostic of 
recurrent NASH between 6 weeks and 2.5 years posttransplant. However, no 
characteristic pattern of biological parameter changes (e.g. serum triglyceride and 
cholesterol levels) was noted in those patients. In contrast with the results of this 
study, five of the 6 patients with recurrent steatosis exhibited hypertriglyceridaemia 
and only one showed hypercholesterolaemia. Interestingly, consistent with the 
findings of this study, three of the 8 patients also showed a weight loss between 5 to 
18% over a postoperative follow-up period of 4 to 6 months (Kim et al. 1996). 
Microvascular structural changes in the transplanted liver grafts were also noted 
in this study, as reflected in the significant decrease in hepatocyte nucleus density due 
to an increase in the size of hepatocytes from intracellular lipid deposition (Fukuda et 
al. 1982) (Table 4.2). The LDF signals in the OLT group showed a significant 
decrease 3 months after OLT as compared with the lean controls in this study (Table 
4.2), indicating that fatty infiltration leads to a reduction in hepatic perfusion. 
Previously, others have also reported that graded steatosis causes a progressive fall in 
HMP (Seifalian et al. 1999). However, no significant differences in sinusoidal 
diameter was demonstrated among the three groups, suggesting that the increase in 
size of hepatocytes without an accompanying increase in sinusoidal diameter may 
contribute to the decrease in HMP after transplantation. The results of this study are 
consistent with those of a previous study that showed a correlation between LDF 
signal and the sinusoidal vascular area fraction due to the constant interrogation area 
of LDF (Tawadrous et al. 2001). The correlation between LDF signals and the 
sinusoidal vascular area fraction in the lean and obese Zucker rat is illustrated in Fig. 
4.7. 
Morphologically, MIFC but not MAFC was noted in the liver grafts at 3 months 
after OLT. Because MIFC of hepatocytes has been reported to be associated with 
impaired mitochondrial ~-oxidation and is a reliable prognostic factor in the prediction 
of outcome after liver retransplantation in humans (Yoong et al. 1999), the results of 






















Figure 4.7 Microvascular bed of steatotic liver contributes to reduced LDF 
signals by decreasing the number of RBC flowing through the liver surface . 
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3 months after transplantation. This is consistent with the progressive increase in 
plasma cholesterol levels after transplantation in this study. The constant exposure of 
the non-steatotic liver grafts to fatty acids may partly account for the subsequent 
accumulation of lipid in the form of MIFC in the animals 3 months after 
transplantation (Wanless and Lentz 1990) (Fig. 4.3C). Glucose intolerance and 
hyperinsulinaemia, which are well documented in the obese Zucker rat, may also 
contribute to the development of hepatic steatosis in this study (Wanless and Lentz 
1990; Marchesini et al. 1999; McCullough 2002). 
In accord with the results of prev10us studies which showed that hepatic 
glycogen levels and rates of glycogen synthesis were significantly increased in obese 
Zucker rat compared to the lean animal (Bach 1977; Triscari et al. 1979), 
morphological analysis of the liver grafts in this study also revealed progressive 
accumulation of glycogen granules from 1 month after OLT and the condition is 
aggravated 3 months postoperatively (Table 4.1). As deposition of glycogen was 
evident as early as one month after OLT when steatotic change of the liver grafts was 
not yet discernible, the results of the current study support that, instead of a primary 
cellular phenomenon of fat-laden hepatocyte, hepatic glycogen deposition is probably 
secondary to systemic metabolic signals. The results are consistent with the previous 
finding by Aiston et al. that leptin has additive effects with insulin in inhibiting 
phosphorylase and stimulating glycogen storage in rat hepatocytes (Aiston and Agius 
1999). On the other hand, another in vitro study by the same group showed that 
although glucokinase activity and the expression of glucokinase regulatory protein in 
the hepatocytes of the obese Zucker rat were twofold higher than in the lean rat, 
hepatocytes from obese Zucker rat exhibited impaired glycogen synthesis probably 
due to increased phosphorylase activity (Aiston et al. 2000). Therefore, whether the 
glycogen deposition in the liver grafts after OLT in this study is also partly due to 
relatively lower phosphorylase activity in the non-steatotic hepatocytes remains to be 
elucidated. However, the possibility that long-term exposure of hepatocytes to leptin 
in vivo down-regulates total phosphorylase activity cannot be excluded (Aiston et al. 
2000). Other proposed possibilities for enhanced hepatic glycogen accumulation in 
obesity also include (1) hyperinsulinaemia that contribute to decreased glycogenolysis; 
and (2) the deactivation of glycogen phosphorylase by elevated concentrations of 
intracellular glucose-6-phosphate and free glucose from an increased gluconeogenesis 
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(Muller et al. 1997). Clinically, the inhibition of glycogenolysis with a resulting 
increase in hepatic glycogen concentrations has been demonstrated in obese non-
diabetic patients (Muller et al. 1997). Another series of liver biopsies from 100 
morbidly obese patients also demonstrated "glycogen nuclei" in hepatocytes in up to 
66% of the cases (Silverman et al. 1990). The exact mechanism, however, remains 
unclear (Muller et al. 1997). 
The adverse effect of hyperlipidaemia on solid organ microcirculation of the 
obese Zucker rat has been illustrated by the improvement in glomerular injury 
following hyperlipidaemia treatment (Kasiske et al. 1983). On the other hand, another 
study using a streptozotocin diabetic rat model has demonstrated the development of 
diabetic glomerular changes in normal kidneys transplanted into diabetic rats (Lee et 
al. 1974). The results of this study also revealed significant hepatic microvascular 
alterations in normal non-steatotic liver grafts after OLT in an obese, diabetic animal 
model. Although it may not be appropriate to extrapolate the results to clinical 
situations, this study may still raise the concern of the possibility of deterioration of 
microvascular function after solid organ transplantation in diabetic and obese patients. 
The results of this study also illustrated the vital role of the liver in lipid metabolism in 
the Zucker rats, especially in the increased synthesis of HDL-C and drop in plasma 
triglyceride level. Although no evidence of fibrosis was noted in the transplanted 
livers in this study, it has been proposed that even non-alcoholic fatty liver without 
inflammatory change may result in progressive disease (i.e. fibrosis) due to the action 
of lipid peroxidation products (Parola and Robino 2001). Also, in a large retrospective 
study, patients with a fatty liver plus ballooning degeneration were found to be more 
likely to develop fibrosis (Matteoni et al. 1999). Hence, the subsequent development 
of liver steatosis in the transplanted animals 3 months after OLT in this study further 
emphasizes the importance of the recipient's underlying conditions in affecting the 
transplant outcome and prognosis. 
The clinical implication from this study is interesting. In addition to routine 
postoperative liver function tests and sonographic liver study, it may be important for 
obese liver transplant recipients to receive long-term dietician consultation for routine 
metabolism follow-up, body weight control and low-calorie dieting (Clain and 
Lefkowitch 1987; Keeffe et al. 1987). Light exercises have also been implicated 
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beneficial in hepatic lipid metabolism (Terao et al. 1988). Drug such as 
ursodeoxycholic acid may also be of therapeutic potential (Laurin et al. 1996; 
McCullough 2002). 
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Chapter 5 ________ _ 
In Vivo Assessment of Hepatocellular 
Mitochondrial Function during 
lschaemia/reperfusion in the Rat 
5.1 lntroduction 
5.2 Materials and Methods 
5.2.1 Experimental protocol 
5.2.2 Animals 
5.2.3 Surgical procedures 
5.2.4 Intravital fluorescence microscopy 
5.2.5 Off-line fluorescence analysis 
5.2.6 Liver enzyme analysis 
5.2. 7 Statistical analysis 
5.3 Results 
5.3.1 Association of Rhl23 fluorescence with hepatocellular mitochondria in vivo 
5.3.2 Effect of hepatic IR on hepatocellular mitochondrial function and viability 
5.3.3 Hepatocellular integrity after hepatic IR injury 
5.3.4 Relationship between alterations in hepatocellular mitochondrial function, cell viability, and 
cell membrane integrity during hepatic IR in the rat 
5.4 Discussion 
5.1 Introduction 
The long-term impact of orthotopic liver transplantation (OLT) in the obese 
Zucker rat has been studied in Chapter 4. The major early complication of OLT, on the 
other hand, is ischaemia-reperfusion (IR) injury (Clavien et al. 1992). One of the major 
consequences of hepatic IR injury is hepatocyte damage of which the precise 
mechanism remains unclear. There is a growing body of evidence suggesting that 
mitochondria are a major target of IR injury (Schild et al. 1997). These findings are of 
particular importance as mitochondria have been shown to play a pivotal role in the 
regulation of cell death under both physiological and pathophysiological conditions 
(Lemasters et al. 1987; Rosser and Gores 1995; Kroemer et al. 1998). For a 
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metabolically active organ such as the liver which is rich in mitochondria, an 
investigation into the changes in mitochondrial function is of particular significance in 
the understanding of the sub-cellular mechanisms underlying hepatic IR injury. 
The mitochondrion is the largest intracellular organelle responsible for cellular 
respiration that produces energy for ATP synthesis through oxidative phosphorylation. 
Under physiological conditions, the mitochondrial proton pump drives protons out of 
the matrix and thereby generates a proton gradient across the almost impermeable 
inner mitochondrial membrane. This electrochemical gradient forms a mitochondrial 
membrane potential (~\jf) of up to -160 m V which is vital for the maintenance of 
normal mitochondrial functions including ATP synthesis from inorganic phosphate 
and ADP, importation of mitochondrial proteins, calcium homeostasis, reintroduction 
of protons through the subunit F0 of complex V and a variety of other metabolic 
transport mechanisms (Kroemer et al. 1998; Jassem et al. 2002). 
The rapid sequestration of lipophilic cations in the mitochondria driven by the 
mitochondrial ~\JI has led to the development of a number of mitochondrion-selective 
probes which enable researchers to follow optically mitochondrial activity, localization 
and abundance of mitochondria, as well as to monitor the effects of some 
pharmacological agents on mitochondrial function (Elimadi et al. 1998; Settaf et al. 
1999). Rhodamine 123 (Rh123) is a cell-permeant, cationic, and mitochondrion-
selective fluorescent dye that is rapidly sequestered by mitochondria (Johnson et al. 
1980). This fluorochrome is subsequently washed out of the cells once mitochondrial 
~\JI is lost (Johnson et al. 1980; Goldstein and Korczack 1981; Johnson et al. 1981) 
(Fig. 5.1). Thus, quantification of the fluorescence intensity of Rhl23 has been 
validated as a measure of mitochondrial membrane potential. Studies performed using 
this mitochondrion-selective probe have been extensive over the years, with the 
majority of investigations performed using cell cultures (DeMartinis et al. 1987; Oh et 
al. 1991; Schneckenburger et al. 1992). Only in the recent past have Suematsu and co-
workers successfully established an approach for the in vitro assessment of 
hepatocellular mitochondrial function with Rh123 in an isolated perfused rat liver 
preparation (Suematsu et al. 1992; Kurose et al. 1993; Shiomi et al. 1998). They 
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demonstrated that hepatocellular mitochondrial A\jf was reduced by low flow-induced 








Figure 5.1 Structure of a mitochondrion and the membrane 
potential (A\jf)-dependent uptake of rhodamine 123 (Rh123). 
In vivo comparison of hepatocellular mitochondrial A\jf in intact rat liver with 
Rh123 is of particular interest because mitochondrial membrane permeability 
transition and disruption of the electrochemical gradient of the inner membrane is one 
of the several critical steps preceding the development of apoptotic cell death 
(Kroemer et al. 1998; Crompton 1999). Using the technique of intravital fluorescence 
microscopy (IVFM), the changes in mitochondrial membrane potential in vivo as 
reflected in the fluctuations of Rh123-derived fluorescence intensity can be visualised 
and compared. 
The fluorescent dye bisbenzimide (Hoechst 33342) rapidly permeates cells and 
binds to the minor groove of DNA in nuclei. This property of bisbenzimide has been 
exploited as a probe for cell viability especially in the field of cell biology where it is 
used to determine DNA content and density of cells. Elstein and co-workers 
demonstrated that only those viable and early apoptotic cells can be stained by 
bisbenzimide (Elstein and Zucker 1994). Vollmar and co-workers have successfully 
applied this fluorochrome in an in vivo study of hepatic structure during CC14- induced 
liver injury (Vollmar et al. 1998). The fluorochrome has been proven useful in the 
comparison of the number of viable hepatocyte and also the visualization of hepatic 
cords and sinusoids after orthotopic liver transplantation in the rat (Chapter 4). 
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The objectives of the present study were (i) to establish the technique of in vivo 
assessment of hepatocellular mitochondrial function by means of applying the 
selective mitochondrial probe Rh123 to the IVFM technique; (ii) to investigate the 
effect of hepatic IR on hepatocellular Rh123 fluorescence intensity which is a measure 
of mitochondrial Ll\!f; (iii) to establish the relationship between the alterations in 
hepatocyte integrity (assessed by estimation of plasma levels of liver enzymes), 
mitochondrial function, and cellular viability (by fluorochrome bisbenzimide) during 
hepatic IR in the rat. 
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5.2 Materials and methods 
5.2.1 Experimental protocol 
Age-matched Sprague Dawley rats were randomly divided into two groups: (i) 
hepatic IR group (n=7) that was subjected to 40 min of warm hepatic lobular ischemia 
followed by 60 min reperfusion; (ii) control group (n=7) which was not subjected to IR 
treatment of the liver. All animals were administered a bolus of heparin (20 U/kg, 
intravenously) following cannula placement in blood vessels. In the hepatic IR group, 
IVFM examination was started 15 min after intravenous bolus injection of Rhl23 and 
bisbenzimide but prior to the commencement of hepatic ischemia (pre-IR). 
Subsequently, IVFM was performed after 40 min of warm ischaemia, and at 15 min, 
30 min, 45 min, and 60 min after reperfusion. In the control group, IVFM was 
performed at 15 min, 55 min, 70 min, 85 min, 100 min and 115 min after intravenous 
injection of the fluorochromes. These time points corresponded to those chosen for the 
hepatic IR group after laparotomy. Blood samples were taken for the analysis of 
plasma enzyme activities prior to IR and at 15 min, 30 min, 45 min, and 60 min after 
reperfusion (Fig. 5.2). 
5.2.2 Animals 
Male Sprague Dawley rats with a body weight of 260 - 350 g were obtained 
from the Department of Laboratory Animal Sciences of Otago University Medical 
School, Dunedin, New Zealand and were housed in groups of 5 in temperature- and 
humidity-controlled animal quarters under a 12-h light/dark cycle. The animals were 
maintained on a standard rat diet with free access to tap water before surgery. This 
study was approved by the Committee on Animal Ethics in the Care and Use of 
Laboratory Animals of the Otago University Medical School. 
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(R't carotid a. & jugular v.) 
2. Dyes injection (Rh123, Bis) 1. Release occlusion 
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IR group: Hilar occlusion 
Control group: no occlusion 






Sprague Dawley rats: IR group (n=7), control group (n=7) 
Figure 5.2 Experimental protocol for the study of fluorescence intensity in 
hepatic IR injury 
IR: Ischaemia/reperfusion 
Rh123: Rhodamine 123 
Bis: Bisbenzimide 
IVFM: Intravital fluorescence microscopy 
A: IVFM examination 
~: Blood withdrawal and saline replacement 
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5.2.3 Surgical procedures 
All surgical procedures were performed under anaesthesia with chloralhydrate 
(36 mg/kg body weight intraperitoneal). Cannulae were inserted into (i) the right 
carotid artery for collecting blood samples and (ii) the right jugular vein for the 
administration of fluorochromes. A laparotomy was performed by an upper midline 
incision plus a left side sub-costal extension. Hepatic IR was accomplished by 
occluding the blood supply to left lobe liver for 40 min with the technique described 
(section 2.5.1.1). Reperfusion of the liver lobe was achieved by the release of the 
occluding suture. 
5.2.4 Intravital fluorescence microscopy 
The equipment and animal preparation procedures were described in section 
2.1.2 and 2.1.3, respectively. To avoid interference from the autofluorescence of 
vitamin A in hepatic stellate cells, 20 sec of ultraviolet light (UV) epi-illumination was 
applied to the microscopic areas to be observed prior to the application of the 
fluorochromes as described in Chapter 3 (Suematsu et al. 1994; Zhang et al. 1994; 
Vollmar et al. 1998). The dual cellular fluorescent probe (Rh123 and bisbenzimide) 
was then administered. Hepatocellular mitochondria were identified by a bolus 
injection of Rh123 (2 µmol/kg intravenously, Molecular Probes, Leiden, The 
Netherlands), while identification of viable hepatocyte nuclei was accomplished by 
intravenous injection of bisbenzimide (20 µmol/kg body weight, Sigma, St. Louis, 
USA). Hepatic fluorescence from Rh123 and bisbenzimide was visualised using filter 
combination of excitation/emission wavelengths 450 - 490 nm (blue light)/520 nm and 
360 nm (UV)/420 nm, respectively (Table 2.1). By shifting the optical filter 
combination, both Rh123 and bisbenzimide-derived fluorescence over the same 
microscopic field can be visualised. 
5.2.5 Off-line fluorescence analysis 
Quantitative analysis of hepatocellular mitochondria ~\jf (Rh123 associated 
fluorescence) and cell viability (bisbenzimide associated fluorescence) was performed 
off-line as described in section 2.1.4. Images acquired with the xlO objective (Fig. 
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2.3A) were used for quantitative data analysis on microfluorographs. Five to eight 
acini located in the centre of microscopic fields were randomly selected for the off-line 
frame-by-frame data analysis to abrogate possible distortion caused by a marginal 
shading effect (Suzuki et al. 1994). To investigate spatial alterations of Rh123 and 
bisbenzimide-associated fluorescence, a standard area of 80 x 200 µm2 was applied in 
individual periportal, midzone, and periportal zones of liver acini (Vollmar et al. 
1994). Using NIH image, the total grey values associated with hepatocellular 
fluorescence from Rh123 and bisbenzimide within the defined measurement area (80 x 
200 µm2) were determined and both the hepatocellular Rh123 and bisbenzirnide 
fluorescence intensity (optical density, OD) were automatically calculated once a 
density calibration was applied to the analysis system. 
5.2.6 Liver enzyme assay 
Blood samples were taken from the arterial catheter prior to IR and at 15 min, 30 
min, 45 min, and 60 min after reperfusion. Equal volume of normal saline was 
replaced through the venous catheter following each blood withdrawal. Plasma was 
separated by centrifugation and kept at -80 °C until measurement. Determinations of 
plasma aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 
concentrations, which are conventional markers of hepatocellular injury, were 
performed by standard spectrophotometric procedures using a BM/Hitachi 704 
Autoanalysor (Hitachi, Tokyo, Japan). 
5.2. 7 Statistical analysis 
Results were expressed as mean ± SEM. Comparison between groups was 
performed using ANOVA and the Bonferroni test. P<0.05 was considered significant. 
To assess the correlation between hepatocellular fluorescence intensity from Rh123 
and bisbenzimide, and the plasma liver enzyme activities (AST and ALT), linear 
regression analysis was performed (InStat V2.02A, GraphPad Software). 
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5.3 Results 
5.3.1 Association of Rh123 fluorescence with hepatocellular mitochondria in vivo 
The association of hepatic Rh123 fluorescence with hepatocellular mitochondria 
was identified with a high magnification objective (xlOO water immersion lens) (Fig 
5.3). Microfluorographs of the liver lobules showing fluorescence from injected 
bisbenzimide (UV epi-illumination, Fig 5.3A) and Rh123 (blue light epi-illumination, 
Fig 5.3B) were captured over the same microscopic area. For the purpose of tracing 
the intracellular origin of the fluorescence, colours were applied to the 
microfluorographs and a composite image (Fig 5 .1 C) was created by superimposing 
the two microfluorographs with the aid of computer graphic software. As is shown in 
Fig 5.3A, the hepatocyte nuclei were clearly shown as well-defined circular spots with 
bisbenzimide fluorescence, whereas no fluorescence was noted in the sinusoids (Fig 
5.3A-C). Bright patches of Rh123 fluorescence were identified within the cell (Fig 
5.3B). However, the origin of these bright spots is unknown. A dominant feature in the 
Rh123 microfluorograph was a circular area of lower fluorescence intensity compared 
with the rest of the hepatocyte (Fig 5.3B). This area with reduced fluorescence 
intensity was co-located with the nucleus of the hepatocyte (Fig 5.3C) indicating that 
the accumulation of Rh123 was in cytoplasm but not in nucleus. 
5.3.2 Effect of hepatic IR on hepatocellular mitochondrial function and viability 
The fluorescence intensity of Rh123 was used for the estimation of 
mitochondrial ~\If. In the control group, Rh123 fluorescence intensity decreased from 
the periportal (PP) to the pericentral (PC) region within the liver lobules (Table 5.1, 
Fig 5.4A). The fluorescence intensity was constant with time showing no significant 
fluctuation during the 110 min of microscopy (Table 5.1). 
In the hepatic IR group, the overall hepatocellular Rh123 fluorescence intensity 
within the liver lobules was significantly reduced by the end of 40 min warm ischemia 
compared with the pre-IR levels. The intensity rebounded significantly after 
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Figure 5.3 Observation of hepatocytes in vivo after concomitant administration of the fluorochromes 
bisbenzimide (Bis) and rhodamine 123 (Rh123). 
A. Appearance of hepatocyte nuclei (arrow) as well-defined circular spots. 
_J 
Q' 
B. Inhomogeneous fluorescence distribution in hepatocyte cytoplasm, showing a hypofluorescent circular region(*) 
in the middle. (Note: absence of fluorescence in the sinusoids) 
C. Computer generated image after superimposing A and B, showing co-location of a hepatocyte nucleus and the 
hypofluorescent region (arrow). 






Table 5.1 Temporal and spatial alterations of hepatocellular fluorescence intensity of Rhl23 and bisbenzirnide in the rats 
of the CONT group. 
Time post-loading fluorescence intensity of fluorescence intensity of bisbenzamide (OD) 
of Rh123 Rh123 (OD) 
pp MZ PC pp MZ PC 
15 min 0.90±0.05* 0.62±0.03 0.45±0.03 1.31±0.10* 1.10±0.08 0.83±0.04 
55 min 0.96±0.06* 0.64±0.02 0.42±0.02 1.35±0.13* 1.15±0.12 0.86±0.09 
70min 0.91±0.02* 0.61±0.05 0.42±0.04 1.32±0.11 * 1.09±0.10 0.83±0.08 
85 min 0.84±0.02 0.62±0.02 0.43±0.02 1.22±0.10* 1.06±0.11 0.90±0.08 
100 min 0.86±0.03 0.58±0.02 0.40±0.01 1.23±0.11 * 0.99±0.10 0.75±0.07 
115 min 0.87±0.05* 0.58±0.04 0.39±0.02 1.35±0.10* 1.12±0.09 0.81±0.08 
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Figure 5.4 Hepatocellular changes in vivo during warm hepatic IR in the rat. 
(A) Characteristic pre-IR zonal distribution of rhodamine 123 (Rh-123) fluorescence over hepatic lobules; 
(B) Overall decrease in Rh-123 fluorescence intensity after 60 min of reperfusion with non-perfused area (arrow); 
(C) Non-perfused region showing no Rh-123 fluorescence(*); 
(D) Pre-TR distribution of viable hepatocyte nuclei afte r bisbenzimide injection (appearing as bright spots); 
(E) Decrease in bisbenzimide fluorescence 60 min after reperfusion with region of non-perfusion (arrow); 
(F) Absence of bisbenzimide fluorescence over non-perfused region (*). 
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Figure 5.5 Summary of changes in Rh123 and bisbenzimide fluorescence intensity 
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Figure 5.6 Temporal and spatial alterations in hepatocellular fluorescence 
intensity of (A) Rhl23, and (B) bisbenzimide during hepatic IR in the rat. 
* P<0.05 vs. respective baseline; #P<0.05 vs. periportal zone at the same time 
point. 
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Hepatocellular viability was assessed by quantifying the hepatocellular 
fluorescence intensity of bisbenzimide. In the control group, bisbenzimide 
fluorescence intensity showed a decreasing gradient from the periportal (PP) to the 
pericentral (PC) region within the liver lobules (Fig 5.4D, Table 5.1). The fluorescence 
intensity was constant with time showing no significant changes during the 110 min of 
microscopy (Table 5.1). In the hepatic IR group, the overall hepatocellular 
fluorescence intensity of bisbenzimide within the liver lobules significantly declined 
during hepatic IR compared with that before IR (Fig 5.5 & 5.6B). 
5.3.3 Hepatocellular integrity after hepatic IR injury 
For the purpose of the present study, plasma liver enzyme activities were used 
for the evaluation of the hepatocyte integrity after hepatic IR. Table 5.2 summarised 
the alterations in plasma liver enzyme activities (AST and ALT) in the rats of the 
hepatic IR group. Both plasma AST and ALT levels were significantly elevated after 
ischaemia compared with the pre-IR levels. 
5.3.4 Relationship between alterations in hepatocellular mitochondrial function, cell 
viability, and cell membrane integrity during hepatic IR in the rat 
Linear regression analysis between alterations in hepatocellular fluorescence 
intensity of Rh123 and bisbenzimide before and after hepatic IR revealed a significant 
correlation with r2=0.76 in the hepatic IR group (P<0.05; Fig 5.7). This parallel 
reduction in fluorescence intensity was well-illustrated in microfluorographs taken 60 
min after reperfusion (Fig. 5.4B & E). Interestingly, in the hepatic IR group, linear 
regression analysis of plasma liver enzyme activities with hepatocellular fluorescence 
intensity of Rh123 and bisbenzimide revealed that the plasma AST levels were 
significantly correlated with hepatocellular fluorescence intensity of Rh123 (r2=0.80, 
P<0.05; Fig 5.8A) and bisbenzimide (r2=0.94, P<0.05; Fig 5.8B). Similarly, the 
plasma ALT levels were also found to be significantly correlated with the fluctuations 
in hepatocellular fluorescence intensity of Rh123 (r2=0.90, P<0.05; Fig 5.8C) and 
bisbenzimide (r2=0.96, P<0.05; Fig 5.8D) during hepatic IR in the rat. 
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Table 5.2 Temporal alterations of plasma AST and ALT levels in the rats of the 
hepatic IR group. 
Time course AST (IU/L) ALT (IU/L) 
Pre-IR 102±13 50±5.3 
15-min reperfusion 98±48 112±28* 
30-min reperfusion 333±57* 116±10* 
45-min reperfusion 352±51* 119±26* 
60-min reperfusion 439±79* 154±62* 
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Figure 5.7 Correlation between hepatocellular Rh123 and bisbenzimide 
fluorescence intensity. 
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Figure 5.8 Correlations of plasma AST (A & B) and ALT (C & D) levels with 
hepatocellular fluorescence intensity of Rh123 and bisbenzimide. 
Symbols shown refer to different time points: pre-IR (0), 15 min (0), 30 min (Li), 45 
min c•), and 60 min (.6.) following reperfusion in the rat. 
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5.4 Discussion 
Suematsu and co-workers first demonstrated a linear relationship between 
hepatocellular fluorescence intensity and the loading concentrations of Rhl23 in the 
perfusates of an ex vivo isolated perfused rat liver model (Suematsu, Suzuki et al. 
1992). The use of IVFM to monitor the fluorescence intensity of Rh123 as a measure 
of mitochondrial ~\JI in different in vitro liver preparations was further validated in 
their subsequent studies (Kurose et al. 1993; Morikawa et al. 1998). In this study, the 
origin of the Rh123 fluorescence was found to be cytoplasmic (Fig. 5.3). It is 
compatible with the cytoplasmic location of mitochondria. The decreasing 
fluorescence gradient from zone 1 to zone 3 of an acinus in the control group can be 
explained by the fact that hepatocytes over different zones of an acinus perform 
different tasks depending on their proximity to the portal triad that determines the 
concentration of nutrients and available oxygen, with zone 1 (i.e. periportal) 
hepatocytes containing the highest concentration of enzymes involved in active 
synthetic processes such as glycogenesis and gluconeogenesis and zone 3 (i.e. 
pericentral) hepatocytes at the other end of the scale (Howard and Billiar 1992). 
Ischaemia-reperfusion injury is a complex process involving leukocyte activation 
(Harada et al. 1999), adhesion molecule expression (Vollmar et al. 1995; Nakano et al. 
1997; Yadav et al. 1999), cytokine production (Lichtman and Lemasters 1999), free 
radical formation (Packer et al. 1996; Chavez-Cartaya et al. 1999), gene and enzyme 
upregulation (Schlossberg et al. 1996; Onishi et al. 1997; Kohli et al. 1999a), 
triggering of cell death (Kohli et al. 1999a & b; Jaeschke 2003) as well as the 
involvement of a variety of vasoactive molecules such as endothelin and nitric oxide 
(Pannen et al. 1998a) (Chapter 7 & 8). It has been shown that ATP levels in liver 
preparations exposed to hepatic hypoxia and/or IR was remarkably reduced, indicating 
a derangement in mitochondria-associated aerobic metabolism (Stefanelli et al. 1997; 
Klauke et al. 1998). Klauke et al. have demonstrated that the fluorescence intensity of 
nicotinamide adenine dinucleotide (NADH), an indicator of mitochondrial oxygen 
consumption (Chapter 3), in a hypothermically-stored rat liver model was increased 
(Vollmar et al. 1997; Klauke et al. 1998), which indicated an interruption of 
mitochondria-associated oxidative phosphorylation due to decreased oxygen supply 
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from hypothermic ischaemia. Moreover, induction of hypoxia in isolated rat 
mitochondria was found to impair ADP-stimulated respiration after reoxygenation. 
The impairment also decreased with time of hypoxia and reoxygenation, suggesting 
that mitochondria play a pathogenic role in IR injury (Schild et al. 1997). Current 
thinking suggests that not only are mitochondria a major target in IR injury, they can 
also trigger a vicious cycle. The reactive oxygen species (ROS) released from 
damaged mitochondria can suppress mitochondrial respiration and cause damage to 
various molecules including lipids, protein, DNA, as well as the electron transport 
chain for oxidative phosphorylation. The damage may then enhance further 
suppression in ATP synthesis, aggravation in electron leakage and further ROS 
formation (Zhang et al. 1990; Chen and Yu 1994). This applies particularly to the liver 
which is the metabolic powerhouse of the body. 
Beside ROS formation, another pivotal role that mitochondria play in IR injury 
is the control of cell death (Jassem et al. 2002). Programmed cell death, or apoptosis, 
has been proposed to be the predominant form of IR-induced cell death (Kohli et al. 
1999b). It has also been shown to be a mitochondrion-dependent process (Kroemer et 
al. 1995). Accordingly, various anti-apoptotic approach, including transfection of cells 
the Bcl-2 gene (Bilbao et al. 1999) or caspase inhibition (Cursio et al. 2000) have been 
demonstrated to be protective against hepatic IR injury. Similarly, administration of 
the antiapoptotic agents such as IGF-I and zVAD-fmk (a caspase inactivator) was 
found to prevent the early onset of not only renal apoptosis, but also inflammation and 
tissue injury at the time of reperfusion (Daemen et al. 1999). The first step in the 
development of apoptosis is a transition in inner mitochondrial membrane permeability 
and loss of transmembrane mitochondrial potential, ~\If (Kroemer et al. 1998; 
Crompton 1999). It has been shown that ischaemia alone can inhibit the Na+/K+ pump, 
resulting in an increase in cytosolic Na+ which in turn causes an increase in cytosolic 
Ca2+. This then leads to an increase in mitochondrial Ca2+ and inner membrane 
permeability (Crompton 1999). Indeed, inhibition of permeability transition has been 
shown to prevent apoptosis under certain circumstances (Marzo et al. 1998). On the 
other hand, another study suggested that mitochondrial permeability transition is a 
common mechanism in mitochondrial autophagy, apoptosis and necrotic cell death 
(Lemasters et al. 1998). Hence, the post-IR reduction in ~\If as reflected in a 
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diminished Rh123 fluorescence in this study can be indicative of a beginning apoptotic 
and/or necrotic process. 
Vollmar and colleagues originally described the application of the fluorochrome 
bisbenzimide as a cell viability probe to the IVFM technique. They demonstrated that 
intrahepatic fluorescence intensity of bisbenzimide was associated with not only the 
perfusion status of liver vasculature, but also with the degree of hepatocellular 
damages in a rat hepatic IR model (Vollmar et al. 1996). In this study, the significant 
correlation between the decline in Rh123 and bisbenzimide fluorescence intensity after 
IR indicates that although the two fluorochromes stain different organelles within the 
cell (Fig. 5.3), they both detect a common cellular event after IR injury. This may be 
due to an overall suppression in cellular metabolic activity resulting from membrane 
pump dysfunction (Crompton 1999), over-accumulation of free radicals (Jassem et al. 
2002) and metabolic products such as acyl-CoA esters (Henke and Jung 1991) as well 
as ischaemic damage to the mitochondrial electron transport chain (Rouslin 1983) 
resulting in ATP depletion. 
The inhomogenous uptake of bisbenzimide from different zones of an acinus 
(Fig 5.4D, Table 5.1) may be due to (i) the difference in hepatocyte population 
distribution within a hepatic lobule; (ii) first-pass effect with the hepatocytes in the 
periportal region taken up most of the dye as blood flows from zone 1 to zone 3 of an 
acinus; (iii) different metabolic activities of hepatocytes; or (iv) an inhomogenous 
distribution in hepatocytic DNA content. As the fluorescence intensity remained 
constant with time, the first-pass effect seems unlikely. Other than the possible 
difference in regional distribution of hepatocytes and DNA content, the difference in 
metabolic activities ( or "viability") of hepatocytes over different zones of an acinus as 
mentioned above may account for the regional difference in bisbenzimide fluorescence 
intensity in the control group. The observation is compatible with the proposal that not 
all hepatocytes show simultaneous metabolic activities and about two thirds of all 
hepatocytes are dormant at any given time (Meyers and Jones 1990). 
Although it was reported that only a few necrotic hepatocytes could be detected 
up to 6h of reperfusion (Kohli et al. 1999b ), a later report demonstrated that oncotic 
necrosis occurs in up to approximately 35% of all hepatocytes at 6h of reperfusion 
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(Gujral et al. 2001). The significant increase in plasma transaminases during 
reperfusion in this study also supports the results of the latter study. The significant 
drop in bisbenzimide fluorescence as soon as 15 min after reperfusion and the 
significant correlation between the bisbenzimide fluorescence intensity and plasma 
transaminase levels during IR suggest that bisbenzimide is a sensitive in vivo indicator 
of hepatocellular integrity. 
In conclusion, this study demonstrated the successful use of IVFM in the 
detection of post-IR derangement in hepatocellular mitochondrial function in vivo. The 
significant correlation between post-IR alterations in fluorescence intensity and plasma 
transaminase activities validated the use of fluorescence intensity as an in vivo 
indicator of hepatocellular integrity. In addition, a parallel relationship between 
mitochondrial membrane potential and cell viability as reflected in a concomitant 
reduction in nuclear and cytoplasmic fluorescence intensity after 40 min of warm 
ischemia was also demonstrated. The results suggest that transition in mitochondrial 
membrane potential is an early mechanism involved in warm hepatic IR-induced 
impairment in hepatocellular integrity and cell death. 
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Chapter 6 ________ _ 
Effect of Ischaemia-reperfusion Injury on the 
Microcirculation of the Steatotic liver of the 
Obese Zucker Rat 
6.1 Introduction 
6.2 Materials and Methods 
6.2.1 Experimental protocol 
6.2.2 Animals 
6.2.3 Surgical procedures 
6.2.4 Intravitalfluorescence microscopy (IVFM) 
6.2.5 Induction of hepatic ischaemialrepeifusion (IR) inju1y 
6.2.6 Off-line microcirculatory analysis 
6.2. 7 Histological analysis 
6.2.8 Enzyme assay 
6.2.8 Statistical analysis 
6.3 Results 
6.3.1 Liver/body weight ratio 
6.3.2 Histology 
6.3.3 Hepatic microcirculation 
6.3.4 Hepatic injury 
6.4 Discussion 
6.1 Introduction 
Profound disruption of hepatic architecture is a common feature in obese 
patients. Morphologically, these changes are characterized by a demonstrable 
deposition of large, macronodular fat droplets in liver parenchymal cells, a condition 
which gives rise to the expression "fatty liver" (Van Steenbergen and Lanckmans 
1995). The clinical classification and significance of the condition were introduced in 
Chapter 4. To date, shortage of donor organs for transplantation remains an unsolved 
problem worldwide. The prevalence of steatotic changes in the potential donor liver 
pool has aroused much discussion as to whether fatty livers should be accepted for 
transplantation (Teramoto et al. 1993; Urena et al. 1998). Experimental models of fatty 
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livers have been reported to be more sensitive to ischaemia/reprefusion (IR) injury 
because of the presence of more tortuous and narrow sinusoids, defective mitochondria 
ATP synthesis and increased sensitivity of IR injury of endothelial cells and 
hepatocytes (Sato et al. 1986; Fukumori et al. 1997; Taneja et al. 1998; Takeda et al. 
1999). Reduced regional hepatic blood flow and decreased tissue oxygenation have 
also been found in the obese Zucker rat (Chapter 3), however, sinusoidal erythrocyte 
flow velocity (Sato et al. 1986), oxygen consumption and the oxidative capacity of 
hepatocytes in the obese animals have been reported to be normal (Wardlaw and 
Kaplan 1986). Therefore clinically, some still propose the acceptance of fatty livers for 
transplantation, once hepatocytic necrosis or other unfavorable donor risk factors are 
absent (Teramoto et al. 1993; Fishbein et al. 1997; Chui et al. 1998; Canelo et al. 
1999). A protocol for the use of steatotic grafts has been suggested (Urena et al. 1999). 
Hepatic IR injury is a complex process involving different cellular elements, 
adhesion molecules, reactive oxygen species (ROS), protease, and a wide variety of 
inflammatory mediators (section 1.5). The impact of IR injury on hepatic 
microcirculation was also discussed in section 1.5.4. Although the steatotic liver has 
been demonstrated to sustain enhanced IR injury, including increased production of 
lactate dehydrogenase and alanine transferase (Taneja et al. 1998), elevated lipid 
peroxidation, enhanced hepatocellular necrosis (Selzner et al. 2000), sinusoidal 
microcirculatory failure (Hakamada et al. 1997), and reduced survival (Koneru et al. 
1995) in the obese animals. The exact mechanisms for the increased vulnerability, 
however, remain unclear. After showing that the change in mitochondrial membrane 
potential is an early significant subcellular alteration contributing to warm hepatic IR 
injury (Chapter 5), the aim of this study was to demonstrate the hypothesis that 
increased depression in mitochondrial membrane potential following IR in the steatotic 
liver contributes to its enhanced injury. In this study, the technique of intravital 
fluorescence microscopy (IVFM) was utilized to investigate the changes in 
mitochondrial membrane potential, hepatocyte nucleus density, the number of perfused 
sinusoids and leukocyte adherence in the steatotic liver of the obese Zucker rat. 
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6.2 Materials and Methods 
6.2.1 Experimental protocol 
Both lean and obese Zucker rats were subjected to 40 mm partial hepatic 
ischemia followed by 60 min of reperfusion. In vivo measurement of liver 
microcirculation by IVFM was performed before hepatic ischemia and at 15 min, 30 
min, 45 min, and 60 min after reperfusion. Blood samples were taken, for liver enzyme 
assay, before hepatic ischemia and at 60 min after reperfusion. At the end of 
experiment, the liver were harvested and weighed and tissue processed for histological 
analysis (Fig. 6.1 ). 
6.2.2 Animals 
Male Obese Zucker rats (14 - 16 weeks of age, n=9) and age-matched lean 
controls (n=9) were used in this study. The whole experiment was conducted in 
accordance with the Care and Use of Laboratory Animals (NIH publication 86-23, 
revised 1985) and with the approval of the Otago University Animal Ethics 
Committee. All animals were housed with controlled 12 hr light/dark cycles with free 
access to water and standard laboratory diet. 
6.2.3 Surgical procedures 
All surgical procedures were performed under chloralhydrate anesthesia (36 
mg/kg body weight intraperitoneal). With the technique described in section 2.4.3, 
cannulae were inserted into the right femoral artery and the right femoral vein for 
collection of blood samples and administration of fluorochromes, respectively. 
Procedures of animal preparation for IVFM were detailed in section 2.1.3. 
6.2.4 Intravitalfluorescence microscopy (IVFM) 
IVFM was performed as previously described m section 2.1.2. A bolus of 
rhodamine 6G (Rh6G, 0.1 µmol/kg, Sigma Chemical Co. USA) was administered 
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Figure 6.1 Experimental protocol for the study of acute warm hepatic IR injury in the obese 
Zucker rat 
(A: IVFM examination) 
membrane potential and hepatocyte nuclei were identified by a bolus injection of 
rhodamine 123 (Rh123, 1 µmol/kg intravenously, Molecular Probes, Leiden, The 
Netherlands) and bisbenzimide (Bis, 2 µmol/kg body weight, Sigma, St. Louis, USA), 
respectively. Three different filter sets with excitation/emission wavelengths 450-490 
nm/>520 nm, 530-560 nm/>580 nm and 330-390 nm/>430 nm were used for the 
detection of fluorescence from mitochondria, leukocyte and hepatocyte nuclei after 
staining with Rh123, Rh6G, and Bis, respectively (Table 2.1). 
6.2.5 Induction of hepatic ischaemia/reperfusion (IR) injury 
Hepatic IR was induced using the method described in section 2.5.1.1. 
6.2.6 Off-line microcirculatory analysis 
The analysis was achieved with the equipment depicted in section 2.1.4.1. 
Methodology for quantitative analysis of leukocyte adherence, hepatocellular Rh123 
fluorescence intensity, and hepatocyte nucleus density as well as the measurement of 
hepatic cord width and sinusoidal diameter were detailed in section 2.1.4.2 (Fig. 2. 7). 
6.2. 7 Histological analysis 
All tissue samples were fixed in 10% buffered formalin, embedded in paraffin 
and processed for hematoxylin-eosin (HE) staining using standard techniques. 
Specimens were compared in a blind fashion with respect to the extent of macro- and 
microvesicular fatty changes and hepatocyte swelling by an independent pathologist 
(AZ). The grading systems were as follows: macrovesicular fatty change (MAFC) (0: 
none, 1: few single hepatocyte with MAFC, 2: small clusters of hepatocytes with 
MAFC, less than 5% of section involved, 3: larger clusters, 5-10% of section involved, 
4: more than 10% involved), microvesicular fatty change (MIFC) (0: none, 1: few cells 
involved, not easily detectable, 2: easily detectable, 3: easily detectable, massive), 
hepatocyte swelling (0: absent, 1: minor swelling, 2: marked swelling). 
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6.2.8 Liver enzyme assay 
The blood samples were taken from the femoral arterial catheter and placed in 
heparinized tubes. Plasma was separated by centrifugation and kept at -80 °C until 
measurement. Analysis of plasma levels of aspartate aminotransferase (AST) and 
alanine aminotransferase (ALT) were performed using a Hitachi 705 Autoanalyser. 
6.2.9 Statistical analysis 
All data were expressed as mean ± SEM. Where appropriate, the Student t test was 
used for analysis of the data. For all other data, repeat measure analysis was also 
performed using SAS software. P<0.05 was considered significant. 
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6.3 Results 
6.3.1 Liver/body weight ratio 
The liver weight, body weight and liver/body weight ratio in the lean and obese 
animals are given in Table 6.1. The livers from the obese animals were 86% heavier 
than those from the lean animals. The obese animals were 59% heavier than the lean 
and the liver/body weight ratio was 15.2% higher in the obese animals. 
6.3.2 Histology 
Liver specimens from both lean and obese Zucker rats had a normal liver 
structure, without signs of hepatitis or fibrosis. In the lean animals, no signs of 
steatosis or hepatocyte swelling were detected (Fig. 6.2A), whereas these features were 
evident in the obese animals (Fig, 6.2B - lD). The obese animals presented with 
marked MAFC which was mostly pericentral in distribution (Fig. 6.2B). The grading 
of the obese animals (3.3±0.1) was remarkably higher than the lean (0.8± 0.4) (Table 
6.2). MIFC was not found in the lean animals (Fig. 6.2A), whereas the obese animals 
had prominent MIFC (Fig. 6.2C). Mixed MAFC and MIFC were also found in the 
obese Zucker rats (Fig. 6.20). Hepatocyte swelling was seen only in samples from the 
obese animals, which was sometimes associated with microvesicular fatty change. On 
the basis of these findings, we confirmed that the liver of the obese Zucker rat was 
steatotic. 
6.3.3 Hepatic microcirculation 
The width of hepatic cord was 15.9±0.5 µm and 23.1±0.8 µm for the lean and 
steatotic livers respectively (Fig 6.3A, P<0.0001). No significant difference was found 
between the sinusoidal diameters of the lean (9.9±1.9 µm) and the steatotic liver 
(9.8±2.0 µm, p>0.05; Fig. 6.3B). The hepatic cord width/sinusoidal diameter ratios 
were 2.5±0.23 and 1.7±0.15 for the steatotic and lean livers, respectively (P<0.0001). 
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Table 6.1 The body weight, liver weight, and liver/body weight ratio of lean and 
obese Zucker rats. 
Lean (L) Obese (0) 
% difference 
= (0-L)/Lx100% 
Liver weight (L W) (g) 14.4±0.9 26.8±2.1 * 86.1% 
Body weight (BW) (kg) 0.4±0 0.7±0* 59.5% 
LW/BW ratio (g/kg) 33±1.5 38±2.5* 15.2% 









Figure 6.2 Characteristics of liver histology in the (A) lean and (B - D) obese 
Zucker rats on hematoxylin and eosin staining. 
(A) Normal portal tract is seen close to the centre. Hepatocytes do not demonstrate any 
fatty change. 
(B) Pericentral area of liver lobule shows marked macrovesicular fatty change of 
hepatocytes (black arrow). 
(C) Numerous enlarged hepatocytes with foamy cytoplasm indicates marked 
microvesicular fatty change (white arrow). 
(D) Considerable fatty change of both macrovesicular and microvesicular type is seen. 
(CV: central vein). 
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Table 6.2 Semi-quantitative analysis of morphological features in livers from 




MAFC: macrovesicular fatty change, 
MIFC: microvesicular fatty change, 














Figure 6.3 Microfluorographs of representative bisbenzimide-stained hepatocyte 
nuclei. (A) lean Zucker rats. (B) obese Zucker rats. The bright spots represent 
positively bisbenzimide-stained hepatocyte nuclei (white arrow). Black arrows 
indicate increased hepatic cord width. S: sinusoids. The bars in the lower right 
corner in each microfluorograph represent 50 µm. 
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A significantly lower hepatic cord density (lean: 8.1±0.2/200 µm vs. steatotic: 
6.5±0.2/200 µm, P<0.0001) and sinusoidal density (lean: 7.6±0.4/200 µm vs. fatty: 
5.9±0.4/200 µm, P<0.0001) was found in the steatotic livers under control conditions. 
A progressive decrease in the functional sinusoidal density during IR was seen in both 
lean and steatotic livers (Fig. 6.4A) which was statistically significant (P<0.05 versus 
baseline) from 30 min after reperfusion onwards. No significant differences between 
groups were found. 
As shown in Fig. 6.4B, the hepatocyte nucleus density was significantly lower in 
the steatotic than in the lean liver before IR (69.9±6.8 vs. 88.8±9.0 /200 x 200 µm2, 
P<0.01), whereas there was no statistically significant deviation in the two groups 
from their baseline values during subsequent reperfusion. 
There was a significant rise (P<0.05, versus respective baselines) in sinusoidal 
leukocyte adherence in both lean (from 30 min reperfusion on) and steatotic livers 
(from 15 min after reperfusion on). There was a tendency towards increased leukocyte 
adherence with time of reperfusion in both groups with an overall 4-fold increase in 
the steatotic liver and 3-fold increase in the lean liver. However, no statistically 
significant difference between the two groups was found (Fig. 6.4C). 
Baseline hepatocellular Rh123 fluorescence intensity was not significantly 
different between the two groups (Fig. 6.5). However, in the steatotic liver a 
significant fall in Rh123 fluorescence over time was found (P<0.05 versus baseline at 
60 min reperfusion), while in the lean liver fluorescence remained constant throughout 
the IR protocol. 
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Figure 6.4 Effect of hepatic IR on (A) functional sinusoidal density, (B) 
hepatocyte nucleus density, and (C) leukocyte adhesion in the sinusoidal lining 
cells in the lean and obese Zuckr rats. *P<0.01 vs. lean group at the same time 
point; #P<0.05 vs. baseline of the same group. 
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Figure 6.5 Effect of hepatic IR on the hepatocellular Rh123 fluorescence intensity 
in the lean and obese Zuckr rats. *P< 0.05 vs. baseline of the same group. 
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6.3.4 Hepatic injury 
Prior to hepatic IR, there was no significant difference in plasma AST levels 
between the lean and obese animals (Fig. 6.6A). However, a 40 fold increase in AST 
following reperfusion was found in the obese animals which was significantly greater 
than the 4.2 fold increase found in the lean animals. The plasma ALT level also 
showed a parallel trend (Fig. 6.6B), with no significant difference in the baseline 
values between the two groups. Again, plasma ALT levels were significantly higher in 


















Figure 6.6 Effect of hepatic IR on (A) serum AST and (B) serum ALT in the 
lean and obese Zuckr rats. * P< 0.05 vs. baseline of the same group. #P<0.01 vs. 
lean group post-IR. 
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6.4 Discussion 
The Zucker rat model of hepatic steatosis has been reported to be preferable to 
the choline and methionine deficiency-induced models in the study of IR injury due to 
the minimal lobular inflammation found in the obese Zucker rat (Koneru et al. 1995). 
A significant MAFC was confirmed in our obese Zucker rats. The distribution was 
mostly pericentral and was consistent with the pattern of hepatic fatty infiltration 
found in human conditions such as obesity, diabetes mellitus, alcoholism and also 
prolonged high cholesterol intake. This is in contrast to conditions such as protein 
malnutrition, Kwashiorkor, pregnancy and low choline-methionine diet which have 
predominantly periportal fat distribution (Seifalian et al. 1999). MIFC of hepatocytes 
has been suggested to be a reliable prognostic factor in the prediction of the outcome 
after liver retransplantation in humans because it has been reported to be associated 
with impaired mitochondrial ~-oxidation (Yoong et al. 1999). In this study, MIFC was 
not detected in the lean animals but was consistently detected in the livers of obese 
Zucker rats. These findings support the use of obese Zucker rats as a model of human 
hepatocellular and microcirculatory change in obesity. 
In accordance with the findings of other authors (Malewiak et al. 1983), we 
found that the size of the hepatocytes in the obese rats was significantly larger than in 
their lean counterparts as reflected in the size of hepatic cords in the two groups. 
Increased hepatocyte volume is believed to be due to the increased lipid content of 
their hepatocytes (Fukuda et al. 1982). However, in our obese Zucker rats increased 
hepatic cord size was not accompanied by a reduction in sinusoidal diameters as noted 
by others (Sato et al. 1986). The results are consistent with those previously described 
in Chapter 4. The significant difference in liver weights between groups may be 
explained by the larger size of hepatocytes in the fatty group. This may also explain 
the significantly reduced number of hepatocyte nuclei counted per unit area using the 
fluorochrome bisbenzimide (Fig. 6.4B). In Chapter 3, reduced regional hepatic blood 
flow and reduced microcirculatory perfusion in steatotic livers have been 
demonstrated. Consistent results have also been reported previously (Sato et al. 1986; 
Seifalian et al. 1999). In accordance with the finding of decreased tissue oxygenation 
in steatotic liver (Chapter 3), a combination of reduced blood flow with an increased 
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hepatocyte width/sinusoidal diameter ratio m fatty livers may cause nutrient and 
oxygen diffusion barriers which may account for the generally noted abnormal liver 
tests in obese human objects (Van Steenbergen and Lanckmans 1995). 
In the present study, hepatocellular swelling was noted only in the fatty livers. 
Some of the swollen cells were ballooned as seen, for example, in transport disorders 
owing to membrane pump defects. This is compatible with the previous finding that 
ischaemia can inhibit the Na+/K+ pump, resulting in a subsequent increase in 
mitochondrial inner membrane permeability and cell death (Crompton 1999) (Chapter 
5). Hence, the results of this study further implies an increased vulnerability of 
steatotic liver to IR injury through this pathway. 
Steatosis is made up of a spectrum of cellular changes, with fat droplets ranging 
from small to large. Consequently it is not possible to calculate a precise "steatosis 
index". As an alternative, experts use board ranges (e.g., <5%, 5-25%, >25%) when 
dealing with cellular involvement and allocate grades of injury to these ranges (0, 1, 
etc) (Wanless and Lentz 1990; Brunt et al. 1999). In this study, we used a grading 
system similar to that employed in human studies, but with a more refined approach in 
lower level steatosis, in order not to miss the lowest level of MAFC. 
Rh123 is a cell-permeant, cationic, and mitochondrion-selective fluorescent dye 
that is rapidly sequestered by mitochondria (Johnson et al. 1980). This fluorochrome is 
subsequently washed out of the cells once the mitochondrial membrane potential (~\jf) 
is lost (Haugland 1999). Thus, quantification of the hepatocellular fluorescence 
intensity of Rh123 is a measure of mitochondria ~\jf (Suematsu et al. 1992) as 
described in Chapter 5. In this study, we found that there was no significant difference 
in the baseline hepatocellular Rh123 intensity between the two groups. Indeed, it has 
been proposed that liver steatosis is unlikely to result in profound impairment of 
hepatocellular mitochondrial function. Studies from other groups have shown that 
there is a lack of notable difference in the oxygen consumption in vivo (Sato et al. 
1986) and oxidative capacity in hepatocytes isolated from obese and lean Zucker rats 
(Sato et al. 1986; Wardlaw and Kaplan 1986). However, we found that Rh123 
intensity at 60 min after reperfusion in the obese animals was significantly reduced as 
compared with the lean rats. This indicates that derangement of hepaocellular 
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mitochondrial function occurred in the obese Zucker rats during hepatic IR injury. This 
is consistent with enhanced liver injury as reflected by marked elevated plasma liver 
enzymes after reperfusion in the obese group in this study and further supports the 
previous proposal that fatty liver is more sensitive to IR injury (Koneru et al. 1995; 
Fukumori et al. 1997; Nakano et al. 1997). 
The significantly increased leukocyte adhesion in both steatotic and lean groups 
found after reperfusion in this study is compatible with the previous evidence that 
leukocyte adherence contributes to IR injury (Vollmar et al. 1995). However, the lack 
of significant difference between the two groups suggested that leukocyte adhesion 
may probably not account for a greater tissue damage observed in the fatty animals 
during IR injury, which is consistent with the results of a previous study by Koneru et 
al (Koneru et al. 1995). 
Steatotic liver is a common feature in obese patients. Evaluation of donor fatty 
livers in the clinical settings is not easily achieved. Nonetheless, sonographic 
examination of the liver and needle aspiration biopsy are the commonly utilized 
methods of graft evaluation, with needle biopsy providing the clinician with a definite 
diagnosis. The normal human liver contains approximately 5 gm of lipid/100 gm wet 
weight, with triglyceride accounting for approximately 20% of this (Cairns and Peters 
1983). However, a mild degree of steatosis may be considered normal in the ageing 
liver (Findor et al. 1973). Pathologically, fatty liver is defined as fat, largely 
triglycerides, exceeding 5% of the liver weight (Sherlock and Dooley 1993). 
Therefore, from a theoretical point of view, any macrovesicular steatosis above 5% 
represents a pathological fatty change which renders the liver not ideal for 
transplantation. However, due to a lack of "normal" donor liver grafts, there has been 
considerable discussion in the literature (Karayalcin et al. 1994) about the acceptable 
level of steatosis that can still offer the transplant recipient minimal risk of primary 
graft nonfunction (Toda et al. 1989). 
The precise mechanism underlying increased vulnerability of fatty livers to IR 
injury is still not fully understood. Current thinking suggests that the enhanced IR 
injury in fatty livers may be attributed to (i) fat solidification during organ preservation 
and hepatocyte disruption during reperfusion; (ii) enhanced lipid peroxidation; (iii) 
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increased damage to the sinusoidal microcirculation and increased leukocyte adhesion 
to the sinusoidal endothelial cells; (iv) increased Kupffer cell activation; (v) 
deterioration of mitochondrial ATP synthesis and (vi) decreased antioxidant defenses 
of the fat-laden hepatocytes (Koneru et al. 1995; Fukumori et al. 1997; Taneja et al. 
1998). Clinically, some authors proposed a fatty infiltration of up to 60% to be the cut-
off point for the acceptance of a liver graft for transplantation (D'Alessandro et al. 
1991). It has also been reported that microvesicular steatosis involving more than 66% 
of hepatocytes is associated with a significantly worse outcome after liver 
retransplantation (Yoong et al. 1999). However, it is more likely that hepatic steatosis 
alone is not the single most important cause of post-transplant initial dysfunction or 
nonfunction (Canelo et al. 1999). Other factors such as advanced donor age, history of 
cardiac arrest, ischemia time, dopamine dosage, oliguria, hypotension and duration of 
intensive care appear to be other significant factors to be considered (De Carlis et al. 
1996; Chui et al. 1998; Canelo et al. 1999). 
Liver graft dysfunction related to IR injury that can occur during transplantation 
is also a contributor to morbidity and mortality in clinical liver transplantation 
(Clavien et al. 1992). The mechanism of IR injury is multi-folded, including leukocyte 
and platelets adhesion, free radicals release and the interactions of vasoactive 
substances such as endothelin and nitric oxide (Connor et al. 1992; Vollmar et al. 
1995; Pannen et al. 1998a; Taneja et al. 1998; Sindram et al. 2000). In the liver, recent 
evidence also suggests that apoptosis play a role in hepatic IR injury (Gao et al. 1998; 
Yoshidome et al. 1999; Sindram et al. 2000) (Chapter 5). With advances in the 
prevention of the IR-related pathological process, however, the adverse effect of graft 
steatosis could be minimized and more marginal cases could be adopted to relieve the 
long-standing problem of organ shortage. 
In conclusion, with the use of a genetically predisposed steatotic liver model, we 
demonstrated that (i) the weight of the steatotic liver of the obese Zucker rat was 86% 
more than that of the lean animals. A significantly higher liver/body weight ratio in the 
fatty animals implies that the amount of lipid deposition in the liver is proportionally 
higher than the rest of the body as a whole in the absence of nutritional or drug factors 
such as alcohol intake; (ii) liver steatosis increased the hepatic cord width but had no 
effect on sinusoidal diameters in the obese Zucker rat model. This can probably 
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explain the overall increased size of their livers, decreased hepatocyte density and 
reduced regional hepatic blood flow. Whether the increased hepatic cord 
width/sinusoidal diameter ratio contributes to an increased oxygen and nutrients 
diffusion barrier in hepatocytes of fatty livers remains to be elucidated; (iii) liver 
steatosis appeared to have no prominent impact on hepatocyte integrity and 
mitochondrial function under normal condition. However, increased vulnerability of 
fatty livers to IR injury was evident as reflected in the elevated liver enzymes, 
decreased Rh123 fluorescence intensity, and hepatocyte swelling after IR. 
Furthermore, this enhanced depression in mitochondrial membrane potential in the 
steatotic liver following reperfusion is probably one of the key mechanisms 
exacerbating its injury during IR. 
- 190 -
Chapter 7 
The Effect of Acute Nitric Oxide Blockade on the 
Hepatic Microcirculation of the Obese Zucker 
Rat during Ischaemia-reperfusion Injury 
7.1 Introduction 
7.2 Materials and Methods 
7.2.1 Experimental protocol 
7.2.2 Animals 
7.2.3 Surgical procedures 
7.2.4 Hepatic haemodynamics measurement 
7.2.5 Hepatic microcirculatory pe,fusion (HMP) and renal microcirculatory pe,fusion (RMP) 
7.2.6 lntravital fluorescence microscopy (lVFM) 
7.2.7 Off-line microcirculatory analysis 
7.2.8 Liver enzyme assay 
7.2.9 Statistical analysis 
7.3 Results 
7.3.1 Systemic haemodynamics 
7.3.2 Hepatic haemodynamics 
7.3.3 Hepatic vascular resistance 
7.3.4 Hepatic microcirculation 
7.3.5 Rhodamine 123 fluorescence intensity 
7.3.6 Plasma liver enzyme activities 
7.3. 7 Renal pe,fusion 
7.4 Discussion 
7 .1 Introduction 
Although the monoxide species, including nitric oxide (NO) and carbon 
monoxide, have been proposed to be vital in the maintenance of hepatic vascular tone 
under physiological and pathological conditions such as haemorrhagic shock (Mittal et 
al. 1994; Suematsu et al. 1994; Pannen and Bauer 1998; Pannen et al. 1998b), the role 
of NO in hepatic ischaemia/reperfusion (IR) injury remains controversial. NO is a 
reactive and highly unstable radical with a half-life of less than 5 seconds. It is a 
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readily diffusible gas synthesized in mammalian cells from L-arginine by a family of 
three NO synthases (NOS) which are neuronal NOS (nNOS), inducible NOS (iNOS) 
and endothelial NOS (eNOS) (Michel and Feron 1997; Mashimo and Goyal 1999). Of 
the three isoforms, eNOS and iNOS are the predominant forms found in the liver 
(Inglott and Mathie 2000) (Chapter 1). While some evidence suggested that NO may 
be detrimental during IR because of its excessive production by iNOS resulting in 
peroxynitrite formation and cellular damage (Ma et al. 1995; Meguro et al. 2003), 
other literature has reported that NO, regardless of its origin, is beneficial in the 
process (Rorie et al. 1997; Inglott and Mathie 2000). Some authors showed a reduced 
peroxynitrite formation but enhanced neutrophil adhesion after NOS blockade (Liu et 
al. 1998). The same group later even demonstrated that low levels of peroxynitrite 
actually play a protective role in hepatic IR injury (Liu et al. 2000). On the other hand, 
the results of another study failed to show any enhanced local or systemic NO or 
peroxynitrite generation after hepatic IR, implying that NO and its metabolites may 
not have a significant role to play in IR-induced oxidant stress and liver injury 
(Jaeschke et al. 1992c). 
Steatosis, which is defined as the abnormal deposition of lipid in non-adipose 
tissue, can affect the function of many organs and has been increasingly identified as a 
health threat because of its close association with obesity. As a result, the term 
"lipotoxic diseases" has been introduced (Unger 2002). NO has been proposed to be 
an important mediator in the causation of lipotoxicity, apoptosis, and major 
dysfunction in steatotic organs including the heart (Zhou et al. 2000) and pancreas 
(Unger and Zhou 2001) of the obese Zucker rat which exhibits widespread tissue 
steatosis and "syndrome X", including dyslipidemia, insulin resistance and noninsulin-
dependent diabetes mellitus (NIDDM) at the age of 14 weeks (Unger and Orci 2001) 
(Chapter 1). The role of NO in the circulation of steatotic liver, however, has not been 
reported. 
Furthermore, although enhanced injury from ischaemia-reperfusion (IR) has been 
well-documented in the steatotic liver both in vitro (Taneja et al. 1998) and in vivo 
(Koneru et al. 1995) (Chapter 6), the precise molecular mechanism remains unclear. 
The hypotheses were that NO has a different role to play in the maintenance of hepatic 
circulation under steatotic conditions compared to the non-steatotic situation and that 
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NO participates in the enhanced IR injury in the steatotic liver. The aim of this study 
were to elucidate the role of NO in hepatic circulation under steatotic conditions and to 
establish the effect of NO blockade on IR injury in the steatotic liver of obese Zucker 
rat while simultaneously investigating the changes in hepatic haemodynamics as well 
as alterations in microvascular structure and perfusion. The systemic effects of NOS 
blockade (L-NAME, lOmg/kg i.a.) including alterations in arterial blood pressure, 
heart rate, and renal microcirculatory perfusion were also studied. To assess the impact 
of NO blockade on IR injury of the steatotic liver, lobular perfusion, mitochondrial 
membrane potential as reflected in rhodamine 123 (Rh123) fluorescence intensity 
(Chapter 5 & 6), and plasma liver enzyme activities which indicate hepatocellular 
membrane integrity were compared before and after IR in all four groups of animals. 
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7 .2 Materials and methods 
7.2.1 Experimental protocol 
Obese Zucker rats were divided into the experimental group (n=7) and the control 
group (n=6). Similarly, the lean Zucker rats were divided into two groups: 
experimental (n=7) and control (n=6). The obese and lean experimental groups were 
given intra-arterial L-NAME through the right carotid artery 30 min before IR 
induction, whereas the remaining 6 obese and 6 lean Zucker rats (i.e. the controls) 
underwent IR without prior L-NAME administration. Baseline data on mean arterial 
blood pressure (MAP), heart rate (HR), portal venous blood flow (PVBF), hepatic 
arterial blood flow (HABF), and portal venous pressure (PVP) were first obtained 
from each animal, followed by L-NAME (lOmg/kg i.a.) administration for the 
experimental groups and equal volume of normal saline for the control groups. 
Measurement of haemodynamic parameters was repeated 15 and 30 min after L-
NAME/normal saline infusion with the exception of PVP measurement which was 
followed only once at the 30 min time point due to the invasiveness of the procedure. 
IVFM examination was then performed on the liver of all the animals, followed by 60 
min of hepatic ischaemia. IVFM examination was repeated at 30 min, 60 min, 90 min, 
and 120 min of reperfusion. At the end of experiment, the liver was harvested and 
weighed for the determination of blood flow per unit wet weight of liver and blood 
drawn for liver enzymes analysis (Fig. 7.1). 
7.2.2 Animals 
Obese Zucker rats (n=13, 25-30 weeks of age, body weight 724.31±27.42 g) and 
age-matched lean littermates (n=13, body weight 464.91±5.29 g) were used in this 
study. The whole study was conducted with the approval of the Otago University 
Animal Ethics Committee. All the animals were housed with controlled 12-hr 
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7.2.3 Surgical procedures 
All surgical procedures were performed under sodium pentobarbitol (50 mg/kg 
body weight intraperitoneal). The right carotid artery was cannulated for measuring 
mean arterial blood pressure (MAP), L-NAME and fluorochromes administration, and 
blood collection at the beginning and end of the experiment. The procedures for partial 
hepatic ischaemia-reperfusion induction was detailed in section 2.5 .1.1. 
7.2.4 Hepatic haemodynamics 
The equipment and procedures for the measurement of PVBP, HABF, and PVP 
were the same as described in section 3.2.6. 
7.2.5 Hepatic microcirculatory perfusion (HMP) and renal microcirculatory 
perfusion (RMP) 
The assessment of HMP by laser Doppler flowmetry (LDF) was previously 
described in section 3.2.7. Similarly, RMP was measured by placing a microprobe 
(PF415: 1) on the surface of the kidneys with a self-adhesive probe holder as 
previously described by us (Hammad,et al. 2000). 
7.2.6 Intravitalfluorescence microscopy (IVFM) 
IVFM was performed as previously described in section 2.1.2. Water immersion 
objectives of x20 (W x20/0.5, Zeiss, Germany) and x63 (W x63/0.90, Zeiss, 
Germany) were used in the microscopic procedure (Fig. 2.3B & C). Hepatocellular 
mitochondrial membrane potential was measured and hepatic cords were identified 
following a bolus injection of rhodamine 123 (Rh123, 1 µmol/kg i.a., Molecular 
Probes, Leiden) and bisbenzimide (Bis, 2 µmol/kg body weight, Sigma), respectively. 
Two different filter sets with excitation/emission wavelengths 450-490 nm/>520 nm, 
and 330-390 nm/>430 nm were used for the detection of fluorescence from 
mitochondria and hepatocyte nuclei after staining with Rh123 and Bis, respectively 
(Table 2.1). 
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7.2. 7 Off-line microcirculatory analysis 
The measurement of hepatic cord width, sinusoidal diameter, erythrocyte velocity, 
and hepatocellular fluorescence from Rh123 were described in section 2.1.4.2 (Fig. 
2.7). Peripheral regions of the liver lobe were excluded in the assessment of 
erythrocyte velocity due to their increased vulnerability to artefactual changes in blood 
flow. Lobular perfusion was quantified by direct observation of the movement of 
FITC-labelled RBCs in 80 to 100 randomly selected lobules per liver with use of the 
xlO objective (Fig. 2.3A). Lobules were graded into three categories: nonperfused, 
irregularly perfused ( < 50% of lobule perfused), and well-perfused. A lobular 
perfusion index (LPI) was calculated by using the formula: (Nw + 0.5 Ni)/N1, where Nw 
and Ni refer to the number of well-perfused and irregularly perfused lobules, 
respectively, and N1 refers to the total number of lobules analyzed (Vollmar et al. 
1994a). 
7.2.8 Liver enzyme assay 
One ml of blood sample was taken from the carotid arterial catheter just after 
cannulation at the beginning of the experiment and replaced by an equal amount of 
normal saline. Blood samples were collected again at the end of the experiment. All 
blood samples were placed in heparinized tubes. Plasma was separated by 
centrifugation and kept at -80°C until measurement. Analysis of plasma levels of 
aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were performed 
using an Hitachi 911 analyser (Hitachi, Tokyo, Japan). 
7.2.9 Statistical analysis 
Units used for blood flow and resistance measurements were ml·min-1-g-1 tissue 
and rnrnHg·mr1-min, respectively. All data were expressed as mean±SEM. Where 
appropriate, the Student t test was used for analysis of the data. Paired test was used 
for the comparison of data from the same animal. For all other data, repeated measure 




7.3.1 Systemic haemodynamics 
The baseline MAP was higher in the obese group (Obese: 125.5±3.5 mmHg vs. 
lean: 106.6±2.8 mmHg). It was elevated by 38.1 mmHg (35.7%) and 28.2 mmHg 
(22.5%) in the lean and obese group, respectively, 30 min after L-NAME 
administration. The heart rate, however, showed a significant decrease by 17 .13% only 
in the obese animals 30 min after L-NAME injection (Lean: 347.3±9.l beats-min-1, 
obese: 342.1±13.7 before vs. lean: 341.8±7.5, obese: 283.5±14.9, 30 min after L-
NAME i.a.) (Fig. 7.2). 
7.3.2 Hepatic haemodynamics 
Portal venous blood flow per unit liver weight (PVBF) was significantly lower in 
the obese rats than in the lean animals before L-NAME administration. It decreased 
drastically by 64.0% and 64.8% in the lean and obese rats, respectively, 30 min after 
L-NAME infusion (Lean: 0.89±0.04 ml-min-1·i1, obese: 0.54±0.02 ml·min-1-g-1 before 
vs. lean: 0.32±0.04 ml·min-1-g-1, obese 0.19±0.02 ml·min-1-g-1 30 min after L-NAME 
i.a.) (Fig. 7.3A). On the other hand, hepatic arterial blood flow per unit liver weight 
(HABF) showed a significant increase by 16.7% only in the lean rats 30 min after L-
NAME administration (0.06±0.01 ml·min-1·i1 before vs. 0.07±0.02 ml·min-1·i1 after 
L-NAME i.a.) (Fig. 7.3B). Consistent with the drop in PVBF, total hepatic blood flow 
per unit liver weight (THBF) showed a 58.1 % and 60.4% reduction in the lean and 
obese rats, respectively, 30 min after L-NAME injection (Lean: 0.94±0.05 ml-min-1·g-
1, obese: 0.60±0.03 ml-min-1-g-1 before vs. lean: 0.40±0.05 ml·min-1·i1, obese: 
0.24±0.03 ml·min-1·i1, 30 min after L-NAME i.a.) (Fig. 7.3C). Portal venous pressure 
also decreased by 12.26% in the lean and 14.03% in the obese after L-NAME 
administration (Lean: 8.40±0.34 mmHg, obese: 8.54±0.90 mmHg before vs. lean: 
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Figure 7.2 Changes in (A) mean arterial blood pressure (MAP), and (B) heart 
rate (HR) in lean and obese Zucker rats after L-NAME administration. *P<0.05 

















































Figure 7.3 Changes in (A) portal venous blood flow, (B) hepatic arterial blood 
flow, and (C) total hepatic blood flow in lean and obese Zucker rats after L-
NAME administration. *P<0.05 vs. respective control, #P<0.05 between the two 
groups at specific time point. 
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Figure 7.4 Changes in portal venous pressure in lean and obese Zucker rats after 
L-NAME administration. *P<0.05 vs. respective control. 
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7.3.3 Hepatic vascular resistance 
No difference was noted in baseline portal venous resistance between the lean and 
obese rats (Lean: 0.55±0.02 mmHg-mr1-min, obese: 0.54±0.06 mmHg-mr1-min) 
(P>0.05). However, portal venous resistance increased significantly 30 min after L-
NAME administration by 1.8 and 1.6 fold in the lean and obese rats, respectively 
(Lean: 1.53±0.23 mmHg-mr1-min, obese: 1.41±0.21 mmHg·ml-1-min) (Fig. 7.5A). 
Lower hepatic arterial resistance was noted in the obese rats before L-NAME 
administration (Lean: 148.4±17.5 mmHg·mr1-min vs. obese: 91.8±8.3 mmHg-mr 
1-min)(P<0.05). After L-NAME infusion, no change in hepatic arterial resistance was 
noted in the obese group. In the lean group, however, the mean hepatic arterial 
resistance rose steadily after L-NAME administration. Nevertheless, these changes did 
not reach statistical significance (Fig. 7.5B). 
7.3.4 Hepatic microcirculation 
The baseline hepatic microcirculatory perfusion (HMP) in the lean Zucker rats 
was significantly higher than the obese rats (Lean: 154.7±13.5 PU vs. obese: 
101.6±12.6 PU, P<0.05). Thirty minutes after L-NAME administration and before IR, 
HMP in the lean and obese rats dropped by 31.61 % and 38.49%, respectively (Fig. 
7.6). No significant difference in mean baseline erythrocyte velocity was noted 
between the lean and obese groups (Lean: 244.88±5.96 µm·sec- 1 vs. obese: 
254.01±6.27 µm·sec- 1) (Fig. 7.7A), although the lean rats appeared to have the highest 
frequency of erythrocytes travelling at a higher velocity (251-300 µm·sec- 1) (Fig. 
7.7B) than that in the obese rats (201-250 µm·sec- 1) (Fig. 7.7C). The mean erythrocyte 
velocity in the lean and obese animals, however, showed a respective decrease of 
50.94% and 54.11% after L-NAME administration (Fig. 7.7A) (P<0.0001). There was 
an overall left-hand shift in erythrocyte velocity towards lower values in both groups 
without noticeable change in frequency distribution (Fig. 7.7B & C). Another 
interesting finding was a significant decrease in mean sinusoidal diameter in both 
groups after L-NAME administration with an overall shrinkage of 9.02% for the lean 
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Figure 7.5 Changes in (A) portal venous resistance (PVR), and (B) hepatic 
arterial resistance (HAR) in lean and obese Zucker rats after L-NAME 
administration. *P<0.05 vs. respective control, #P<0.05 between the two groups at 
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Figure 7.6 (A) Changes in hepatic microcirculatory perfusion (HMP), and (B) 
percentage decrease in HMP 30 min after L-NAME administration in lean and 
obese Zucker rats. * P<0.05 vs. respective control, #P<0.05 between the two 
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Figure 7.7 Changes in (A) mean erythrocyte velocity, and velocity distribution in 
(B) lean, and (C) obese Zucker rats 30 min after L-NAME administration. 
*P<0.05 vs. respective control. Note the left shift in both groups after NO 
blockade. 
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8.8±0.lµm, obese: 9±0.lµm after L-NAME administration) (Fig. 7.8). There was no 
significant difference in sinusoidal diameter between the lean and obese animals either 
before or after L-NAME. 
Before IR, lobular perfusion was normal in the lean and obese control groups. In 
the lean animals, L-NAME treatment had no significant effect on LPI. In the obese 
animals, however, irregularly perfused lobules were noted following L-NAME 
especially in the peripheral regions of the liver lobe (LPI: 0.89±0.034) (P<0.05 vs. 
other groups). Following IR, LPI decreased significantly in all 4 groups of animals 
(Fig. 7 .9). The obese controls exhibiteq a more notable LPI drop compared with the 
lean controls (Lean 0.92±0.013 vs. obese: 0.84±0.006 after 120 min reperfusion, 
P<0.05). The L-NAME-treated lean rats also showed significant LPI reductions 
compared with the lean controls at 30, 90 and 120 min after reperfusion (Control: 
0.92±0.013 vs. L-NAME-treated: 0.78±0.02 120 min after IR, P<0.05), whereas the L-
NAME-treated obese rats showed the steepest decline and demonstrated a marked 
disparity from the obese controls after reperfusion (Control: 0.84±0.006 vs. L-NAME-
treated: 0.58±0.037, 120 min after IR, P<0.05). 
7.3.5 Rhodamine 123 fluorescence intensity 
Baseline Rh123 fluorescence intensities were 11.38±0.24 aU and 10.68±0.34 aU 
for the lean and obese rats, respectively, without L-NAME administration (P>0.05). In 
the obese animals, there was a significant decrease in Rh123 fluorescence intensity 30 
min after L-NAME infusion but not in the lean group (Lean: 11.3±0.32 aU vs. obese 
10.3±0.48 aU) when compared with their respective controls (Fig. 7.10 & Fig. 7.11). 
At 30 min after reperfusion, the differences in intensity between the lean L-NAME 
and saline groups became prominent (p<0.05). However, there was no significant 
difference between the lean NO blockade and control groups at all time points 
thereafter. On the other hand, persistently lower fluorescence intensity was noted after 
reperfusion at all time points in the obese rats after L-NAME administration compared 
to the obese controls. The fluorescence intensity was also lower in the obese saline 
group than the lean saline group at 60 min after reperfusion (Fig. 7 .10 & 7 .11 ). 
- 206 -
,.-.... 10.5 
E • ~ 10 LEAN ..._.. 
\... D OBESE (I) 
+-' 
(I) 9.5 E 
ro * ·-'"O 9 * 
ro 




Control L-NAME ( +) 
Figure 7 .8 Changes in mean sinusoidal diameter in lean and obese Zucker rats 30 
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Figure 7.9 Changes in lobular perfusion index (LPI) before and after ischaemia-
perfusion (IR). *P<0.05 vs. baseline, #P<0.05 vs. respective control at particular 
time point, t P<0.05 vs. obese control at respective time point. 
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Figure 7.10 Changes in hepatic rhodamine 123 fluorescence intensity after L-
NAME administration in lean and obese Zucker rats during ischaemia-
reperfusion (IR). 
A. Lean rat before IR without L-NAME infusion; 
B. Lean rat before IR, 30 min after L-NAME administration; 
C. Lean rat with prior L-NAME treatment, 120 min after IR; 
D. Obese rat before IR, without L-NAME infusion; 
E. Obese rat before IR, 30 min after L-NAME administration; 
F. Obese rat received L-NAME, 120 min after IR. 
(Note the decrease in fluorescence intensity in the obese rat after L-NAME 
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Figure 7.11 Changes in hepatic rhodamine 123 fluorescence intensity in lean and obese Zucker rats with and without 
L-NAME administration. *P<0.05 vs. baseline, #P<0.05 vs. obese L-NAME (-) group, tp<0.05 vs. lean L-NAME (-) 
group. 
7.3.6 Plasma liver enzyme activities 
Two hours after IR, plasma AST showed a significant increase in both the lean 
and obese groups having received L-NAME as compared with the control IR groups 
without the drug (Fig. 7.12A). Plasma ALT, on the other hand, demonstrated a 
significant 3-fold increase only in the obese Zucker rats with L-NAME compared to 
the obese group undergoing IR without the drug (Fig. 7.12B). 
7.3. 7 Renal perfusion 
With regard to renal microcirculatory perfusion (RMP), systemic L-NAME 
caused a dramatic decrease in laser-Doppler flow signals of up to 65.63% in the lean 
and 76.1 % in the obese Zucker rats. The reduction in the obese animals is significantly 
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Figure 7.12 Changes in (A) plasma AST, and (B) plasma ALT in lean and obese 
Zucker rats after L-NAME administration. *P<0.05 vs. pre-IR value, #P<0.05 vs. 
respective L-NAME (-) group. 
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Figure 7.13 Changes in renal microcirculatory perfusion (RMP) in lean and 
obese Zucker rats 30 min after L-NAME administration. *P<0.05 vs. respective 
control, #P<0.05 between two groups. 
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7 .4 Discussion 
Steatosis has been proposed to be an important contributor to organ dysfunction 
(Unger and Orci 2001). Ceramide, which is a nonoxidative product of long-chain fatty 
acids, has been proposed to increase iNOS expression up to 4 times in the steatotic 
heart of obese Zucker rat (Zhou et al. 2000). NO thus formed has been proposed to 
produce potent oxidants, such as peroxynitrite, which causes apoptosis (Unger and 
Orci 2001). Similar "lipotoxicity" has also been reported in the pancreas of the obese 
Zucker rat and proposed to be a potent mechanism in the development of its diabetic 
status (Unger and Zhou 2001). The results of this study suggest that, instead of 
offering protection, blockade of NO before IR causes an enhanced injury to the 
steatotic liver as reflected in the diminished LPI, reduced Rh123 intensity as well as 
the elevated plasma ALT levels after IR. The results further support the proposal that 
NO is a benefactor in the hepatic IR process (Rorie et al. 1997; Inglott and Mathie 
2000), especially in the steatotic liver. The results of this study further support the 
hypothesis that the steatotic liver relies more on NO than the normal liver for the 
maintenance of normal metabolic function and cellular integrity under pathological 
conditions such as IR. This is also compatible with the finding of another study that 
demonstrated an increased vulnerability of the heart to IR-induced tachyarrhythmias 
after NOS blockade (Kawahara et al. 2003). However, in this study, another possibility 
is that the NOS isoform inhibited by L-NAME was actually eNOS since it is possible 
that iNOS, which is believed to be responsible for the overproduction of NO and 
peroxynitrite formation, had not yet been induced after merely 2hr of reperfusion. 
Indeed, iNOS mRNA was not detected up to 5 and 6 hours after hepatic reperfusion in 
previous studies on mice (Kawachi et al. 2000; Hines et al. 2001), although another 
study showed an iNOS upregulation in post-ischaemic rat liver as soon as 1 hr post-IR 
(Hur, Ryu et al. 1999). 
A recent study on hepatic microcirculation after IR in rats using general NOS and 
selective iNOS inhibitors showed a significant decrease in NO production in both 
groups. However, the degree of microcirculation failure, elevation in serum 
transaminase levels, and lowered survival rate were more prominant in the general 
NOS blockade group than the iNOS blockade and control groups. The authors also 
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showed a reduction in serum transaminase after selective iNOS blockade (Morisue et 
al. 2003). The results suggested a protective role of eNOS which is more pronounced 
than the detrimental effect of iNOS in terms of post-IR hepatic microcirculatory 
impairment. However, there is still much controversies about the role of iNOS in the 
IR-induced injury to the microcirculation (Rorie et al. 1997; Kawachi et al. 2000; 
Hines et al. 2001). 
Since there was no significant decrease in hepatic arterial resistance m both 
groups after L-NAME administration, the increase in HABF in the lean group was 
more likely a passive event caused by the increase in mean arterial pressure. The 
absence of a concomitant decrease in hepatic arterial resistance in the face of a drastic 
decrease in PVBF after NO blockade also suggested that NO may play a role in the 
triggering of hepatic arterial buffer response which, however, was previously shown 
intact after NO blockade (Grund et al. 1997). Moreover, the decrease in mean RBC 
velocity of over 50% after L-NAME infusion in both lean and obese animals is 
accountable by a corresponding decrease in THBF. 
In contrast with the results of a previous in situ hepatic perfusion study that 
showed an increase in PVP after intraportal infusion of another NO biosynthesis 
inhibitor, Nm-nitro-L-arginine (L-NNA) (Mittal et al. 1994), this study showed small 
but significant reductions in PVP in both lean and obese animals after systemic NO 
blockade (i.e. 12.26% and 14.03 % for the lean and obese animals, respectively) (Fig. 
7.4). The results can probably be explained by the fact that PVF is a passive event 
determined by the splanchnic arterial blood flow. Hence, in this study, the remarkable 
decrease in PVBF reflected a significant reduction in splanchnic perfusion after 
systemic NO blockade. As a result of the dramatic drop in PVBF, PVP could not be 
maintained despite a remarkable increase in portal venous resistance (Fig. 7.5A). The 
reciprocal relationship between nitric oxide release and portal venous resistance has 
been demonstrated in previous in situ perfusion studies (Mittal et al. 1994; Ricciardi et 
al. 2001). 
Another intriguing result of this study is the finding of decreased sinusoidal 
diameters in both lean and obese animals after systemic NO blockade. While the 
sinusoidal shrinkage can be a passive event brought about by the decrease in PVBF 
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and PVP, the active participation of hepatic stellate cells (HSC) cannot be excluded, 
especially when HSC has been considered a contributor to endothelin-1-induced 
sinusoidal constriction (Zhang et al. 1994). 
Despite the fact that there is no significant difference in mean erythrocyte velocity 
between the lean and obese animals under basal conditions (Sato et al. 1986) (Fig. 
7.7 A), the widened hepatic cords in the obese rats decreases the number of 
erythrocytes flowing through the same interrogative area under the probe of the laser 
Doppler flowmeter (LDF) (Tawadrous et al. 2001), resulting in a decreased HMP in 
the obese rats (Chapter 4) (Fig. 4.7). Following NO blockade, the increase in HABF 
cannot compensate for the remarkable reduction in PVBF, resulting in a significant 
decrease in THBF and mean erythrocyte velocity which is a major determinant of LDF 
signals. The decrease in sinusoidal diameter in both lean and obese animals after L-
NAME infusion also reduced the number of erythrocytes detected by LDF, resulting in 
a further diminution in HMP. Following NO blockade, the degree of heterogeneity in 
sinusoidal blood flow increased, resulting in a net reduction in lobular perfusion in the 
steatotic liver of the obese rats. During IR, similar situation occurred in the normal 
liver of the lean rats with prior L-NAME administration but with a significantly milder 
degree compared to that of the obese rats (Fig. 7 .9), implying that NO may participate 
in the cellular (i.e. neutrophil/Kupffer cell activation) and/or molecular mechanisms 
(e.g. regulation of reactive oxygen species generation, cytokine formation, and 
adhesion molecule expression) which protect the steatotic liver against IR injury. 
There is a body of evidence suggesting that leptin has a dual role to play in the 
cardiovascular system. On the one hand, it acts on the CNS to increase sympathetic 
nerve activity (SNA) including accentuation of vascular tone and cardiac contractility. 
On the other hand, it triggers NO formation which causes an attenuation of vascular 
tone and cardiac contractility (Kuo et al. 2001). This explains the relatively minor 
cardiovascular impact on chronic leptin infusion (Fruhbeck 1999). Elevated heart rate 
and arterial blood pressure by leptin infusion has been demonstrated under NO 
synthesis inhibition (Kuo et al. 2001), suggesting a blockade of the NO pathway of 
leptin action (Fruhbeck 1999). In the lean Zucker (Fa/?) rat, which has a functional 
leptin receptor, a blockade of this NO pathway theoretically does not inhibit the 
central sympathetic action of leptin. However, blocking NO in the obese Zucker rat 
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(fa/fa), which does not have functional leptin receptors, unmasks no sympathetic 
component of leptin. This may explain the significant drop in HR after L-NAME 
infusion in the obese Zucker rat. 
In this study, NO was also shown to have an important role to play in renal 
perfusion, especially in the obese Zucker rats. The results are consistent with the 
previous finding that eNOS expression in the kidney cortex and medulla was 
remarkably increased in the obesity-prone rats than in the obesity-resistant rats 
(Dobrian et al. 2001). The lack of significant impact of chronic L-NAME 
administration on glomerular filtration rate and renal plasma flow in another study 
(Kuo et al. 2001) may represent a compensated state of renal circulation. 
In conclusion, the results of this study showed that not only is NO vital in the 
control of portal venous blood flow and resistance as well as hepatic microcirculatory 
perfusion, it is also important in the maintenance of hepatic rnicrostructure and the 
alleviation of hepatic IR injury in both lean and obese Zucker rats. NO may also has a 
role to play in hepatic arterial buffer response when PVBF is reduced. Moreover, the 
steatotic liver appeared to be more susceptible to the detrimental effect of NO 
blockade after IR compared to the lean liver, suggesting that NO may play a protective 
role in the maintenance of metabolic functions and cellular integrity during short-term 
IR in the steatotic liver of the obese Zucker rat. Systematically, NO blockade had 
different effects on heart rate in lean and obese Zucker rats presumably related to the 
existence of functional leptin receptors. Beside an elevation in mean arterial blood 
pressure, systemic NO blockade also caused a remarkable reduction in splanchnic and 
renal perfusion - an action similar to that of an a-agonist. 
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Three different isoforms of nitric oxide synthase (NOS), nNOS, iNOS, and 
eNOS (Alexander 1998), are responsible for the production of nitric oxide (NO) 
previously known as the endothelium-derived relaxing factor (EDRF) (Ignarro et al. 
1987) because of its original discovery in blood vessel endothelium and its potent 
vasodilating property (Furchgott and Zawadzki 1980). The biological role and 
chemical fate of nitric oxide (NO) is highly variable, depending on the source of 
production, the interaction with other molecules and also the target sites. NO may be 
stabilized or degraded through interacting with diverse intra- or extracellular chemical 
moieties (Alexander 1998). To address the specific pathophysiological function of 
each NOS isoform and to avoid the undesirable side-effects of various NOS inhibitors, 
the nNOS, iNOS, and eNOS gene knockout mice were developed (Mashimo and 
Goyal 1999). The significance of the development of these NOS gene knockout 
mutants has been discussed in section 1.6.2.2. 
The first report of nNOS knockout mice was made by Huang et al. with 
targeted disruption of the gene (Huang et al. 1993), while the first report on iNOS 
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knockout mice was from Wei et al. who disrupted the murine iNOS gene by 
homologous recombination (Wei et al. 1995). The development of eNOS gene 
knockout mice was also reported by Huang et al. through targeted disruption of the 
exons encoding the NADPH ribose and adenine binding sites (amino acids 1010-1144) 
(Huang et al. 1995) (Fig. 8.1). 
The objective of this Chapter was to confirm the genotype of the wild-type, 
iNOS and eNOS gene knockout mice to validate their use in the study of the role of 




Figure 8.1 (A) Targeted disruption of the eNOS gene using a targeting vector that 
contains 5' and 3' flanking region (FR) of homology and is designed to replace the 
Hindlll to Sall fragment of the native eNOS gene. NEO:neomycin resistance gene 
(redrawn after Huang et al., 1995), (B) Translated sequence of eNOS mRNA 
(Gnanapandithen et al., 1996) showing the deleted region in the eNOS-/- mice (shaded 
segment) that contains both NADPH ribose and adenine binding sites. 
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GVCPPNRPGLVEALLSRVEDPPPSTEPV A VEQLEKGSPGGPPPGWVRDPRLPPCTLRQ 
ALTYFLDITSPPSPRLLRLLSTLAEESSEQQELEALSQDPRRYEEWKWFSCPTLLEVL 
EQFPSV ALPAPLIL TQLPLLQPRYYSVSSAPSAHPGEIHLTIA VLA YRTQDGLGPLHY 
GYCSTWMSQLKAGDPVPCFIRGAPSFRLPPDPNLPCILVGPGTGIAPFRGFWQDRLHD 
IEIKGLQP APMTL VFGCRCSQLDHL YRDEVLDAQQRGVFGQVLT AFSRDPGSPKTYVQ 
DLLRTELAAEVHRVLCLEQGHMFVCGDVTMATSVLQTVQRILATEGGMELDEAGDVIG 
VLRDQQR YHED IFGL TLRTQEVTSRIRTQSFSLQERQLRGA VPWSFDPPGPEfPGS " 
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8.2 Materials and Methods 
8.2.1 Animals 
Our study focused on the iNOS knockout (iNOS-/-) and eNOS knockout 
(eNOS-/-) mice. Strains of wild-type (WT), iNOS-/- (stock number 002609), and 
eNOS-/- mice (stock number 002684) of C57BL/6J background were obtained from 
the Jackson Laboratory (Bar Harbor, Maine, USA) with the subsequent breeding 
carried out in the Department of Laboratory Animal Science, University of Otago, 
Dunedin, New Zealand. Only homozygous strains were used in the experiments 
described. The 3 strains were strictly isolated for reproducing homozygous inbred 
offsprings. Genotype was confirmed on three animals of different age chosen 
randomly from each group. 
8.2.2 Blood collection 
The animals were anaesthetized with sodium pentobarbital (50 mg/kg i.p.) and 
put in supine position. Blood was obtained with cardiac puncture technique using 
heparinized syringes and collected in DNA-free 1.5 ml centrifugation tubes (Porex Bio 
Products Inc., USA). 
8.2.3 Genomic DNA extraction and quantification 
Genomic DNA purification was carried out with the QIAamp DNA Blood 
Mini Kit (Qiagen GmbH, Hilden, Germany) using 200 µl of whole blood sample from 
each animal as recommended by the manufacturer. The concentration and purity of the 
extracted DNA was determined using an MBA 2000 spectrophotometer (Perkin-
Elmer, Connecticut, USA). Only specimens with an OD26o/OD280 ratio of 1.8 or above 
were accepted for subsequent procedures. 
8.2.4 Polymerase chain reaction (PCR) and DNA identification 
Genotyping was carried out following protocols recommended by the Jackson 
Laboratory (website: http://www.jax.org/). The DNA samples were diluted using 
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PCR-quality milli-Q water to a concentration of 7.5-10 ng/µl. Primers were obtained 
from Invitrogen (Auckland, New Zealand) with sequences as provided by the Jackson 
Laboratory. For the differentiation of the WT, heterozygous and homozygous iNOS-/-
strains, the primers oIMR1216 (5'-ACA TGC AGA ATG AGT ACC GG-3'), 
oIMR1217 (5'-TCA ACA TCT CCT GGT GGA AC-3'), and oIMR1218 (5'-AAT 
ATG CGA AGT GGA CCT CG-3') were used (Fig. 8.2). To distinguish WT, 
heterozygous and homozygous eNOS-/- strains, the primers oIMR0498 (5'-CTC CAA 
CTT AGT GCA GGT CT-3'), oIMR0499 (5'-ATG GTT GCC TTC ACA CGC TT-
3'), and oIMR0500 (5'-CTT CCT CGT GCT TTA CGG TA-3') were used. Primers 
for murine ~-actin (5'-TCA CTA TTG GCA ACG AGC GG-3' and 5'-GCC ACC 
GAT CCA CAC AGA GT-3', kindly provided by Dr. Jo-Ann Stanton, Department of 
Anatomy, University of Otago) were used as positive control primers for PCR. DNA-
free distilled water served as the negative control for all PCR reaction. PCR was 
performed with the Perkin-Elmer GeneAmp PCR system 2400 (Perkin-Elmer, 
Connecticut, USA) using HotStar Tag DNA polymerase (Qiagen Pty Ltd., Australia) 
with initial heating of the samples at 95°C for 15 min. The rest of the cycling 
conditions was according to the protocol provided by the Jackson Laboratory as 
detailed in Fig. 8.3. Electrophoresis was performed on the resulting PCR products 
using 1.5% or 3% agarose gel (Cat. No. 15510-019 Gibco BRL, Auckland, New 
Zealand) containing 0.5 µg/ml ethidium bromide with a voltage of 80V for the 
identification of iNOS-/- and eNOS-/- strains, respectively. DNA molecular weight 
marker XIV, 100 base pair ladder (Roche Diagnostics Corp., Indianapolis, IN, USA) 
was used as the molecular weight reference for each gel. The gels were viewed with 
ultraviolet light transillumination from an UV light transilluminator (Hoefer Scientific 
Instruments, San Francisco, USA) and the images were captured with a Kodak DC40 
camera (Kodak Digital Science, New Haven CT, USA) using the Kodak ds lD 




Figure 8.2 Using the primer oIMR1216 (S) and oIMR1217 (AS) that act on exon 12 of 
the iNOS gene, the typical 108bp segment can be obtained from mouse (A) complete 
iNOS mRNA, (B) iNOS mRNA from macrophage, and from (C) iNOS genomic DNA. 
(D) The site of action for the primer oIMR1218 used for the identification of iNOS-/-
mice can be found in the sequence of the cloning vector pMClneo that was used to 
produce the iNOS mutant strain through homologous recombination. 
(A) Mus musculus strain ICR inducible nitric oxide synthase (Nos2) mRNA, complete 
eds. 
(Hagiwara et al. Mouse inducible nitric oxide synthase mRNA) 
..... 1261 ttccagaagc agaatgtgac catcatggac caccacacag cctcagagtc cttcatgaag 
S 1321 cacatgcaga atgagtaccg ggcccgtgga ggctgcccgg cagactggat ttggctggtc 
AS 13 81 cctccagtgt ctgggagcat cacccctgtg ttccaccagg agatgttgaa ctatgtccta 
1441 tctccattct actactacca gatcgagccc tggaagaccc acatctggca gaatgagaag .... 
(B) Mus musculus nitric oxide synthase 2, inducible, macrophage (Nos2), mRNA. 
(Lyons et al. Molecular cloning and functional expression of an inducible nitric oxide 
synthase from a murine macrophage cell line. J. Biol. Chem. 1992, 267 (9), 6370-6374) 
. . ... 1441 tttccagaag cagaatgtga ccatcatgga ccaccacaca gcctcagagt ccttcatgaa 
S 1501 gcacatgcag aatgagtacc gggcccgtgg aggctgcccg gcagactgga tttggctggt 
AS 1561 ccctccagtg tctgggagca tcacccctgt gttccaccag gagatgttga actatgtcct 
1621 atctccattc tactactacc agatcgagcc ctggaagacc cacatctggc agaatgagaa .... 
(C) Mus musculus inducible nitric oxide synthase gene, complete eds. 
(Coge et al. Cellular and Molecular Pharmacology) 
...... 23641 ctctcctctg ctgctgcatc tcagtccact ccatcttctt ctccttcaga agcagaatgt 
23701 gaccatcatg gaccaccaca cagcctcaga gtccttcatg aagcacatgc agaatgagta 
S 23761 ccgggcccgt ggaggctgcc cggcagactg gatttggctg gtccctccag tgtctgggag 
AS 23821 catcacccct gtgttccaccaggagatgttgaactatgtc ctatctccat tctactacta 
23881 ccaggtcagg gagaagcctc cacccacctg cccatccccg ccccacctcc catcttatag .. .. 
(D) Cloning vector pMClneo, complete sequence 
..... .. 361 ggggggatgt gctgcaaggc gattaagttg ggtaacgcca gggttttccc agtcacgacg 
421 ttgtaaaacg acggccaggg ccagtgaatt ctcgagcagt gtggttttgc aagaggaagc 
481 aaaaagcctc tccacccagg cctggaatgt ttccacccaa tgtcgagcag tgtggttttg 
541 caagaggaag caaaaagcct ctccacccag gcctggaatg tttccaccca atgtc gagca 
601 aaccccgccc agcgtcttgt cattggcgaa ttcgaacacg cagatgcagt cggggcggcg 
AS 661 cggtcccagg tccacttcgc atattaaggt gacgcgtgtg gcctcgaaca ccgagcgacc 
721 ctgcagccaa tatgggatcg gccattgaac aagatggatt gcacgcaggt tctccggccg 
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Figure 8.3 Polymerase chain reaction cycling conditions for the identification of (A) iNOS-/-, and (B) eNOS-/- mouse strain 
8.3 Results 
Table 8.1 shows the concentration and purity of extracted genomic DNA 
preparations. The mean concentration of extracted DNA was 27.91±10.34 ng·µr 1 
(mean±SD) with the OD26o/OD2so ratio equal to 2.23±0.38 that signified an acceptable 
purity of DNA for genotyping. As expected, all animals tested were found to be 
homozygous for their specific genotypes. Fig. 8.4 shows that the samples from WT 
(i.e. wtl, 2, and 3) and eNOS-/- mice (i.e. el, 2, and 3) gave a typical 208 bp PCR 
product using iNOS primers. Following PCR of genomic DNA from iNOS-/-mice (i.e. 
il, 2, and 3), a single 270 bp band consistent with disruption of the iNOS gene was 
demonstrated (Fig. 8.2). Similarly, samples from WT (i.e. wtl, 2, and 3) and iNOS-/-
mice (i.e. il, 2, and 3) showed a single band of 370 bp, while PCR products from the 
eNOS-/- mice (i.e. el, 2, and 3) gave a 450 bp band (Fig. 8.5) that confirmed the 
knockout of the eNOS gene by the targeting vector (Fig. 8.1). A summary of the 
results was shown in Fig. 8.6. The results confirmed the genetic identity of the inbred 
WT, iNOS-/- and eNOS-/- mice and validated their use for the subsequent studies. 
8.4 Conclusions 
The results confirmed the genetic identity of the inbred WT, iNOS-/- and 
eNOS-/- mice and validated their use for the study of hepatic ischaemia-reperfusion 
(IR) injury in Chapter 9. 
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Table 8.1 Genomic DNA concentrations and purity after extraction from whole blood of wild-type, iNOS-/-, and eNOS-/- mice 
Genotype Wild-type iNOS-/- eNOS-/-
Samples 
wt 1 wt2 wt3 i 1 i 2 i 3 e 1 e2 e3 
I 
N 
Concentration (ng-µr 1) N 18.0 29.2 30.4 17.2 29.2 50.8 20.8 33.2 22.4 °' ' 
OD26o/OD2so 2.81 2.15 2.05 2.87 2.43 2.12 1.86 1.89 1.93 






i2 i3 el e2 
Figure 8.4 Results of PCR of genomic DNA samples from wild-type (wtl, wt2, wt3), 
iNOS-/- (il, i2, i3), and eNOS-/- (el, e2, e3) mice using iNOS identification primers 
oIMR1216, oIMR1217, and oIMR1218. Murine ~-actin primers with genomic DNA 
from wild-type mice and distilled water were used as the positive ( +ve) and negative (-
ve) control, respectively. All animals were homozygous with the iNOS-/- group 
showing typical 270 bp bands, whereas the wild-type and eNOS-/- group displayed 
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Figure 8.5 Results of PCR of genomic DNA samples from wild-type (wtl, wt2, wt3), 
eNOS-1- (el, e2, e3), and iNOS-/- (il, i2, i3) mice using eNOS identification primers 
oIMR0498, oIMR0499, and oIMR0500. Murine ~-actin primers with genomic DNA 
from wild-type mice and distilled water were used as the positive ( +ve) and negative (-
ve) control, respectively. All animals were proven homozygous with the eNOS-/- group 
showing typical 450 bp bands, while the wild-type and iNOS-/- group demonstrated the 






















Figure 8.6 The iNOS-/- mice (lane b) showed the typical 270 bp band with the WT 
(lane a) and eNOS-/- (lane c) both showing the 108 bp band after PCR using the 3 
iNOS identification primers. Similarly, the eNOS-/- mice demonstrated the specific 
450 bp band (lane e) that is slightly heavier than the 370 bp band of the WT (lane d) 
and iNOS-/- (lane f) after PCR with the 3 eNOS identification primers . 
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Chapter 9 
The Role of Different Nitric Oxide Isof orms in 
Hepatic Ischaemia-Reperfusion Injury 
9.1 Introduction 
9.2 Materials and methods 
9.2.1 Experimental protocol 
9.2.2 Animals 
9.2.3 Surgical procedures 
9.2.4 Hepatic haemodynamics measurement 
9.2.5 Intravitalfluorescence microscopy (IVFM) 
9.2.6 Induction of hepatic ischaemia/repeifusion (IR) injury 
9.2. 7 Off-line microcirculatory analysis 
9.2.8 Hepatic microcirculatory peifusion (HMP) and renal microcirculatory pe1fusion (RMP) 
9.2.9 Measurement of plasma nitrite levels 
9.2. JO Enzyme assay 
9.2.11 Histologic analysis 
9.2.12 Statistical analysis 
9.3 Results 
9.3.1 Liver/body weight ratio 
9.3.2 Systemic and hepatic haemodynamics 
9.3.3 IVFM study of hepatic microcirculation 
9.3.4 Hepatic and renal microcirculatory peifusion 
9.3.5 Plasma nitrite levels and reactive oxygen species (ROS) formation 
9.3.6 Plasma liver enzyme activities 
9.3. 7 Histologic analysis 
9.4 Discussion 
9.1 Introduction 
The protective role of NO in hepatic IR injury has now been commonly accepted 
as reflected in the well-established detrimental effects of NOS blockade in the IR 
process (Chapter 7) (Isobe et al. 1999; Koeppel et al. 1997). It has been proposed that 
IR-induced microcirculatory disturbance stems from an imbalance between 
vasodilators (e.g. NO) and vasoconstrictors (e.g. endothelin) (Clemens et al. 1997; 
lnglott and Mathie 2000). A transient NO production has also been implicated in the 
beneficial effect of liver preconditioning on hepatic IR (Peralta et al. 2003). However, 
the contribution by different NOS isoforms (i.e. eNOS and iNOS in the liver) in the IR 
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process is still controversial. While a body of evidence suggests a hepatoprotective 
role for eNOS in hepatic IR (Kawachi et al. 2000; lnglott and Mathie 2000), the role of 
iNOS in the process has been reported to be: (1) detrimental due to its excessive 
production of NO leading to the generation of the toxic radical peroxynitrite (Hur et al. 
1999; Morisue et al. 2003); (2) beneficial because of the anti-inflammatory property of 
NO and its antagonistic action against endothelin as well as a possible protective effect 
of peroxynitrite by reducing adhesion molecule-mediated, leukocyte-dependent 
hepatic reperfusion injury (Hines et al. 2002; lnglott and Mathie 2000; Liu et al. 2000); 
or (3) hard to define because of failure to detect increased free radical formation and 
iNOS expression following hepatic IR (Jaeschke et al. 1992b; Kawachi et al. 2000; 
Hines et al. 2001) (section 1.5.6). 
As mentioned in Chapter 1 (section 1.5.2.4), the generation and disposal of 
reactive oxygen species (ROS) under physiological conditions is highly regulated by 
an intricate enzymatic system (Jassem et al. 2002). During IR, however, the anti-
oxidant capacity is impaired by depressed enzymatic activity (e.g. superoxide 
dismutase, SOD) (Arduini et al. 1988) which may lead to a cascade of events including 
excessive ROS formation, mitochondrial damage, electron leakage, and further ROS 
formation (Zhang et al. 1990; Chen and Yu 1994). 2', 7'-dichlorofluorescin diacetate 
(DCFH), which is a hydroperoxide-sensitive fluorescent probe that is trapped within 
viable cells as a nonfluorescent form and is converted into fluorescent 
dichlorofluorescein (DCF) by hydroperoxides (Suematsu et al. 1993), has been 
successfully used in the quantitation of hydrogen peroxide production both in isolated 
hypoxic liver (Motoyama et al. 1998) and in vivo mesenteric venule preparations 
following neutrophil activation (Suematsu et al. 1993). The fluorochrome was utilized 
in this study to investigate the oxidative stress in the wild-type mice and the NOS 
knockout mutants during hepatic IR injury. 
In an attempt to further clarify the picture and avoid the side-effects of 
nonselective and selective NOS inhibitors as well as attain a state of chronic inhibition, 
NOS knockout mice were introduced as study tools (Chapter 1). After genotyping 
(Chapter 8), the WT, iNOS-/-, and eNOS-/- mice were used in this study. 
- 231 -
The aims of this study were to investigate in vivo the effect of nitric oxide 
synthase (NOS) gene knockout on hepatic haemodynamics and its microcirculatory 
and hepatocellular impact during the early (i.e. acute) and late (i.e. subacute) phase of 
hepatic ischaemia-reperfusion (IR) injury (Experiment 1). The hypothesis of oxidative 
stress from iNOS-derived NO during IR causing hepatocellular damage was also tested 
(Experiment 2). 
- 232 -
9.2 Materials and Methods 
9.2.1 Experimental protocol 
Experiment 1: 
Age-matched wild-type (WT) (n=56), iNOS knockout (iNOS-/-) (n=56), and 
eNOS knockout mice (n=56) were each divided into 4 groups (i.e. 14 animals in each 
group). With the exception of the control group which only underwent laparotomy, the 
rest were subjected to 60' /120' ischaemia/reperfusion (IR) of the left lobe liver 
through hilar clamping and examined before ischaemia and at 3 different time points 
after IR. The 14 animals in each group were further divided into 2 groups one of which 
was for haemodynamic measurement (n=7) and the other for intravital fluorescence 
microscopic (IVFM) examination (n=7). Mean arterial blood pressure (MAP), portal 
venous blood flow (PVBF) and portal venous pressure (PVP) were measured. The left 
liver lobe was observed using IVFM before IR and at 2h (n=7), 8h (n=7), and 24h 
(n=7) after reperfusion. The images were recorded and analysed for hepatic cord 
width, sinusoidal diameter, sinusoidal erythrocyte velocity, and rhodamine 123 
(Rh123) fluorescence intensity that reflects mitochondrial membrane potential. 
Changes in hepatic microcirculatory perfusion (HMP) and renal microcirculatory 
perfusion (RMP) were also assessed with laser Doppler flowmetry. Plasma was 
obtained for liver enzyme analysis and liver was harvested for liver/body weight ratio 
measurement as well as histological analysis at the end of the experiment (Fig. 9.lA). 
Experiment 2: 
Age-matched wild-type (WT) (n=20), iNOS knockout (iNOS-/-) (n=20), and 
eNOS knockout mice (n=20) were similarly divided into 4 groups as in Experiment 1 
(i.e. n=5 in each group) for observation over 4 different time points (i.e. pre-IR, 2h, 8h, 
and 24h post-IR). After anaesthesia and right carotid artery cannulation, partial hepatic 
ischaemia was induced. Two hours before IVFM examination (Motoyama et al. 1998), 
2', 7' -dichlorofluorescin diacetate (DCFH) was infused through the arterial catheter. 
The images were recorded and the fluorescence intensity compared (Fig. 9.lB). 
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A: Haemodynamics measurement 
Mean arterial blood pressure (MAP); 
';;:/: lntravital fluorescence microscopy (IVFM) 
Rhodamine 123 (Rh123) fluorescence intensity; 
Portal venous blood flow (PVBF); Hepatic cord width/sinusoidal diameter; 
Hepatic arterial blood flow (HABF); Erythrocyte velocity. 
Portal venous pressure (PVP); 
Hepatic microcirculatory perfusion (HMP); 
Renal microcirculatory perfusion (RMP). 
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A: lntravital fluorescence microscopy (IVFM) 





(Note: 2', 7'-dichlorofluorescein diacetate (DCFH) was injected 120 min before IVFM examination) 




(A) Hepatic haemodynamics & warm hepatic IR injury in WT (n=56), iNOS-/-
(n=56), and eNOS-/- mice (n=56); 
(B) DCF fluorescence intensity in WT (n=20), iNOS-/- (n=20), and eNOS-/- mice 
(n=20) during hepatic IR injury. 
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9.2.2 Animals 
The source of the animals was described in section 8.1.2.1. Age-matched adult 
mice of body weight between 30g and 35g were used. The whole experiment was 
conducted with the approval of the Otago University Animal Ethics Committee. 
9.2.3 Surgical procedures 
All surgical procedures were performed under sodium pentobarbitol anaesthesia 
(50 mg/kg body weight intraperitoneal). With the technique described in section 2.4.3, 
a specially prepared catheter (Fig. 2.15B) was inserted into the right carotid artery for 
the recording of MAP, administration of fluorochromes and collection of blood 
samples. Procedures of animal preparation for NFM were detailed in section 2.1.3. 
9.2.4 Hepatic haemodynamics measurement 
The procedures for hepatic haemodynamics measurement were essentially the 
same as described in section 3.2.6 except that the ultrasonic probe (Model 0.5VB405, 
Transonic Systems Inc., NY, USA) (Fig. 2.13B) was used in the measurement of 
PVBF. The portal venous resistance (PVR) was calculated by dividing the PVP 
(mmHg) with the total portal venous blood flow (ml·min-1). 
9.2.5 Intravitalfluorescence microscopy (IVFM) 
NFM was performed as previously described in section 2.1.2. For Experiment 1, 
a bolus of rhodamine 123 (Rh123, 1 µmol/kg intravenously, Molecular Probes, 
Leiden, The Netherlands) and bisbenzimide (2 µmol/kg body weight, Sigma, St. 
Louis, USA) was infused through the right carotid artery for the assessment of 
mitochondrial membrane potential and visualization of hepatocyte nuclei, respectively. 
FITC-labelled RBCs were prepared as described in section 2.1.4.2 and were 
introduced after recording of Rh123 fluorescence intensity. Two different filter sets 
with excitation/emission wavelengths 450-490 nm/>520 nm, and 330-390 nm/>430 
nm were used for the detection of fluorescence from mitochondria/FITC-labelled 
RBCs and hepatocyte nuclei, respectively. Lobular perfusion index (LPI) was 
calculated as described in section 7.2.7. For Experiment 2, DCFH at a dose of 0.3 
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µmol/k:g was administered 120 min before observation with a x20 objective and a 
filter set with excitation/emission wavelengths 450-490 nm/>520 nm (Table 2.1). 
9.2.6 Induction of hepatic ischaemialreperfusion (IR) injury 
Hepatic IR was induced using the method described in section 2.5.1.2 (Fig. 
2.18C). 
9.2. 7 Off-line microcirculatory analysis 
The analysis was achieved with the equipment described in section 2.1.4.1. 
Methodology for quantitative analysis of hepatocellular Rh123 fluorescence intensity, 
sinusoidal RBC velocity as well as the measurement of hepatic cord width and 
sinusoidal diameter were detailed in section 2.1.4.2 (Fig. 2.7). 
9.2.8 Hepatic microcirculatory perfusion (HMP) and renal microcirculatory 
perfusion (RMP) 
HMP and RMP were measured by laser Doppler flowmetry (section 2.2) before 
ischaemia and at 2h, 8h, 24h after reperfusion. The signal was obtained at 300 Hz 
using a time constant of 0.03s. The LDF signal was then digitized with MacLab 
software (AD Instrument, version 3.5.4) and expressed in arbitrary perfusion units 
(PU). 
9.2.9 Measurement of plasma nitrite levels 
Blood samples were obtained from the arterial catheter at the end of the 
experiment and placed in heparinized centrifuge tubes. Plasma was prepared by 
centrifugating samples at 1200 x g for 5 min. The plasma was then made into 100 µl 
aliquotes and stored in liquid nitrogen till use. Nitrite was measured using the Griess 
reaction as described (section 2.6) (Jude et al. 1999). Briefly, 100 µl of standard (0-100 
µmol/1 sodium nitrite) or sample were added to 100 µl of reagent that consisted of 
equal volumes of 10 g/1 sulphanilamide (in 0.5% H3P04) and 1 g/1 of 
N aphthylethylenediamine all prepared using milliQ water. Nitrite formation was then 
assessed spectrophotometrically at a wavelength of 570 nm. 
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9.2.10 Enzyme assay 
Analysis of plasma levels of aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) were performed using a Hitachi 705 Autoanalyser (Hitachi, 
Tokyo, Japan). 
9.2.11 Histologic analysis 
After the experiments, the left liver lobes were fixed in 10% buffered formalin, 
embedded in paraffin and processed for hematoxylin-eosin (HE) staining using 
standardized techniques. Specimens were compared with respect to the extent of 
cellular injury and sinusoidal congestion by an independent pathologist (H.S.). 
9.2.12 Statistical analysis 
All data were expressed as mean ± SEM. Where appropriate, the Student t test 
was used for analysis of the data. For all other data, repeat measure analysis was also 
performed using SAS software. P<0.05 was considered significant. 
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9.3 Results 
9.3.1 Liver/body weight ratio 
Liver/body weight ratio of the iNOS-/- mutants (4.1±0.12%) was significantly 
lower than that of WT (4.54±0.10%) and eNOS-/- (4.44±0.20%) mice (Fig. 9.2). 
9.3.2 Systemic and hepatic haemodynamics 
MAP of eNOS-/- mice (96.26±4.3.98 mmHg) was higher than that of WT 
(83.03±1.63 mmHg) and iNOS-/- (87.18±2.16 mmHg) mice (Fig. 9.3A) (P<0.05). 
PVP was also significantly higher in eNOS-/- mutants (7.24±0.31 mmHg) compared to 
WT (6.24±0.22 mmHg) and iNOS-/- (5.8± 0.55 mmHg) mice. All three groups 
showed an increase in PVP during hilar clamping (WT: 25.8%, iNOS-/-: 42.6%, 
eNOS: 25.1 %)(P<0.05) (Fig. 9.3B). PVBF of iNOS-/- mutants (0.87±0.04rnl-min-1) 
was higher than WT (0.76±0.03 ml-min-1) and eNOS-/- (0.84±0.03 ml·min-1) animals 
(Fig. 9.3C), whereas portal venous resistance was lowest in the iNOS-/- mice (iNOS: 
4.86±0.30 mmHg-mr1-min, WT: 6.40±0.32 mmHg·mr1-min, eNOS-/-: 6.35±0.44 
mmHg·rnl-1-min) (Fig. 9.3D)(P<0.05). 
9.3.3 IVFM study of hepatic microcirculation 
There was no significant difference in RBC velocity among the three groups 
(Fig. 9.4A). However, the eNOS-/-mutants were found to have narrower sinusoids 
(4.91±0.llµm) compared with the other two groups (WT: 6.08± 0.16 µm; iNOS-/-: 
5.98±1.19 µm)(P<0.05) (Fig. 9.4B). Hepatic cord width was also found to be 
significantly higher in the eNOS-/- mutants (14.81±0.10 µm) than that of WT 
(14.39±0.09 µm) and iNOS-/- (14.42±0.11 µm) (Fig. 9.4C). All 3 groups showed a 
significant reduction in Rh123 fluorescence intensity on reperfusion. While the iNOS-
/- mice showed a reduced intensity 8h post-IR compared to the other two groups 
(P<0.05), the eNOS-/- mutants demonstrated the lowest intensity 24h after reperfusion 
(P<0.05) (Fig. 9.5). 
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Figure 9.3 Hepatic haemodynamics in WT, iNOS-/-, and eNOS-/- mice (*P<0.05 
vs. baseline; #P<0.05 vs. value before hilar clamping) 
A. MAP: Mean arterial blood pressure; 
B. PVP: Portal venous pressure; 
c. PVBF: Portal venous blood flow; 
D. PVR: Portal venous resistance 
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Although focal perfusion deficits were noted in the reperfused livers (Fig. 9.6), 
they were sparsely distributed and in most cases involved only one or two adjacent 
sinusoids and seldom up to 50% of a hepatic lobule. As a result, there were only minor 
fluctuations in LPL However, significant decrease in LPI was noted in all three 
genotypes of animals after reperfusion (Fig. 9.7). Drop in LPI was noted in all groups 
of animals at 2h and 8h after reperfusion, whereas significant decrease was noted only 
in iNOS-/- and eNOS-/- mice at 24h post-IR. There was no significant difference in 
LPI among the three genotypes of animals at each specific time point. 
9.3.4 Hepatic and renal microcirculatory perfusion 
During reperfusion, the WT mice showed a significant decrease in HMP of left 
lobe liver at 2h and 8h after reperfusion (P<0.05) but not in the other two groups (Fig. 
9.8A). HMP of the median lobe liver (i.e. the non-ischaemic lobe) increased in all 3 
groups during ischaemia induction (P<0.05) but decreased at 8h after reperfusion in 
both WT and eNOS-/- animals (Fig. 9.8B). RMP also showed a notable decrease in all 
three groups during hepatic hilar clamping. It then fell significantly to lowest values in 
all groups 8h after reperfusion and returned to pre-IR levels at 24h after reperfusion in 








Figure 9.6 Representative hepatic microfluorographs showing focal areas of 
sinusoidal nonperfusion (arrows) in (A) Wild-type, (B) iNOS-/-, and (C) eNOS-/-
mice 24h after reperfusion. 
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Figure 9.7 Changes in hepatic lobular perfusion index (LPI) on reperfusion. 
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Figure 9.8 Effect of hepatic IR on microcirculatory perfusion of (A) left lobe 
liver, and (B) anterior lobe liver. *P<0.05 vs. control of the same group, #P<0.05 
vs. wild-type. 
HMP: Hepatic microcirculatory perfusion 










~ 300 I + 
CL 250 ~ 
0::: 2001 -(t- wild-type -b- iNOS-/-
150 -o- eNOS-/- I *+ 
T 
0 
Control 0 2 8 
Time of Reperfusion (h) 
Figure 9.9 Effect of hepatic IR on renal microcirculatory perfusion (RMP). 
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9.3.5 Plasma nitrite levels and reactive oxygen species (ROS) formation 
Plasma nitrite levels fell significantly at post-IR 2h and Sh for both WT and 
eNOS-/- mice and at post-IR Sh for the iNOS-/- mutants. The plasma nitrite of iNOS-/-
mice at post-IR Sh dropped to a level significantly lower than that of WT and eNOS-/-
mice (Fig. 9 .10). On the other hand, there was a significant increase in ROS formation 
as reflected in hepatic DCF fluorescence intensity that reached a peak value at 8h post-
IR in both WT and eNOS-/- mice. However, no significant increase was noted in the 
iNOS-/- mutants (Fig. 9.11). 
9.3.6 Plasma liver enzyme activities 
There was a significant increase in plasma AST/ALT levels that peaked at 8h 
after reperfusion (Fig. 9.12A & B). However, no significant discrepancy was noted 
among the 3 groups except at 24h post-IR when the eNOS-/- mutants showed higher 
AST activities compared with the WT animals (P<0.05) (Fig. 9.12B). 
9.3. 7 Histologic analysis 
There was no essential histological difference among the controls from WT, 
iNOS-/-, and eNOS-/- animals. In WT mice, there was diffuse degeneration of the liver 
at 2h of reperfusion, and focal degeneration with sinusoidal congestion at 8h. At 24h 
the liver recovered, but interestingly all the sinusoids became wider as compared with 
the control group. In iNOS-/- mutants, there was also diffuse degeneration of the liver 
at 2h which persisted at 8h. At 24h after reperfusion, focal degeneration still existed. 
Hence, there was a delay in the recovery process compared to that of WT mice. In 
eNOS-/- mice, there was diffuse degeneration of the liver at 2h, focal degeneration 
with congestion of the sinusoids at Sh which recovered at 24h after reperfusion. 
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Figure 9.10 Changes in plasma nitrite concentrations during hepatic IR. 
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Figure 9.11 Changes in fluorescence intensity of dichlorofluorescein (DCF) during hepatic IR. 
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Figure 9.12 Changes in (A) Plasma AST, and (B) Plasma ALT activities on 
hepatic IR in WT, iNOS-/-, and eNOS-/- mice. (*P<0.05 vs. baseline; #P<0.05 vs. 
WT at the same time point) 
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9.4 Discussion 
As reported previously by other authors (section 1.7.1), the results of this study 
showed an elevated MAP in the eNOS-/- mutants. Although eNOS-derived NO has 
been well-known for its vasodilatory action, it has recently been reported that isolated 
aorta from WT and eNOS-/- mice after nitroglycerin pre-treatment showed no 
difference in vascular relaxation and cGMP accumulation between the two groups. 
There was also no change in eNOS protein expression in WT mice, suggesting that 
eNOS may not have a significant role to play in nitrate tolerance development in mice 
(Wang et al. 2002). In addition to the role of eNOS in the regulation of systemic 
vasoconstriction (i.e. total peripheral resistance) (Huang et al. 1995; Kojda et al. 1999) 
and baroreceptor set point (Huang et al. 1995), another study showed that, after the 
induction of maximal vasodilation with sodium nitroprusside, arterial pressure and 
total peripheral resistance (TPR) remained significantly higher in eNOS-/- mice than in 
WT mice. The results suggest that both vasoconstriction and arteriolar rarefaction are 
involved in the development of hypertension in the eNOS-/- mice (Kubis et al. 2002). 
Another finding of this study is a significantly lower liver to body weight ratio in 
the iNOS-/- mutants compared to the WT and eNOS-/- mice, suggesting that the iNOS 
gene may play a part in the control of hepatic development. 
In this study, the elevated PVP in eNOS-/- mice was probably due to an 
increased PVBF secondary to an elevated arterial blood pressure as the PVR was 
comparable to that of WT mice. The increased PVBF in the iNOS-/- mutants could be 
explained by a reduced liver-to-body weight ratio. Also, the combination of an 
elevated PVBF and a reduced PVR in the iNOS-/- mice resulted in a PVP comparable 
to that of the wild-type mice. The elevation in HMP of hepatic median (i.e. non-
ischaemic) lobe after occlusion of the left lobe blood supply in all three genotypes was 
probably caused by a diversion of hepatic blood flow. 
Although beneficial effect of eNOS-derived NO was implicated at the end of the 
subacute phase of hepatic IR injury (i.e. 24h post-IR) in this study as reflected in the 




AST activities in the eNOS-/- mutants, the protective effect of eNOS in the early phase 
could not be demonstrated. The iNOS-/- mutants appeared to be more susceptible to 
hepatic IR injury in terms of the depressed Rh123 fluorescence intensity, reduced LPI, 
and the delay in histologic recovery in the subacute phase of the insult (i.e. from 8h 
post-IR), suggesting that iNOS-derived NO may have a beneficial part to play in the 
maintenance of cellular function during that particular time period. 
The results of this study showed that HMP of the left and anterior liver lobe, 
RMP as well as LPI all reached the lowest levels at 8h after reperfusion. Thereafter, 
the values rose again. Plasma transaminases also reached the highest levels following 
8h of reperfusion. The results are consistent with those from previous studies which 
demonstrated maximal increase in serum AST 6 to 12 hours after hepatic reperfusion 
and absence of further elevation 24h post-IR (Yadav et al. 1999; Selzner et al. 2000). 
The timing is also consistent with the maximal expression of IL-10 and IL-13 which 
happens after 8 hours of reperfusion (Kato, Oka ya et al. 2003), implying that cytokines 
may have a role to play in hepatocellular integrity impairment and microcirculatory 
perfusion disturbance of the liver and other organs during hepatic IR (section 
1.5.2.6.2). 
In the current study, there was a significant decrease in plasma nitrite levels 
during reperfusion in all 3 groups of animals, suggesting several possibilities: (1) 
increased NO consumption during reperfusion, and/or (2) low levels of cofactors (i.e. 
NADPH and oxygen) for NO synthesis after ischaemia (Stewart et al. 1999), and/or (3) 
decrease in eNOS-derived NO release due to reduced eNOS expression and/or 
endothelial cell damage during IR. Although the last possibility seems somewhat 
unlikely as a previous study has demonstrated no decrease in eNOS expression as long 
as 5h after hepatic reperfusion (Kawachi et al. 2000). The results of this study also 
suggested a relationship between the post-IR ROS formation as reflected in the rise in 
DCF fluorescence intensity and the decrease in plasma nitrite levels. If NO is being 
consumed in the IR process and it is related to ROS formation, another two 
possibilities exist: (1) NO acts as an anti-oxidant and was consumed during 
reperfusion; or (2) NO produced is utilized in ROS formation. There is a body of 
evidence supporting the role of NO as an important modulator of IR-induced cellular 
injury, including its anti-oxidant and anti-inflammatory properties (Mojena et al. 2001; 
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Hesse et al. 2000; Kanno et al. 2000). NO released during IR has also been suggested 
to modulate the release of proinflammatory cytokines such as TNF-a and IL- I B 
through the activation of nuclear factor kappa B (NF-KB) (Hur et al. 1999). However, 
there were also reports suggesting a detrimental role of NOS in the IR process (Wang 
et al. 1998; Isobe et al. 1999), including the formation of the cytotoxic, highly oxidant 
peroxynitrite anion (ONOff) (Packer et al. 1996). Hence, the significant decrease in 
plasma nitrite levels 8h after reperfusion in the iNOS-/- mice probably signified the 
consumption of their eNOS-derived NO in the IR process, whereas the lack of a 
corresponding increase in DCF fluorescence intensity in the iNOS-/- mutants supports 
the role of iNOS-derived NO in ROS formation, rather than in anti-oxidation. 
However, no significant advantage of reduced ROS formation in the NOS-/- animals 
was noted in terms of Rh123 fluorescence intensity and plasma transaminase activities. 
On the contrary, instead of showing reduced injury after IR, the iNOS-/- mice 
exhibited enhanced histologic damage. The results imply that iNOS-derived NO may 
play a protective role in the IR process, possibly through the formation of peroxynitrite 
which has been proposed to reduce adhesion molecule-mediated, leukocyte-dependent 
reperfusion injury (Liu et al. 2000). 
Although beneficial effects of eNOS-derived NO on the liver during IR have 
been reported in the literature using eNOS-/- mice (Kawachi et al. 2000; Lee et al. 
2001), previous results on hepatic IR injury using iNOS knockout mice were far from 
unanimous. While one study demonstrated the presence of iNOS mRNA as soon as 3h 
after reperfusion and the detrimental effect of iNOS on the liver in hepatic IR injury 
(Lee et al. 2001), another group failed to identify iNOS message as long as 6h after 
hepatic IR and even reported exacerbated IR-induced liver injury with enhanced 
myeloperoxidase activity in the iNOS-/- mutants (Hines et al. 2001). The discrepancy 
in experimental outcome is difficult to explain especially when both studies adopted 
similar ischaemia duration and reperfusion periods. Selective pharmacological 
inhibition of iNOS in mice also showed no significant difference from the saline group 
in terms of hepatocellular injury after hepatic IR (Hines et al. 2001). Moreover, 
although it has been proposed that iNOS-derived NO causes peroxynitrite formation, 
oxidative stress, and hepatocellular damage (Ma et al. 1995; Meguro et al. 2003; 
Morisue et al. 2003), other authors revealed no evidence for any enhanced generation 
of NO or peroxynitrite either systemically or locally during hepatic reperfusion 
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(Jaeschke et al. 1992c). Indeed, iNOS has been shown to be protective against hepatic 
inflammatory injury (Mojena et al. 2001). The disparity in results may be due to the 
differences in ischaemic period and animal species used. Further effort is needed to 
shed light on the unsettled issue. 
Consistent with the decrease in plasma transaminases and the recovery of hepatic 
microcirculatory perfusion at 24h post-IR, histologic analysis revealed that the IR-
induced cellular derangement recovered 24h after reperfusion with the exception of the 
iNOS-/- mutants which showed a delay in recovery. The lack of enhanced histologic 
damage in the eNOS-/- mutants after reperfusion compared to the WT mice suggest a 
lack of apparent histologic protective effect of eNOS in the IR process. However, the 
sinusoidal dilatation 24h after reperfusion, which may act as a compensatory 
mechanism in response to IR injury in the WT mice, is absent in the eNOS-/- mice. 
This may partly explain the elevated plasma AST levels in the eNOS-/- mice 24h after 
reperfusion in this study. 
An increased hepatic blood flow in the iNOS-/- mutants may give rise to an 
increased baseline hepatic Rh123 fluorescence intensity, while their elevated basal 
RMP is consistent with the previous proposal that high levels of iNOS-derived NO 
may inhibit eNOS activity, resulting in renal vasoconstriction and reduced glomerular 
filtration rate (Gabbai 2001). The finding of a relative decrease in liver weight in the 
iNOS-/- mice compared to the WT and eNOS-/- in this study is compatible with the 
results of a previous study that demonstrated an impaired liver regeneration in the 
iNOS-/- mutants due to the lack of potential hepatoprotective effect of iNOS that 
includes the inhibition of TNF-a-mediated caspase 3 activation and promotion of the 
effects of hepatic viability enhancement cytokines such as TNF-a and IL-6 (Rai et al. 
1998). The baseline differences among the animals in this study again raised the 
concern about the validity of using genetically-engineered animals to address a 
particular gene function as other different gene(s) may have been up- or down-
regulated as a compensation (Hines et al. 2001) to enable the animal to survive with a 
knockout gene. The possibility of over-compensation also cannot be excluded. Such 
mechanism(s) may also affect the response to IR injury. Hence, the results have to be 
interpreted with caution. 
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The results of this study showed that disturbance in hepatic circulation can affect 
renal microcirculation as reflected in a drop in RMP during hepatic hilar clamping. In 
addition, reperfusion after partial hepatic ischaemia not only caused microcirculatory 
disturbance to the ischaemic lobe, but it also affected the microvascular perfusion to 
the non-ischaemic portion and renal perfusion up to 24h after reperfusion. The 
relationship between hepatic and renal circulation during IR has been recently 
demonstrated by the renal protective effect of a brief period of hepatic IR after 
induction of renal ischaemia (Ates et al. 2002). The exact mechanism, however, 
remains unclear. Our results are also compatible with the proposal that certain 
proinflammatory cytokines produced by activated Kupffer cells, such as tumor 
necrosis factor alpha (TNF-a), are released into the circulation from the ischaemic 
liver during the early phase of hepatic IR injury and affect the physiology of 
extrahepatic organs (Remick et al. 1994). Indeed, the blockade of TNF-a using anti-
TNF-a antiserum has been shown to reduce hepatic IR-induced liver and also lung 
injury (Colletti et al. 1990; Scales et al. 1994). The systemic impact of hepatic IR 
insult is further supported by the results of this study that demonstrated characteristic 
suppressions in renal microcirculatory perfusion (RMP) during hepatic reperfusion. 
The decrease in RMP is not secondary to changes in MAP which showed no 
significant fluctuation after hepatic hilar clamping in this study. The involvement of 
cytokines ( e.g. TNF-a) in the process, however, remains to be elucidated. 
In conclusion, the results of this study showed that not only does NOS have a 
role to play in systemic haemodynamics, it also affects basal hepatic circulation and 
may have a role to play in hepatic development. Moreover, partial hepatic IR is a 
systemic insult that affects both hepatic and renal perfusion and peaked at the end of 
the early phase (i.e. 8h) after reperfusion. The discrepancy between Rhl23 
fluorescence intensity and HMP 24h post-IR in the animals implies that impairment in 
hepatic metabolic function persists despite a restoration in microcirculation. In 
addition, the elevated plasma AST levels and diminished Rh123 fluorescence in the 
eNOS-/- mice 24h after reperfusion suggests a protective role of eNOS in the subacute 
phase of hepatic IR injury in spite of a lack of histologic evidence for an enhanced 
cellular derangement in the eNOS-/- mutants. The findings of a lack of significant 
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ROS formation, decreased Rhl23 fluorescence intensity, depressed LPI, and the delay 
in histologic recovery in the subacute phase of hepatic IR injury suggest that ROS (e.g. 
peroxynitrite) and/or iNOS-derived NO itself may serve as modulator(s) in the process. 
However, the beneficial effect was not reflected in plasma transaminase levels and 
HMP as iNOS knockout did not lead to a reduction in either parameter during 
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10.1 The use of the obese Zucker rat model and its clinical 
significance 
As compared with the environmentally induced, polygenic nature of human 
obesity, the monogenic mutation in the obese Zucker rat makes it an excellent model 
for the study of obesity as the presentations of "syndrome X" including dyslipidemia, 
insulin resistance and noninsulin-dependent diabetes mellitus (NIDDM) in human 
(Reaven 1993) can be found in almost 100% of the obese animals at the age of 14 
weeks (Unger and Orci 2001). The obese Zucker rat also makes possible the study of 
the impact of genetically predisposed obesity on various organ systems from molecular 
to integrative physiological levels because of its body size that greatly facilitates 
various physiological measurements and delicate surgical procedures. Similar pattern 
of obesity-induced hepatic lipid deposition between the obese rat and human also 
boosts its use for hepatic steatosis study (Chapter 4 & 6). However, the autosomal 
recessive nature of the fa gene and the sterility of the obese adults greatly reduce the 
- 258 -
yield. Age is another limiting factor in its use as the Zucker rats tend to lose weight 
and develop renal complications around one year of age (Zucker and Zucker 1962). As 
a result, the use of animals not older than 30 weeks is recommended for normal 
physiological study. This is the reason for reducing the post-transplant follow-up 
period to 3 months to minimize age-related complications (Chapter 4). In addition, 
since hepatic fibrogenesis has been shown to be leptin receptor-mediated (Ikejima et 
al. 2002), a lack of normal leptin receptor in the obese Zucker rat limits its use in the 
study of liver cirrhosis. 
10.2 The blood supply to the obesity-induced steatotic liver and its 
clinical significance 
The results from the first part of this thesis showed that although the overall 
perfusion per unit of liver weight is remarkably reduced in the steatotic liver, the 
hepatic arterial contribution remains unchanged compared to the normal condition due 
to a decrease in arterial resistance. Undoubtedly the highly oxygenated arterial blood 
helps in bringing oxygen to the enlarged liver. However, since portal venous blood 
normally supplies up to 30-50% of the hepatic oxygen requirement (section 1.3.1), the 
drastic decrease in PVBF leads to a relative decrease in tissue oxygenation which may 
account for the prevalence of elevated serum transaminase levels in patients with non-
alcoholic fatty liver disease (NAFLD) (Clark et al. 2003). 
10.3 The microvascular bed of the steatotic liver and its clinical 
significance 
To elucidate the cause of hepatomegaly in the steatotic liver, the liver from the 
obese Zucker rat was examined under IVFM. The results showed significantly 
widened hepatic cords and a remarkable decrease in hepatocyte density in the obese 
animals, suggesting that it is cellular hypertrophy, rather than hyperplasia, that leads to 
the overall increase in liver size. The cause is lipid deposition in hepatocytes which is 
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evident in histologic sections (Chapter 4 & 6). The sinusoidal width of the obese 
animals, however, is found to be normal. This is in contrast with the results of previous 
studies using rat models of alcohol- (Akamatsu et al. 1993) and choline/methionine 
deficiency-induced (Teramoto et al. 1993a) liver steatosis which were shown to exhibit 
reduced sinusoidal/space of Disse volume and narrow, irregular sinusoids, 
respectively. The importance of a distortion in microvascular structure in hepatic 
function has been reported in a previous study which showed that proper liver function 
depends on the accessibility of hepatocytes to the required nutrients, rather than their 
metabolic capacity (Villeneuve et al. 1996). The findings of normal sinusoidal 
diameter and erythrocyte velocity in the genetically predisposed steatotic liver in this 
research is compatible with the proposals that hepatocytes function differently in 
obesity- and chemical (e.g. alcohol)-induced hepatic steatosis and that obesity-induced 
steatotic liver has an enhanced capacity for extracting oxygen (Sato et al. 1986; 
Kasahara et al. 1988) and also, clinically, a better prognosis compared to alcohol-
induced hepatic steatosis (Kasahara et al. 1988). 
10.4 NAD(P)H fluorescence intensity of the steatotic liver and its 
clinical significance 
Not only is NAD(P)H an indicator of tissue oxygenation status (Chance et al. 
1962; Vollmar et al. 1998a), it also inhibits B-oxidation of fatty acids and enhances 
their esterification to triglyceride (Eaton et al. 1997). Hence, the observation of an 
increased NAD(P)H fluorescence from the steatotic liver not only suggests an 
impaired tissue oxygenation from an altered geometry between steatotic hepatocytes 
and sinusoids, but it also implies that the distorted microvasculature may be an 
independent contributing factor in the development and/or maintenance of the hepatic 
steatotic status. In addition, NAD(P)H has been proposed to show an inverse 
relationship with free radicals formation (Bandy and Davison 1990) and NAD(P)H 
oxidase isoforms are considered important mediators of ROS generation (Droge 2002). 
Hence, a disturbance in the intricate balance may result in enhanced ROS formation 
which is believed to cause lipid peroxidation in the steatotic liver leading to the 
development of steatohepatitis (Pessayre et al. 2001) and hepatic fibrosis (Paro la and 
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Robino 2001). On the other hand, increased ROS production may promote the 
oxidation of fluorescent NAD(P)H to non-fluorescent NAD(Pt (Bandy and Davison 
1990). Hepatocellular hypoxia has also been shown to cause inhibition of hepatocyte 
growth factor (HGF) (and of c-Met)-mediated proliferation and thereby might 
contribute to liver regeneration failure in cirrhotic liver (Corpechot et al. 2002). 
Whether an hypoxic insult also contributes to the reported retarded liver regeneration 
in the obese Zucker rat (Selzner and Clavien 2000), however, remains to be elucidated. 
10.5 Hepatic stellate cells (HSCs) in steatotic liver and the clinical 
speculations 
An in vivo upregulation of the expression of connective tissue growth factor 
(CTGF), which is an intermediate key molecule involved in the pathogenesis of 
fibrosing chronic liver diseases, has been demonstrated on transcriptional and 
translational levels in hepatic stellate cells (HS Cs) from both the obese Zucker rat and 
patients with non-alcoholic steatohepatitis. CTGF upregulation has also been shown in 
vitro when HSCs were incubated with either glucose or insulin (Paradis et al. 2001), 
suggesting that steatotic livers are at increased risk of developing fibrosis. 
Furthermore, HSCs are oxygen-sensing cells. Hypoxia has been shown to stimulate 
cell signalling in HSCs, resulting in the induction of vascular endothelial growth factor 
(VEGF) and Flt-1 mRNA expression as well as VEGF secretion. This hypoxic 
induction of VEGF is believed to have a role to play in the pathogenesis of hepatic 
wound healing and hepatocarcinogenesis (Ankoma-Sey et al. 2000). Although the 
preliminary work in this thesis demonstrated that hepatic steatosis leads to tissue 
hypoxia, the existence of this hypoxia-induced HSC signalling pathway in the steatotic 
liver remains speculative. In addition, despite of the well-accepted role of HSC in 
regulating hepatic microcirculation (section 1.3.3.3), the question of whether the 
possibly activated HSCs in the steatotic liver also contribute to the observed hypoxic 
conditions is still unanswered. Nevertheless, since the obese Zucker rat has no 
functional leptin receptor which is believed essential in the development of hepatic 
fibrosis (Ikejima et al. 2002), the hypothesis that hepatic steatosis may trigger these 
RSC-mediated fibrogenesis mechanisms and lead to identifiable fibrosis has to be 
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elucidated using a different animal model. The speculation of a vicious cycle among 
lipid deposition in hepatocytes, hypoxic change, HSC activation and fibrosis is 
depicted in Fig. 10.1. 
10.6 The mutual effects between the liver and an obese metabolic 
environment and their clinical significance 
Part of this thesis was devoted to elucidating the 'egg-and-chicken' relationship 
between liver steatosis and obesity (Chapter 4). Since NAFLD has gained so much 
attention these days that clinicians nowadays tend to focus their efforts on treating the 
mechanisms underlining the detrimental effects of hepatic steatosis, such as TNF-a 
inhibition, probiotics for bowel decontamination (Li et al. 2003), the use of 
antioxidants (e.g. vitamin E, N-acetylcysteine, and betaine) (Mehta et al. 2002), and 
bile salts (e.g. ursodeoxycholic acid) (Laurin et al. 1996). However, the fundamental 
question remains: If NAFLD is, at least partly, a disease secondary to the systemic 
metabolic status of obesity, is it adequate to focus on treating the liver rather than 
correcting the underlying conditions? The results of this thesis suggest that the 
underlying metabolic environment is no less important a treatment target than the 
steatotic condition of the liver itself. The clinical implication is that the treatment 
strategy for NAFLD should be an all-rounded, integrative approach combining the 
conventional treatment for the metabolic disorders (i.e. obesity, diabetes mellitus, and 
hyperlipidaemia) with the latest approach to the deleterious effects of hepatic steatosis 
on the body. The results also imply a specific follow-up protocol for obese patients 
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Figure 10.1 Possible vicious cycle among lipid deposition in 
hepatocytes, hypoxic change, HSC activation and fibrosis. 
Obesity results in lipid deposition and an increase in size of hepatocytes 
which is not accompanied by a corresponding increase in sinusoidal 
diameter. This change in hepatic micro-architecture causes a decrease in 
regional hepatic blood flow and relative tissue hypoxia due to an increased 
oxygen and nutrients demand in the absence of an adequate supply. To 
compensate for this, the hepatic arterial buffer response is triggered 
resulting in a decrease in hepatic arterial resistance (HAR). Also, oxygen 
extraction of the fat-laden hepatocytes increases. In addition, tissue 
hypoxia also causes activation of HSC and an increase in tissue NADH. 
The former has been reported to induce Flt-I mRNA expression and 
vascular endothelial growth factor (VEGF) secretion which are believed to 
play a role to in hepatic wound healing and hepatocarcinogenesis. An 
increase in tissue NADH not only causes a direct inhibition of beta-
oxidation of free fatty acids (FFA) and enhanced triacylglycerol formation, 
but it also results in an elevated NADH/NAD+ redox ratio which in turn 
activates the free radical generating enzyme xanthine oxidase. Free radicals 
also contribute to hepatic fibrosis and lipid peroxidation in fat-laden 
hepatocytes. Lipid peroxidation in turn results in hepatic mitochondrial 
ultrastructural lesions and free radical leakage which are subcellular 
features of primary steatohepatitis. All reactive oxygen species thus formed 
have been proposed to increase oxidation of NAD(P)H back to NAD(Pt. 
Hyperglycemia and hyperinsulinemia, which usually accompany obesity in 
type 2 diabetes mellitus, have been shown to be possible pathways for the 
development of fibrosis in patients with non-alcoholic steatohepatitis 
through up-regulation of connective tissue growth factor (CTGF). (Note: 
Relevant reference(s) are shown over right upper corner of each box. 
Dashed arrows represent inhibitory pathways.) 
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10.7 Enhanced IR injury to the steatotic liver and the clinical 
implications 
Although myriad of theories have been put forward to explain the enhanced IR 
injury to steatotic liver (Chapter 6), most of them are speculative. The research in this 
thesis also showed elevated plasma transaminase levels and reduced Rh123 
fluorescence intensity in the obese group after short-term IR (Chapter 6). However, no 
enhanced tethering of neutrophil was noted in the steatotic liver 60 min after 
reperfusion. To elucidate further the mechanism of IR injury in the steatotic liver, the 
role of NO was evaluated by administration of the NOS blocker L-NAME (Chapter 7). 
The enhanced impairment in microcirculation and hepatocyte integrity in the obese 
group after NOS blockade suggests a protective role of NO against IR injury in hepatic 
steatosis. The findings appear contradictory to the previous proposal of "lipotoxic 
diseases" in steatotic organs such as the heart, pancreas, and skeletal muscle in which 
ceramide, a nonoxidative product of long-chain fatty acids, increases the expression of 
iNOS through activation of NF-KB. The enhanced NO release then gives rise to potent 
oxidants such as peroxynitrite that leads to cellular dysfunction and apoptosis (Unger 
and Orci 2001). In the steatotic liver, however, the protective effect of NO during IR 
may be potent enough to overrule this potentially detrimental pathway. 
10.8 NO: a friend or a foe during hepatic IR? 
NO has been described as a "double-edged" molecule. Its mode of action varies 
so widely under different circumstances that it is practically impossible to give a 
general statement describing its function. However, it is commonly accepted that NO 
from eNOS, albeit not as important as CO in the maintenance of basal microvascular 
tone of the liver (Suematsu et al. 1996), plays a protective role against hepatic IR 
injury (Kawachi et al. 2000; Lee et al. 2001). The role of NO from iNOS in the hepatic 
IR process, however, is less well-defined (section 8.2.4). Preliminary results from the 
research in this thesis failed to demonstrate a protective role of eNOS until 24h after 
reperfusion. The results also suggested a role of iNOS-derived NO in ROS formation 
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and during IR. Although an overall improved hepatic microcirculatory perfusion was 
observed in the iNOS-/- mutants compared to the WT mice, no significant difference 
was found in terms of plasma transaminase levels and Rh123 fluorescence intensity. 
Hence, although iNOS appears to participate in ROS formation during hepatic IR, it 
seems unlikely that it has a dramatic role to play in the IR-induced hepatic injury. 
10.9 Future directions 
The future direction of hepatic steatosis research would be to clarify the 
mechanisms that can help in answering the commonly asked question: "Why does a 
simple lipid deposition in the liver cause so complicated a problem with clinical 
manifestations ranging from an elevation in serum transaminases (Clark et al. 2003) 
and asymptomatic liver fibrosis (Silverman et al. 1990) to steatohepatitis (Pessayre et 
al. 2001), cirrhosis (Silverman et al. 1990), and even malignancy (Marrero et al. 
2002)?". The speculations proposed here (Fig. 10.1) may be merely part of the picture 
that needs to be expanded. A better understanding of these key mechanisms is pivotal 
in developing the appropriate clinical strategies against this common medical 
condition which is still increasing in prevalence and severity in the developed nations. 
Since the obese Zucker rat is resistant to hepatic fibrosis as mentioned above, the 
use of another animal model would be of interest in filling the missing link between 
hepatic steatosis and cirrhosis. For example, the leptin-deficient ob/ob mice have been 
widely used for obesity- and type-II diabetes-related studies. However, unlike humans 
with NAFLD, they seldom, if ever, develop cirrhosis spontaneously (Yang et al. 2001). 
Therefore, the development of a suitable model which can reasonably reflect the 
clinical condition is another direction for future hepatic steatosis research. 
The last part of this thesis attempted to use NOS gene knockout mice to address 
the function of the iNOS and eNOS gene during hepatic IR. As the use of genetically-
modified animals has its limitations (Hines et al. 2001), complementary use of 
selective NOS blockers may help in clarifying the specific role of each NOS isoform 
in future studies. 
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